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ABSTRACT
Cortactin Phosphorylation by Casein Kinase 2 Regulates Actin Related Protein 2/3 Complex
Activity and Invadopodia Function
Steven Michael Markwell
Malregulation of the actin cytoskeleton enhances tumor cell motility and invasion. The actinbinding protein cortactin facilitates branched actin network formation through activation of the
actin-related protein (Arp) 2/3 complex. Arp2/3 complex activation is responsible for driving
increased migration and extracellular matrix (ECM) degradation by governing invadopodia
formation and activity. While cortactin-mediated activation of Arp2/3 complex and invadopodia
regulation has been well established, signaling pathways responsible for governing cortactin
binding to Arp2/3 are unknown. In this dissertation we identify casein kinase (CK) 2α
phosphorylation of cortactin as a negative regulator of Arp2/3 binding. CK2α directly
phosphorylates cortactin at a conserved threonine (T24) adjacent to the canonical Arp2/3 binding
motif. Phosphorylation of cortactin T24 by CK2α impairs the ability of cortactin to bind Arp2/3 and
activate actin nucleation. Decreased invadopodia activity is observed in HNSCC cells with
expression of CK2α phosphorylation-null cortactin mutants, shRNA-mediated CK2α knockdown,
and with the CK2α inhibitor Silmitasertib. Silmitasertib inhibits HNSCC collective invasion in tumor
spheroids and orthotopic tongue tumors in mice. Although overall cancer incidence rates are
declining across the United States, the incidence of head and neck squamous cell carcinoma
(HNSCC) continues to increase within the Appalachian region. To better understand the
underlying factors leading to disproportionate outcomes, our group has established an
Appalachian-specific HNSCC patient tissue cohort from surgically-resected tumors. This cohort
represents all HNSCC stages, lesion types and morphologies, as well as cases that contain
human papillomavirus (HPV) and/or tobacco and alcohol use. Moreover, we have generated
several patient derived xenografts (PDXs) from these tissues, allowing further cellular,
biochemical and preclinical therapeutic evaluation. Utilization of PDX tumors from this cohort will
allow examination of critical steps in the development and potential treatment of invasive,
metastatic, and recurrent Appalachian-associated disease. Matched patient and PDX sample
availability enables personalized medicine and co-clinical trials aimed at reversing this
Appalachian cancer health disparity and ultimately improving regional HNSCC patient care.
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Literature Review
Head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) arises from epithelial cells lining the upper
aerodigestive tract, encompassing the lips, oral cavity, nasopharynx, larynx, and hypopharynx
(1,2). Clinically HNSCC is further subdivided by anatomical location into disease of the oral cavity
and pharynx or the larynx, based on differences in progression, response to therapy, and patient
outcome (1,2). Genetically HNSCC comprises two subtypes based on infection with human
papilloma virus (HPV): HPV-positive and HPV-negative (1,2). The largely positive prognosis
associated with HPV-positivity in HNSCC resulted in the American Joint Committee on Cancer
(AJCC) down-staging all HPV-positive disease effective January 1st, 2017 (3). Likewise, clinical
trials have established dose de-escalation protocols for treatment of HPV-positive HNSCC (4).
HPV-negative HNSCC is associated with prolonged tobacco and alcohol exposure (1,2). As
tobacco consumption in the United States declines, there has been a corollary decrease in HPVnegative HNSCC incidents (5). However, HPV-positive HNSCC has increased over this same
time period, leading to an overall plateau in total HNSCC incidence over the past decade (5).
Recent projections suggest that at the national level HPV-related HNSCC will become the
predominant form of this cancer as early as 2020 (5).
While HPV-positive HNSCC accounts for nearly 20% of all HNSCC incidents, it is significantly
enriched in oropharyngeal tumors where it is responsible for 60-80% of all HNSCC in this
subregion (5–7). High-risk HPV subtypes 16 and 18 contribute to the vast majority of HPV-positive
HNSCC (6–8). HPV is a circular double stranded DNA virus encoding 7 “early” stage proteins
(E1-7) and 2 “late” stage proteins (L1 and L2) (7,8). The early proteins E6 and E7 primarily target
tumor suppressor genes p53 and Rb in host cells, transforming the infected epithelium and
increasing susceptibility to oncogenic insult (7,8). Despite impairment of these key tumor
suppressor pathways, HPV-positive tumors have similar yet distinct mutational burdens as
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compared with HPV-negative tumors (9–11). Due to the influence of the other HPV encoded
genes, these tumors tend to be poorly differentiated and highly metastatic to regional lymph nodes
(12). Tumor differentiation is characterized by the invasive front, where the tumor interacts with
the stroma. Well differentiated tumors show a clearly defined front, while poorly differentiated
tumors show tumor cells intermixed with stromal cells making the exact tumor border difficult to
discern (13). Moderately-differentiated tumors display either an intermediate phenotype or have
regions along the tumor border than display both well and poorly differentiated segments (13).
Conversely, HPV-negative HNSCC tumors tend to be well- to moderately-differentiated, invading
as collective strands which cause immense loco-regional destruction of vital tissues leading to
worse overall patient survival (12).
Further genomic analysis identified 5 distinct subtypes within HNSCC; two HPV-positive and three
HPV-negative (9,11). Characteristically, these tumors stratify into three supergroups: 1) the
inflammation/mesenchymal group, 2) the basal group, and 3) the classical group. The basal
supergroup is exclusively HPV-negative, while the other two can be further subdivided based on
HPV status (9). The basal supergroup is enriched in hypoxia-responsive gene signatures and
epithelial cell markers while the classical supergroup shows higher proliferation rates and highly
correlates with tobacco consumption (9). The inflammation/mesenchymal supergroup exhibits an
immune-responsive signature, enriched in CD8+ T lymphocyte infiltration and a poorly
differentiated morphology (9). Despite similarities within supergroups, the HPV-positive tumors
still display increased overall survival as compared to any of the HPV-negative subtypes (9).
Another study further validated the distinct HPV-positive subtypes, again molecularly segregating
the well differentiated tumors from the immune-responsive mesenchymal tumors (11).
While loco-regional disease is a hallmark of HNSCC progression, metastasis to distant organs
such as the lungs, bone, brain, and liver have been noted (14,15). Metastatic progression is a
multi-step process during which tumors cell must breach the basement membrane, forge a path
2

through the extracellular matrix (ECM) to reach local vasculature or lymphatics, intravasate
through the endothelium, extravasate into the secondary tissue, and engraft at the metastatic
niche. Invasive carcinoma cells utilize an array of modalities in order to take advantage of cues
from the tumor microenvironment, as well as internal aberrant signal transduction to accomplish
these steps (16).
Mechanisms of cancer cell invasion
The inherent invasive tumor cell phenotype, along with its particular microenvironment, requires
differing modes of cellular invasion as single cells or as collective invasive groups (Figure 1)
(17,18). Single-cell invasion can be subdivided into two modes. Non-proteolytic amoeboid motility
driven through membrane blebbing allows cells to squeeze through pores in the ECM. Proteolytic
mesenchymal invasion requires stromal cells or cells that have undergone epithelialmesenchymal transition (EMT) to degrade basement membrane and ECM components in order
to generate permissive invasion pathways (18). Amoeboid invasion can be further characterized
based on intracellular signaling involving specific Ras-family small GTPases of either the RhoRho-associated protein kinase (ROCK) pathway or the Rac pathway (19–24). Rho-dependent
signaling results in actino-myosin contractility, compressing the cell and propelling the trailing
edge of the cell forward (20,23,24). At the leading edge of the cell, Rac signaling produces
filopodial extensions, lamellipodia and podosomes driving the membrane forward and attaching
to the ECM. Lamellipodia formation in response to extracellular growth factors, such as EGF,
initiate membrane protrusion (25,26). Podosomes anchor the actin cytoskeleton to the ECM
allowing contractility at the trailing edge to push the cell forward (19,23,24). Mesenchymal
invasion relies almost entirely on the Rac-based signaling for directed cell motility (18,19,24).
Unlike amoeboid invasion, mesenchymal cells produce invadopodia, membrane protrusions
specialized in proteolytic ECM cleavage through localization and secretion of specific matrix
metalloproteinases (MMPs) (17,27–29). Both single cell modalities can give rise to multi-cellular
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streaming in which cells form loose transient cell-cell adhesions or simply take advantage of the
cleared “tracks” left behind by previous invasive cells. It has also been noted that stromal cells
can be involved in these multi-cellular streams, particularly when cancer-associated fibroblasts
(CAFs) are recruited to “trail-blaze” a pathway through the ECM (30–32).

Collective

cellular

invasion is classified into
four

main

subtypes

based on morphologic
differences

in

the

collective groups arising
from

differences

inherent to the invasive
cell and the surrounding
tissue:

1)

cluster-like

invasion, 2) solid strand
invasion,

3)

containing

lumenstrand

invasion, 4) protrusive
strand invasion (17,18).
All
Figure 1. Tumor cell invasion modalities. Tumor cells utilize a
spectrum of invasive modalities depending on the cell-cell
interactions, tumor cell morphology and surrounding ECM.
Adapted from Figure 2 in Friedl, P. and Alexander, S. (2011) Cell
147 (5), p.992-1009.
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tumor cells and infiltrating stromal cells within the tumor microenvironment (17,18,33). Clusterlike invasion occurs when a compact “ball” of cells breaks away from the main tumor mass and
invades as a tight group of epithelial cells (17,18). Strand-like invasion can take on several
morphologies based on cell morphology near the leading edge and is dependent upon
maintaining polarity within the invasive group (17,18). Solid strand collective invasion involves
mesenchymal cells localizing to the leading edge of the strand, either through recruitment of
stromal cells such as CAFs or from subregional EMT of tumor cells termed “tip” cells (18,30,31).
These tip cells maintain some expression of epithelial cell surface markers while maintaining
junctions with the rest of the invasive strand to allow force transduction down the length of the
collective group. Based on cell type and polarity, some invasive strands maintain a clear luminal
region at the center of the strand, typically only exhibited in well-differentiated tumors (17,18). In
the absence of EMT or recruitment of mesenchymal stromal cells, collective strands display a
rounded epithelial morphology where the collective mass extends a multi-cellular protrusion into
the surrounding stroma (17,18). At the extreme end of the collective invasion spectrum lies
expansive growth-driven invasion wherein accelerated tumor cell proliferation (as compared to
the surrounding tissue) generates an outward facing force that allows for pushing expansion of
the invasive front (17,18). The extent of this expansive growth depends on the rigidity of the
surrounding tissue and can lead to extracapsular spread when metastatic lymph nodes can no
longer contain the expanding tumor mass (17,18). Tumor cells are typically capable of undergoing
several if not all of these collective invasion modalities, where it is not uncommon to observe
multiple differing modes within a single tumor or within a patient with multiple tumors (17).
Therefore, a deeper understanding of the underlying mechanisms giving rise to these different
modes of invasion is needed in order to better target and prevent invasive spread and improve
patient outcomes.
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Rearrangement and organization of the actin cytoskeleton is necessary for formation of various
cellular structures involved in cellular migration and invasion, as well as the transduction of forces
through multi-cellular tumor cell groups. Migratory cells generate several actin-rich subcellular
structures including podosomes, filopodia, lamellipodia and invadopodia (34–36). Formation and
maturation of each of these structures requires tightly regulated cycles of actin polymerization
and depolymerization through a variety of actin-binding proteins (ABPs) (35,36). These proteins
are key modulators of filamentous (F-) actin production, branching, stabilization, and eventual
turnover and recycling of globular (G-) actin for further cycles of F-actin assembly (26,37). F-actin
is formed through ATP-bound G-actin monomer polymerization which rapidly adds to the “barbed’
end of the filament (38). As the filament ages, ATP hydrolysis occurs rending ADP-bound actin
towards the “pointed” end of the filament, leading to spontaneous depolymerization in the absence
of filament-stabilizing ABPs (38). Specific ABPs enable complex structures to arise from F-actin,
allowing for the formation of branches, bundles, and sheets dependent upon the specific ABPs
involved (26,35–37). Filopodia contain mostly bundled actin strands, lamellipodia consist of
mostly branched actin networks, while podosomes and invadopodia contain both branched actin
near the base and bundled actin strands in the membranous extensions (35,36). F-actin assembly
is highly dependent on actin-related protein (Arp) 2/3 complex-mediated nucleation activity
enhanced through nucleation promoting factors (NPFs) containing either a verprolin, central,
acidic (VCA) domain found in the Wiskott-Aldrich Syndrome protein (WASp) family or an
N-terminal acidic (NTA) domain found in the cortactin family (35,36,38). The type of specialized
membrane protrusion formed depends upon the microenvironment as well as intrinsic cellular
signals. In a 2D environment, cells typically exhibit lamellipodia and filopodia at the leading edge
of the cell which is sufficient to pull the cell along a layer of ECM (35,36). In a 3D environment, it
becomes difficult to differentiate podosomes from invadopodia since both subcellular structures
have nearly identical components (39–44). While distinct markers distinguishing podosomes from
invadopodia are contested in the field, consensus opinion proposes that WASp and Grb2 are
6

considered posodosome-specific, while Nck1 and Mena appear invadopodia-specific (29). 3D
protrusions containing F-actin and associated proteins such as cortactin, β1 integrin, MMP14,
N-WASp, paxillin, and talin have been observed in macrophages, dendritic cells, lymphocytes,
melanoma, fibrosarcoma and breast cancer cells (43,45). Recent studies have observed similar
structures in tumor and endothelial cells in vivo (40,43,46,47).
Invadopodia
Invadopodia were first identified by Chen et al. and characterized as membrane protrusions with
localized ECM proteolytic activity in oncogenically transformed cells (48). Invadopodia share
many ABPs found in other membrane protrusions. Invadopodia also contain microtubules and
associated stabilizing proteins with the necessary transport machinery required for localization
and secretion of MMPs (49–52). Invadopodia formation occurs in discrete spatial-temporal
stages: 1) precursor core initiation, 2) precursor stabilization and 3) invadopodia maturation
(29,53).
Invadopodia are formed in response to chemotactic and proliferative environmental cues such as
epidermal growth factor receptor (EGFR) stimulation by epidermal growth factor (EGF) (48,49,54–
56). Intracellular signals are transmitted through Ras family GTPases, Src tyrosine kinase, protein
kinase C (PKC), Erk1/2, and others. Core initiation begins with cortactin-mediated recruitment of
Arp2/3 complex, N-WASp, and cofilin to preexisting F-actin filaments (29,53,57,58).
Stabilization

is

achieved

through

Src-dependent

Tks5

binding

to

phosphoinositol

3,4-bisphosphate (PIP2) on the plasma membrane (58–60) along with recruitment of β1 integrin
to the precursor where it binds to the ECM and initiates maturation signaling (29,53,61). β1
integrin activation through ECM binding creates an Arg kinase binding site on β1 integrin initiating
assembly of a Mena-Arg-SHIP2 complex that generates additional PIP2, further adhering the
precursor core to the membrane (61). Simultaneously, cofilin severs existing F-actin filaments
near the membrane, generating new barbed ends (62–64). Src and/or Arg-dependent cortactin
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phosphorylation creates docking sites for Nck1, recruiting N-WASp and Arp2/3 complex to initiate
actin polymerization at the membrane (29,55,58–60,65–68). WIP, Nck, and N-WASp bind to Src
or Abl/Arg tyrosine kinases which target key C-terminal residues on cortactin (55,65,69,70).
Phospho-cortactin then interacts with various SH2 domain containing proteins , Arp2/3 complex
through the NTA domain, and F-actin through the repeats region (RR) (71,72). This multi-protein
complex facilitates Arp2/3-mediated branched actin network formation, providing protrusive force
on the cellular membrane to initiation invadopodia elongation (35,36,71,72).
Invadopodia maturation involves elongation through the combined action of the actin bundling
protein fascin and straight-filament NPFs of the formin family (52,73). Additional recruitment of
MMP14 as well as exosomes containing MMPs secreted at the invadopodia tip promote focalized
matrix degradation (50,74–76). Microtubules and certain intermediate filaments arrive at nascent
invadopodia and are also involved in the maturation process (29,52,77,78). Regulation of F-actin
barbed ends at invadopoida tips is achieved by the uncapping activity of formins and Ena/Vasp.
This enables G-actin addition to filament barbed ends near the inner membrane face, directly
contributing in invadopodial membrane protrusion (52,73,79,80). Bundling of the F-actin network
within invadopodia is achieved through the activity of fascin, α-actinin, and caldesmon. The
combined activity of these dual F-actin bundling proteins serves to organize F-actin filaments in
to parallel arrays, stabilizing the F-actin invadopodia core (80). The adhesion proteins talin and
paxillin localize at the invadopodia tip to connect the F-actin network to various integrins, forming
a bridge between the actin cytoskeleton and the ECM (29,53,56,78,81–83).
Invadopodia maturation is a tightly regulated process, striking a balance between the ECM
adhesion necessary for motility and the proteolysis required maintain directed cellular invasion
(29). As noted above, focal ECM degradation occurs when MMP14 (also known as membranetype 1 (MT1)-MMP) and a disintegrin and metalloproteinase (ADAM)-family sheddases localize
to invadopodia. These transmembrane proteases in turn act on the pro- forms of secreted
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extracellular MMP2 and MMP9, cleaving the pro- fragments to enable full enzymatic activity
(51,57,84–86). MMP14 disruption through reduced expression, inhibition of activity or
mislocalization profoundly diminishes invadopodia-mediated proteolysis and tumor cell invasion,
highlighting a central role for this MMP in tumor invasion (87–92). MMP14 localization is regulated
by plasma membrane dynamics, where recycling to the invadopodia tip can occur via clathrinmediated endocytosis or exocytic trafficking in a cortactin-dependent manner followed by exocyst
complex-mediated sequestering at the membrane for rapid reincorporation at newly formed preinvadopodia (49,76,89,91–96).
Although invadopodia were initially characterized in 2D cell culture, several 3D models
demonstrate that these structures are not culture artifacts. Physiological in vivo and in vitro assays
using native ECM have identified tumor cells that display invadopodia-like structures with NWASp, Tks5, cortactin, Src, MMP14 and Arp2/3 complex localization at sites of ECM proteolysis
(39,40,91,97–99). Furthermore, tumor cell lines that exhibit greater invadopodia function in 2D
models almost universally display enhanced invasion capacity in 3D model systems. Similarly,
podosomes have been found on osteoclasts, macrophages, smooth muscle and endothelial cells
mediating homeostatic ECM reorganization (100–104). It is likely that tumor cells utilize this
inherent cellular phenomenon in an attempt to pursue a more hospitable microenvironment as a
result of increased primary tumor growth, resulting in depletion of local resources or by preventing
adequate nutrient exchange due to incomplete angiogenesis and subsequent hypoxic conditions
(105–107).
Cortactin
The ABP cortactin was originally identified as a Src kinase substrate that localized to peripherial
F-actin (108,109). Cortactin is a cytoplasmic protein ubiquitously expressed in all mammalian
tissues of non-hematopoietic origin (71). Subsequent studies have elucidated roles in cell
adhesion, migration, endocytosis, and invasion (71). Fittingly, cortactin localizes to various actin9

rich membrane protrusions including lamellipodia, filopodia, podosomes, and invadopodia
(72,110). Cortactin is overexpressed in several invasive cancers including HNSCC, melanoma,
breast, lung, bladder, colorectal, hepatocellular, and esophageal cancers (111–121). The CTTN
gene that encodes cortactin is found on chromosome 11q13. Chromosome 11q13 amplification
occurs in nearly 1/3 of HNSCC patients and is responsible for a significant portion of cortactin
overexpression events in this disease, though it is not a prerequisite for enhanced cortactin
protein expression in all HNSCC patients (122–127). CTTN amplification is a poor prognostic
marker, corresponding with increased lymph node involvement, distant metastasis, and
decreased time to recurrence (110,112,124,128–130). Regardless of the mechanism,
overexpression of cortactin mRNA and/or protein corresponds with poor patient outcome in
multiple patient cohorts (119,125,131,132).
On the mechanistic level, cortactin is a multi-domain scaffolding protein that has been proposed
to adopt several conformations. A closed “lollipop” auto-inhibitory conformation is thought to
represent the inactive form, in which the Src homology (SH) 3 domain folds back to bind to the
proline-rich region (PRR). The active form is thought to assume an open “rod-like” conformation
in which the molecule is linearized, allowing multi-protein complex formation (109,133,134).

Figure 2. Diagram representing cortactin functional domains. NTA, N-terminal acidic
domain; R1-R6, repeats regions; Helix, alpha helical domain, PRR, proline rich region; SH3,
Src homology 3 domain.
Based on primary structure and functional analysis, cortactin has been subdivided into multiple
domains/regions, including the NTA domain, the RR, an α-helical domain, the PRR, and an SH3
domain (Figure 2)(135). The NTA domain mediates binding to and activation of Arp2/3 complex
via a highly conserved DDW motif common to most NPFs (72,109,110,136–143). Arp2/3
activation by cortactin alone is weak compared to WASp-family NPFs, requiring direct and/or
indirect WASp-protein binding to cortactin to facilitate robust Arp2/3 complex activation
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(72,110,137,144,145). Following the NTA domain, the F-actin interacting domain contains 6.5 37
amino acid tandem repeats. Binding to F-actin occurs at sequences around the 4th repeat
(109,139). Lysine acetylation/deacetylation within the repeats region modulates F-actin binding
efficiency. HDAC6-mediated cortactin deacetylation enhances F-actin binding, while a group of
histone acetyltransferases including pCAF/p300 and SIRT1 acetylate cortactin to impair F-actin
binding (146–148). The ability of cortactin to simultaneous bind Arp2/3 and F-actin stabilizes the
overall F-actin network. This is achieved by cortactin NTA binding to Arp2/3 complex at the base
of one actin filament, and the F-actin binding domain interacting directly with the side of a second
F-actin filament. This stabilization effect is required for enhanced cell migration and tumor cell
invasion (71,72,146,149). The α-helical domain contains a calpain cleavage site that when
proteolyzed by calpain 2, enhances cellular migration likely due to the inability of the cleaved
product to adopt the closed conformation (150,151). Both the PRR and SH3 domain are
responsible for integrating upstream signaling events via post-translational modifications and
mediating protein-protein interactions with other cortactin binding proteins (66,70,128,137,152–
156).
The cortactin C-terminus contains the vast majority of its post-translational modification sites
(157). Src and Abl family kinases phosphorylate tyrosine 421, 470, and 486 in the PRR, leading
to enhanced tumor cell motility, invasion, and metastasis (65,72,128,158). Tyrosine
phosphorylated cortactin is enriched in lamellipodia, invadopodia, and dorsal waves (153). SH2
domain containing cortactin-binding proteins including Nck1, Crk, and Abl family kinases utilize
these phospho-tyrosine residues dock with cortactin, ultimately recruiting other binding partners
to form large multi-protein complexes (65,66,158–160). The Nck1 SH2 domain binds pY421 and
pY466 then recruits N-WASp whose PRR interacts with the cortactin SH3 domain (65,158). This
trimolecular complex enhances Arp2/3 complex nucleation activity through synergistic activities
of the cortactin NTA and N-WASp VCA domains. Some controversy exists regarding the function
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of tyrosine phosphorylated cortactin on NPF activity. One study concluded that Src-dependent
cortactin phosphorylation diminished N-WASp binding and Arp2/3 actin nucleation activity
through maintaining a closed conformation (161), while another study found that cortactin tyrosine
phosphorylation does not induce a closed conformation (158). How these various posttranslational modifications to C-terminal cortactin residues impact one another and ultimately how
these signals integrate to control actin dynamics remains unresolved.
In order to increase ABP recycling, protein tyrosine phosphatase (PTP) 1B dephosphorylates
cortactin tyrosine residues (162). The actin capping protein MenaINV protects cortactin from
PTP1B-mediated dephosphorylation, though the exact mechanism remains unclear (163).
Tyrosine dephosphorylation plays a major role in invadopodia regulation, as impaired
phosphorylation at Y421, Y466, and Y482 significantly decreases invadopodia formation
(72,128,164). Additionally, FAK has been shown to modulate Src-dependent cortactin
phosphorylation at Y421, Y470, and Y486, enhancing focal adhesion turnover and allowing for
increased cell motility (128). Cortactin is also a substrate for a variety of serine/threonine kinases.
Erk1/2 targets serine (S) 405 and 418; p21-activated kinase Rac1/Cdc42 activated kinases (PAK)
1, 3, and 4 phosphorylate S405 and S418 as well as S113 in first repeat region (128,152,153,165).
Erk1/2-mediated phosphorylation of S405/418 enhances binding between cortactin SH3 domain
and the N-WASp PRR by releasing cortactin from the auto-inhibited state. Erk phosphorylation of
N-WASp causes a similar release of VCA autoinhibition. The newly formed complex between
activated cortactin SH3 and N-WASp PRR domains promotes Arp2/3 nucleation activity, leading
to increased lamellipodia persistence and subsequent enhanced motility in HNSCC cells
(128,166–168). S113 phosphorylation appears to further regulate interaction between the RR and
F-actin filaments (152). Other studies show that both Erk1/2 and PAK-dependent serine
phosphorylation are required for optimal ECM degradation in melanoma cells (49). In addition,
protein kinase D (PKD) phosphorylates cortactin S298 in the sixth repeat and S348 preceding the
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helical-PRR (169,170). PKD phosphorylated cortactin shows impaired binding to β-catenin and
vinculin in adherens junctions, uncoupling E-cadherin mediated cell-cell interactions from the actin
cytoskeleton, resulting in junction dissolution (169–172). While these studies provide important
mechanistic insights into cortactin regulation by phosphorylation, several phosphorylation sites
identified by comprehensive mass spectrometry screens currently do not have assigned functions
(157).
The cortactin SH3 domain mediates binding to a variety of PRR-containing cortactin binding
partners. These interactions allow cortactin to integrate signals that control signal transduction
(Fgd1, BPGAP1, Abl family kinases), actin polymerization (N-WASp, WIP), cell-cell and cell-ECM
adhesions (ZO-1, FAK), endocytosis and exocytosis (ACK1, HIP1R, AMAP, Dynamin-2,
SHANK2, CD2AP), and actomyosin contractility (myosin light chain kinase (MLCK))
(71,128,134,173). These processes collectively play major roles in directed cellular chemotaxis
and migration, as well as invadopodia function and ECM invasion.
While many studies have focused on modification and interactions with the cortactin C-terminal
domain, the cortactin NTA domain that harbors the NPF activity centered around the DDW motif
has also been extensively studied. Several studies have demonstrated that removal of the DDW
motif significantly impairs binding to Arp2/3 complex and subsequently prevents invadopodia
formation and maturation in a variety of cell lines (137–143,174). NPFs enhance Arp2/3-mediated
actin polymerization by stabilizing a conformation in which Arp2 and Arp3 subunits mimic an Factin barbed end, allowing for rapid assembly of a new actin filament (137,140,175). The cortactin
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NTA domain directly binds
both Arp2 and Arp3 along the
surface

opposite

to

the

barded end mimic, pinching
the two subunits together in
order to stabilize the active
Arp2/3 complex conformation
Figure 3. Cortactin Arp2/3 interaction modeling
3D reconstruction of cortactin bound Arp2/3 complex reveals
cortactin NTA domain bridging the pointed end mimic. Panels
display views of Arp2/3 complex from the pointed end (left) and
Arp3 (left center) as well as an Arp2&3 dimer from the side
(right center) and Arp3 alone (right). Arp2/3 complex is shown
in the top row with color subunits. On the bottom, Arp2/3
complex is colored white and cortactin is shown in red.
Adapted from Figure 3 in Xu, X. et al. (2012) EMBO, 31(1),
p.236-247.

(38,175).
from

Similarly,

proteins

domains

bridge

with

NPFs
VCA

between

Arp2 and Arp3 along the
pointed end of the complex,
stabilizing Arp2/3 complex in
a manner conducive to G-

actin binding (175). Since the VCA domain is also capable of binding G-actin, these NPFs
demonstrate a greater ability to activate Arp2/3 complex, enhancing the nucleation rate.
Mechanistic studies to determine the spatial and temporal coordination of cortactin and WASpfamily NPFs in Arp2/3-mediated branch point assembly have yielded differing mechanisms. One
proposed mechanism involves simultaneous binding of N-WASp and cortactin to Arp2/3 complex
(137). A second mechanism proposes that N-WASp binding and activating Arp2/3 complex prior
to displacement by cortactin. In this mechanism, cortactin then binds to and stabilizes Arp2/3
complex free of N-WASp while anchoring the newly formed “daughter” filament to the existing
“mother” filament via the RR (176). Further work is required to fully elucidate the precise
mechanisms utilized by cells in regulating motile and invasive behavior reliant on Arp2/3 activity,
as well as how upstream signaling events alter NPF binding and activation during these cellular
events.
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Cortactin is a key component of the actin-based invadopodia machinery and as such is
recognized as the canonical invadopodia marker (71,72,128). Initial work demonstrated that
cortactin formed a complex with paxillin and PKC within invadopodia that correlated with sites of
ECM degradation (72). Likewise, cortactin expression and subcellular localization correlates with
invadopodia formation and maturation in transformed fibroblasts and multiple invasive cancer cell
lines (71,72). Mechanistically, cortactin initiates invadopodia formation through recruitment to
sites of actin polymerization and ECM adhesion giving rise to immature pre-invadopodia
(139,141,142). Subsequently, other invadopodia-associated proteins including Arp2/3 complex,
N-WASp, and Tks5, are recruited to enhance and maintain Arp2/3 activity in order to drive
membrane protrusion. Invadopodia maturation is characterized by subsequent recruitment and
localization of

MMPs, particularly MMP14, to sites of focalized ECM degradation

(74,76,87,89,91,95). One model suggests the following order of events for cortactin-mediated
invadopodia initiation (176). First, non-phosphorylated cortactin arrives at an actin filament, then
recruits N-WASp, Arp2/3 complex, and cofilin. Cortactin tyrosine phosphorylation releases cofilin
to begin severing F-actin, generating a localized increase in free barbed ends, and clearing a
docking site for Nck1 binding to cortactin. Nck1 recruits N-WASp into the trimolecular complex
described previously. Lastly, PTP1B dephosphorylates cortactin, releasing Nck1 and N-WASp
and inhibiting cofilin in order to stabilize the newly formed actin network. Invadopodia turnover is
necessary for efficient tumor cell invasion (177,178). Two mechanisms have been elucidated for
driving invadopodia disassembly, one involving Rac1-Trio-PAK1 signaling cascade and another
through RhoG activity. In the first pathway Trio, a Rac1 guanine exchange factor (GEF), activates
Rac1 which in turn activates PAK1 or PAK4 (165,178,179). PAK-dependent phosphorylation of
cortactin S113, S150 and S282 destabilizes invadopodia resulting in disassembly presumably
through decreased interaction between the cortactin RR and F-actin (152,178,179). The second
pathway involves RhoG-dependent paxillin Y31 and Y118 phosphorylation leading to calpain
activation (180,181). Calpain cleaves several ABPs including cortactin, talin, and WASp
15

destabilizing the invadopodia F-actin core leading to invadopodia disassembly (150,151,181–
183).
In addition to forming invadopodia actin networks, cortactin is also involved in endocytic transport
and secretion of various MMP cargoes at invadopodia. During endocytosis, the cortactin SH3
domain binds dynamin-2, linking the cortical actin cytoskeleton to the membrane severing
machinery around clathrin-coated vesicles (155,184–187). De novo cortactin-mediated actin
network formation initiates membrane invagination prior to membrane severing through
dynamin-2 (155,184–187). Following vesicle formation, cortactin and Arp2/3 complex remain
attached to a subset of vesicles where further actin polymerization propels newly formed vesicles
through the cytoplasm (188). RNAi-mediated cortactin reduction dramatically reduces MMP2 and
MMP9 secretion as well as MMP14 localization to invadopodia tips. Conversely, overexpression
of cortactin corresponds with increased MMP secretion (189,190).
CK2
CK2, previously misnamed casein kinase-2, is a ubiquitously expressed, highly conserved,
constitutively active serine/threonine kinase consisting of two catalytic subunits (α or α’) and two
β regulatory subunits (191–193). The CK2 holoenzyme exists as a heterotetrameric complex or
as lone catalytic subunits in cells. The complex is exclusively cytoplasmic, while the catalytic
subunits can be found in both the cytoplasm and nucleus (191,192,194–197). The regulatory
subunits play a role in substrate recognition as well as modulating catalytic function of the
holoenzyme (192,193,196,198,199). This is dissimilar to most heterotrimeric kinases in which the
regulatory subunit serves as a molecular switch, activating the catalytic subunit’s kinase activity.
Unlike most kinases, the CK2 catalytic subunit can facilitate phosphorylation utilizing either ATP
or GTP hydrolysis (191,195,198,200). CK2α contains two lobular domains with the catalytic site
residing at the interface between the domains (201,202). The constitutive activity arises from a
unique structure, leaving the activation segment and the third α helix (termed αC) permanently in
16

the active conformation (201,202). Additionally, human
CK2α subunits

exhibit

remarkable conformational

heterogeneity even when compared to evolutionarily
similar

orthologs

which

remain

sequentially

and

structurally similar (202). One recent study identified 5
distinct regions of conformational flexibility, a glycine-rich
p-loop, the β3/αC loop, the β4-β5 region, the Hinge/αD
Figure 4. CK2α flexible regions

region, and the αGH2 helix (201). The β4-β5 region

Crystal structure of CK2α bound to
CX-4945 (PDB ID 3PE1). Flexible
regions are shown in red. Portions
of CK2 are identified in color text.

mediates binding to the regulatory subunit, while the

Adapted from Figure 1 in
Srivastava et al. (2017) Proteins:
Structure, Function, and
Bioinformatics, 86(3), p.344-353.

representing “closed” vs. “open” conformations (201). As

glycine-rich p-loop and the Hinge/αD region confer
differences in access to the ATP binding pocket, therein

of yet, no functional role has been elucidated for the
β3/αC loop or the αGH2 helix. Due to its very general

recognition motif (S-X-X-E/D/pS/pT) CK2 is recognized as one of the most promiscuous kinases
in the genome with over 300 proposed substrates and more than 700 predicted CK2 phosphosites matching its recognition motif in the PhosphoSitePlus dataset (191,194). With the advent of
CRISPR/Cas9-mediated knockout technology, a recent study attempted to verify substrate
specificity for proposed CK2 targets, confirming 48 catalytic subunit regulated phospho-sites and
another 163 heterotetrameric complex regulated phospho-sites in C2C12 mouse myoblast cells
(194).
Despite its constitutive activity, CK2 appears to be regulated at the protein level rather than
transcriptionally (203,204). Early studies reveal intracellular shuttling between the nucleus and
cytoplasm and subcellular localization as the major regulatory mechanism in CK2-dependent
signaling (196,205–208). While holoenzyme shuttling between the nuclear and cytoplasm
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appears to be commonplace in normal cells, subunit specific responses have been noted in
various cancer cell models where nuclear CK2 is associated with a pro-survival phenotype
(203,207,209,210). One study found that Bcr-Abl mediated-CK2α phosphorylation suppresses
CK2 activity, which can reversed with PTP1B, demonstrating a post-translational regulatory
mechanism of CK2-mediated signaling networks (211).
CK2 is critical for maintaining cellular homeostasis, as minor changes in expression or nuclear
localization have robust effects on proliferation and cell viability (203,207,208,210,212–214).
Initial studies on CK2 signaling demonstrated enhanced activity and nuclear localization in
response to androgenic growth stimuli, whereas androgen depletion or decreased CK2
expression induced apoptosis (205,212,214,215). Additionally, CK2 modulates many canonical
cell proliferation signaling networks including the Wnt, EGFR, Ras, AKT, Hedgehog and
JAK/STAT pathways (216–220). CK2 mediates crosstalk between the Wnt and EGFR pathways
via Erk2-dependent CK2 phosphorylation. This results in inhibiting α-catenin phosphorylation and
promotes subsequent β-catenin translocation to the nucleus that drives glioblastoma invasion
(216). In some cases CK2 is required for downstream signal transduction, as demonstrated in
Hedgehog signaling where CK2 phosphorylates Smoothened and stabilizes Cubitus interruptus
(Ci) and JAK/STAT signaling necessary for JAK2-mediated STAT activation that is required for
expression of suppressor of cytokine signaling (SOCS)-3, both of which are necessary for tissue
homeostasis and repair as well as maintaining local stem cell populations (219,220). In other
cases CK2 merely enhances oncogenically driven proliferation as seen in H-Ras and AKT models
(217,218). Likewise, CK2 mediates many cell death signals, particularly responses to DNA
damage. CK2 directly modulates the DNA damage response pathway, phosphorylating BRCA1
C-terminal residues that are notably mutated in breast cancer to disable a key checkpoint in DNA
repair (221). Indirectly CK2 modulates the DNA damage response by phosphorylating several
tumor suppressor proteins including p53, structure-specific recognition protein (SSRP)1,
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promyelocytic leukemia gene (PML), and PTEN. This alters transcription and replication activity
within the nucleus (222–226). CK2α suppresses apoptotic signaling via a multitude of posttranslational modifications to apoptotic machinery including the PI3K/AKT pathway, survivin,
various inhibitors of apoptosis proteins (IAPs), caspases, the Bcl2 pathway, and the reactive
oxygen species response pathway (195,227). As further evidence of the pro-survival role of CK2,
impairment of CK2 signaling, either through removal of either CK2α or CK2β in mice or
simultaneous removal of CK2α and CK2α’ in yeast is lethal (192,195). The fine-tuning between
pro and anti-survival signaling is best demonstrated in retinal astrocytes, where CK2 expression
is necessary for neo-angiogenesis during development, while extended CK2 signaling ultimately
results in retinopathy (228,229).
CK2β is necessary for localizing the holoenzyme to the plasma membrane, where it
phosphorylates several ABPs including spectrin, ankyrin and adducin (200,230). Important to this
Dissertation, CK2 phosphorylates the cortactin homologue HS1 at an unidentified site in the
comparable NTA region, as well as residues near the DDW region in the Arp2/3 regulatory
proteins N-WASP and WAVE2 (231–235). There is conflicting evidence about the nature of CK2mediated phosphorylation surrounding the DDW motif in WASp family proteins. Phosphorylation
of the DDW flanking residues in WAVE/SCAR proteins impairs their ability to act as NPFs
(233,236).

Similarly,

CK2-mediated

phosphorylation

impairs

N-WASp

activity

while

simultaneously enhancing clathrin-mediated EGFR endocytosis (235). Contrary to these finding,
another study demonstrated that WASp phosphorylation by CK2 enhanced binding to and
activation of Arp2/3 complex (234). Work in this Dissertation indicates that CK2-dependent
cortactin NTA phosphorylation impairs binding to and activation of Arp2/3 complex (237). In
addition to modulating actin dynamics, CK2 also phosphorylates many microtubule associated
proteins including microtubule-associated protein (MAP)-1A, MAP-1B, MAP2, MAPτ, β-tubulin,
stathmin, and dynein. This is congruent with association of CK2 with the mitotic spindle in dividing
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cells (196,197,238–244). Collectively these data demonstrate a role for CK2 signaling having a
direct impact on the actin and tubulin cytoskeletons involved in cellular motility, mitosis, and
cytokinesis.
Given that CK2 influences many prominent pathways utilized during tumor initiation and
progression, it is not surprising that CK2 is overexpressed in a multitude of different cancer types
(191,195,204,227,245–247). Increased tumor cell CK2 expression correlates with transformation,
cell growth, cell cycle progression, cell survival, angiogenesis, and tumor cell motility, as well as
decreased apoptosis and drug resistance (191,195,203,227,245). One study identified CK2
among a 186-gene “invasiveness signature”, where enhanced expression correlates with
decreased overall and metastasis-free survival in medulloblastoma, lung, breast, and prostate
cancers (245,248). Specific to HNSCC, CK2 overexpression correlates with increased tumor
grade, stage, and clinical outcome as well as radio- and chemotherapy resistance (227,246,249–
252). CK2 is enriched at the invasive tumor front, primarily within tumor cells, cancer-associated
fibroblasts, and tumor-infiltrating lymphocytes. This implies that CK2 overexpression plays
important roles in tumor-associated inflammation, invasion, and metastatic progression
(251,253). With regards to directed cellular invasion, CK2 expression is critical for IL-6-driven
tumor cell chemotaxis (254). In addition, CK2 activity further enhances a tumor stem cell
phenotype and sphere formation, supporting an important a role in cancer progression and
disease recurrence (255).
While CK2 is not an oncogene in the traditional sense, modest increases in CK2 expression
enhance the tumorigenicity of other driver oncogenes in various transgenic mouse models
(195,247,256–259). In addition, CK2 directly phosphorylates several cancer-promoting
transcription factors including NF-κB, p53, TAp73, and Twist to promote a pro-malignant
phenotype (227,246,247,254–256,258). CK2 also phosphorylates IκBα and RELA to promote
IKKβ activity while simultaneously suppressing p53 expression at both the mRNA and protein
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levels (227,246,247). One study found that transgenic CK2 overexpression in mice leads to loss
of p53 expression, enhancing lymphoma onset (256). In a Tal-1-driven murine acute
lymphoblastic leukemia (ALL) model, CK2α co-overexpression enhanced tumorigenesis and
significantly decreased overall survival (258). Other studies found that CK2α overexpression
enhances Notch1, c-Myc and Wnt pathway component expression while modulating NF-κB
signaling, ultimately leading to tumorigenesis (247,259,260). Conversely CK2 impairment
decreases expression of β-catenin, c-Myc, CCND1, Bcl-XL, Integrins-α3,-α6,-β4, VEGF, Slug,
Snail, vimentin and Notch1 while increasing expression of p53,TAp63, TAp73 and E-cadherin
(227,247,255,259–261). CK2α expression (but not CK2β) is sufficient to confer drug resistance
in acute myeloid leukemia (AML) and osteosarcoma models (203). Similarly, increased CK2
activity is induced in prostate cancer cell lines upon treatment with cytotoxic agents and correlates
with resistance to apoptosis (214). Exogenous CK2α expression alone is sufficient to abrogate
drug-induced apoptosis in certain tumor cell lines (210,214). Collectively these studies support a
global role for CK2 in promoting and maintaining signaling necessary for oncogenic initiation and
progression.
Given the myriad signal transduction pathways enhanced through CK2 activity, CK2 has garnered
much interest as a drug target. This one target modulates cellular response to mitogenic signals,
inflammatory cytokines, apoptosis and cell survival as well as drug efflux pump efficiency,
angiogenic signaling, and tumor invasion and metastasis (195,203,227,229,247,262). Many
preclinical models have shown anti-cancer benefits using antisense and siRNA targeted CK2
reduction (195,213,227,261). Antisense oligodeoxynucleotides (ODN) against CK2 inhibits
growth and induces apoptosis in prostate cancer and HNSCC cell lines along with associated
xenografts (212,213,227,252,263,264). Tenfibgen nanocapsule-mediated anti-CK2 ODN delivery
exhibits high tumor specificity in vivo (195,213,263,264). Reduced CK2 expression resultant from
antisense ODN or RNAi treatment impaired HNSCC cell migration and invasion while
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simultaneously resensitizing HNSCC tumors and cell lines to cisplatin (227,261). Furthermore,
impaired CK2 signaling abrogates stem-like gene expression, clonal survival, and spheroid
formation (255,260).
While preclinical CK2 modulation studies continue to show promise, clinical trials targeting CK2
specific signaling have shown marginal benefit. Pharmacological CK2 inhibitors developed to date
include apigenin, CIGB-300, 2-Dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), 5,6dichloro-1-β-D-ribofuranosylbenzimidazole (DRB), emodin, hematein, Silmitasertib (also known
as

CX-4945),

4,5,6,7-tetrabromobenzotriazole

tetrabromophenyl)acrylic

acid

(TBCA),

and

(TBB),

quinalizarin,

(E)-3-(2,3,4,5-

6,7-dichloro-1,4-dihydro-8-hydroxy-4-[(4-

methylphenylamino)methylen]dibenzo[b,d]furan-3(2H)-one (TF). These compounds display
varying degrees of anti-tumor efficacy and enzyme specificity (191,262,264–276). Nearly all of
these CK2-targeted inhibitors are competitive ATP/GTP small molecules, inherently leading to
poor target specificity due to the inherent conservation of this pocket in the active sites of kinases
(262,277,278). CK2 pharmacological inhibition decreases proliferation in breast carcinoma and
lymphoma cell lines (247,259,279). Although CK2 inhibition as a single agent has shown limited
success, combination therapies with CK2 inhibitors show improved efficacy. One such study
demonstrated that CK2 inhibition in Imatinib insensitive Bcr-Abl-driven ALL reduced cell viability
and resensitized the surviving cell population to Imatinib treatment (279). Similarly, increased
apoptosis was found in prostate and colorectal carcinoma using CK2 inhibitors with doxorubicin
(278). CK2 inhibition also sensitizes colorectal carcinoma and rhabdomyosarcoma cells to TNFrelated apoptosis-inducing ligand (TRAIL)-mediated apoptosis (280,281). Likewise, CK2 inhibition
sensitizes HeLa cells to ionizing radiation (282). Cells within the tumor microenvironment similarly
rely on CK2 activity in response to various signals emanating from the tumor cells. CK2 inhibition
reduced endothelial cell migration and chemotaxis disrupting neoangiogenesis and hematopoetic
stem cell recruitment (229). These studies indicate that CK2 inhibition has limited utility as a single
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agent but may play an important role as a key component in combination therapies where
diminished CK2 activity abolishes a drug resistant phenotype.
To date, only two CK2 inhibitors have entered clinical trials: Silimitasertib and CIGB-300
(NCT01199718, NCT00891280, NCT02128282, NCT01639625, NCT01639638). Silmitasertib is
a benzonaphthyridine derivative that binds CK2α with high specificity that inhibits catalytic activity
at low concentrations (201). Crystal structure and computational modeling confirm that
Silmitasertib-bound CK2α exhibits the open conformation in the Hinge/αD region and a stretched
glycine-rich p-loop, confirming the ATP competitive nature of this inhibitor (201). Silmitasertib
treatment in murine glioma and breast cancer models blunts NF-κB, PI3K/AKT, and JAK/STAT3
signaling. This results in diminished cell cycle progression, cell viability, and cell migration
(246,283). Inhibitor studies in lung and prostate cancer models demonstrate significantly reduced
tumor cell proliferation (246,284,285). Silmitasertib treated HNSCC cell lines and xenografts
display decreased proliferation, increased cell death and loss of stem-like characteristics
(227,246,255). Silmitasertib resistance correlates with upregulated MEK-Erk1/2 signaling which
can be abrogated using PD-3025901, a selective MEK inhibitor (246).
CIGB-300 is a small peptide inhibitor that blocks CK2 phosphorylation sites at the CK2 substrate
phospho-acceptor site (265,286). CIGB-300 administration induces apoptosis in human cell lines
as well as in xenograft models (265,271). Phase I studies have found that intralesional CIGB-300
administration is well tolerated and resulted in cervical cancer patient tumor reduction, with some
patients experiencing full histological regression (265,286,287). Similar to previous CK2 inhibitor
studies, CIGB-300 synergistically enhanced paclitaxel and cisplatin treatment in human lung and
cervical cancer xenografts (288). While only a limited sample, these trials demonstrate promising
advances in patient treatment and an opportunity to overcome drug resistance to potentially
enhance the clinical standard of care for cancer patients.
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Patient-Derived Xenografts (PDXs)
Modeling human cancer and developing pharmaceutical interventions has largely been carried
out using cell lines in 2D culture or subcutaneous and orthotopic xenograft models with minimal
efficacy, with only 5-13.4% of promising preclinical trial drugs achieving success at the clinical
level (289–292). Cell line xenografts fail to recapitulate the tumor microenvironment, therein
limiting applicability to the human disease (32). In addition, in vitro cell culture methods select for
highly proliferative, pro-survival subclonal populations within the tumor, resulting in an artificially
increased cellular homogeneity than what is found in patient tumors (292).
Genetically engineered mouse models (GEMMs) allow for modeling tumorigenesis concurrent
with disease progression, evaluation of tumor-stroma interactions, and immune surveillance of
the tumor. These traits collectively allow for greater biological relevancy in these models than cellbased systems (293–295). GEMMs enable cancer researchers to induce tissue specific
alterations and temporally regulate specific factors to pinpoint critical stages in tumor onset and
progression that cannot be achieved using cell line xenografts (293,294). GEMM studies have a
variety of applications including validating oncogenic drivers, determining therapeutic responses,
and evaluating drug-resistance and disease recurrence in a manner that closely resembles the
human disease (293,295–298). However, GEMMs tend to be time consuming to generate, display
less tumor heterogeneity due to reliance on specific oncogenic drivers rather than chromosomal
instability and de novo DNA damage, and often fail to predict drug efficacy in heavily pretreated
patients (297,299–301). While GEMMs are better able to phenocopy the human disease, certain
genetic abnormalities found in human patients cannot be recapitulated in any mouse model due
to differences between species (296,301). This is particularly true when observing large
chromosomal amplification events common in human patients which have no genetic equivalent
in rodents.
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As an alternative to these systems, recent advances in generating immune-compromised mouse
strains have allowed for the ability of directly implant intact patient tumor tissue that can survive
in mice. These patient-derived xenografts (PDX) models maintain a greater degree of tumor
heterogeneity and recapitulate the majority of the genetic landscape found in the patient tumor,
thus providing a platform for precision oncology testing (300–307). Directly culturing tumors in
vivo maintains many conditions of the tumor microenvironment encountered in the patient,
including reduced oxygen levels, nutrient and hormone delivery, and tumor-stromal interactions
(32,293,305).
PDX development begins with direct patient tumor sample implantation into immunodeficient mice
which maintains many histological and genetic characteristics of the primary patient tumor (302–
304,306–308).

Patient samples for PDX work are typically obtained as either fine needle

aspirates (FNAs) or following surgical resection (305). Tumor samples are implanted in the
recipient mice as small tumor pieces or as a single-cell suspensions mixed with artificial ECM
and growth factors (299,303–307,309–311). Single-cell suspension is achieved by digesting
patient stroma with ECM-cleaving proteases and/or mechanical mincing of the tissue
(299,305,310–312). These suspension techniques expose tumor cells to harsh chemical and
mechanical challenges that reduce cell viability, leading to decreased tumor engraftment and
heterogeneity in the mouse (299). PDXs can be implanted or injected into heterotopic (typically
subcutaneous flank or subretinal space) or orthotopic sites (305,309,313). Site selection is
influenced by several factors including tissue size, the orthotopic organ (both size and
accessibility), and the goal of that individual PDX model (tissue expansion vs. modeling tumor
phenomenon vs. drug treatment evaluation) (305,312).
Engraftment success depends on a host of factors including inherent tumor aggressiveness,
histological grade, tumor composition, sample size, and preservation of endogenous tumor
signaling such as resistance to anoikis and apoptosis (299,302,308,310,313). Other extraneous
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factors can also impact engraftment including time (from surgical removal from the patient to
implantation in the mouse), tissue temperature, lack of continuous nutrient exposure, and
implantation location (299,311).
Nomenclature for PDX development and expansion varies between research groups but is
typically denoted using either F0, G0, or P0 for the initial implantation of patient tissue into the
mouse (299,305,313). Subsequent implantations following the P0 tumor growth add to the
number to indicate how many rounds of growth has occurred within the animal model (ex. P1, P2,
P3). A PDX is widely considered to be established and reliable upon reaching P3, assuming that
the tumor has not deviated from the characteristics of the primary patient sample (299,305,313).
At this point, PDX models are usually utilized for drug evaluations or tumor progression studies
rather than tissue expansion/PDX establishment that occurs during the first three passages
(299,305,313). Criteria for passaging the PDX tumor into the subsequent mouse are highly
variable due to differing Institutional Animal Care and Use Committee (IACUC) standards and
tumor monitoring techniques. Passaging is commonly performed when the tumor reaches ~1 cm
in the largest dimension. At this point, tumor tissue is removed, processed then reimplanted (313).
During tissue processing the tumor mass is broken down into small pieces, several of which may
be evaluated for tumor drift or utilized for deriving novel primary cell lines (305).
A critical step in establishing PDX tumors is avoiding host rejection of the tumor xenograft. This
is largely achieved using immunodeficient mouse models for tissue implantation (Table 1).
Immune compromised mice were first discovered by N.R. Grist in 1962, which were later
characterized by Dr. S.P. Flanagan as mice lacking functional T cells (314). In 1983 Bosma et
al. published the first severe combined immunodeficient (SCID) mouse model, showing deficiency
in functional B and T cell populations (315). Non-obese diabetic (NOD) mice developed to study
diabetes mellitus were soon discovered to contain several cellular immunological deficiencies,
including dysfunctional dendritic, macrophage, and NK cells (316). Crossing these two stains
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generated the first NOD/SCID mice capable of enhanced human tumor engraftment rates
compare to either prior line (317). Combining the NOD/SCID phenotype with IL2Rγnull (NSG) mice
further enhanced human tumor tissue engraftment and reduced incidence of spontaneous
lymphomas that frequently occur from implanted human tumors in the immune-permissive
environment (318). While additional immunocompromised mouse stains have been established,
none have achieved the widespread utilization of the stains described above (299,319). NSG
mice are currently the most commonly utilized model due to their combined adaptive and innate
immune response impairment resulting in improved tumor engraftment (299,305,313,318,320).
Tumor implantation in NSG mice shows also allows for prolonged survival of associated patient
tumor infiltrating lymphocytes (TILs) up to 9 weeks post implantation, allowing for short-term study
of patient immune response in this system (305,321). In order to further improve human tumor
engraftment, transgenic mice expressing human stem cell factor (SCF), granulocyte-macrophage
– colony stimulating factor (GM-CSF), and interleukin (IL)-3 in the NSG background have been
established and are termed NSG-SGM3 mice (322). These specific murine cytokines show little
cross-reactivity with their human ortholog receptors and have been attributed to poor engraftment
of human hematopoetic stem cells and leukemia xenografts, which is countered by the expression
of these human cytokines (322).

Mouse Strain
Nude

Modifications
No functional T
cells

Advantages
Allows for human tumor
engraftment, hairless
phenotype allows for easier
subcutaneous tumor
monitoring, radioresistant

SCID

No functional B
and T cells

NOD/SCID

No functional B
and T cells;
dendritic,
macrophage,

Higher allogeneic and
xenogeneic engraftment rate
than nudes (above), lacks
complement
Low dendritic, macrophage,
and NK cell activity, lacks
complement, engrafts
hematopoietic cancer cell lines
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Disadvantages
Lowest human tumor
engraftment rate,
functional B and NK
cells, T cell function
improves with age,
intact complement
Functional NK cells,
spontaneous
lymphoma
development
Radiosensitive, higher
rate of spontaneous
lymphoma
development

Rag2γnull

and NK cell
impairment
No functional B,
T, and NK cells

NSG

High human tumor
engraftment rate, low rate of
spontaneous lymphoma
development, radioresistant
Higher allogeneic and
xenogeneic engraftment rate
than all stains listed above,
low rate of spontaneous
lymphoma development, lacks
complement
Highest allogeneic and
xenogeneic engraftment rate,
low rate of spontaneous
lymphoma, maintains cytokine
sensitive tumor
subpopulations, lacks
complement

No functional B,
NK, and T cells;
dendritic cell
and
macrophage
impairment
NSG-SGM3
No functional B,
NK, and T cells;
dendritic cell
and
macrophage
impairment
Human SCF,
GM-CSF, and
IL-3 expression
Table 1. Immunocompromised mouse models

Functional dendritic
cells and
macrophages, intact
complement
Poor lymph node
development,
maintains tumor
stromal cells for a short
duration (~9 weeks),
radiosensitive
Poorly characterized,
slightly deficient lymph
node development,
radiosensitive

While these advances have increased human tumor engraftment in mice, they require the loss of
host immune surveillance. This makes such models unsuitable for studying tumor-immune
interactions. To reestablish proper immune system interactions without compromising
engraftment rates, current development in the field is centered on producing mice with a
humanized immune system. In these models, human CD34+ hematopoietic stem cells (HSCs) are
selected from bone marrow, cytokine-mobilized peripheral blood, or umbilical cord blood samples.
Cells are injected into an immunodeficient recipient mouse’s circulation to seed the marrow and
function as in the patient (318,323,324). Humanized mice express a wide array of immune lineage
cell subtypes and are fully capable of eliciting the expected immune response when challenged
(318,323). Not only do these models provide paracrine signaling factors lost in a standard PDX
model, they also provide tumor immune surveillance and can be utilized in cancer immunotherapy
preclinical studies.
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PDX models have been successfully established for many tumor types (299). Several HNSCC
PDX models exist, covering both HPV+ and HPV- subtypes (311,312,325–328). As seen in other
tumor PDX models, engraftment rates vary based on the tissue of origin (312). Surprisingly,
neither recurrence nor HPV status show any effect on PDX establishment, but these PDXs
recapitulate overall survival differences seen in such patients (311,312). The only factor that
appears to influence PDX engraftment is metastatic development in the patient prior to surgical
resection, but this is inconsistent across cohorts (311,325–327). Epigenetic marker analysis
shows that while tumor cell lines are significantly different from primary tumors, established PDXs
maintain identical methylation signatures to the primary tumor from which they are derived (329).
Preclinical studies demonstrate enrichment for resistance to cisplatin and susceptibility to
diaziquone in HNSCC PDXs, which correlates with p53 mutation and cyclin D1 amplification in
specific tumor samples (328,330). These data recapitulate findings from various HNSCC clinical
trials (331,332). One study showed PI3K enrichment in Cetuximab-resistant HNSCC tumors
which respond to PX-866, a PI3K inhibitor, treatment demonstrating predictive therapeutic
intervention based on genomic and proteomic markers (312).
Several studies have evaluated specific tumor subpopulations, seeking to identify the HNSCC
CSCs which are display enhanced tumor initiating capacity and drug resistance (307,310,333).
Establishing treatment modalities to target these distinct subpopulations is key in developing
second line therapies and preventing disease recurrence.
PDX models exhibit responses similar to the patient when exposed to clinical therapeutics
(302,334,335). The successful translation of PDX treatment to clinical efficacy prompted the
National Cancer Institute (NCI) to shift its drug screening program from an established panel of
cell lines to a PDX cohort (336). Likewise, the Novartis Institutes for BioMedical Research
published a large drug screening study utilizing a library of 1,075 PDX tumors (337). PDX
samples can be evaluated post-treatment to identify shifts in tumor expression that may provide
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additional insight towards secondary treatments (312,338). For instance, identifying an expanding
drug-resistant subpopulation susceptible to another chemotherapeutic agent that was previously
undetectable in the untreated sample provides a beneficial change in clinical intervention
(312,334,338,339). One study found that a drug-resistant tumor was addicted to the drug itself,
which regressed following treatment cessation (334). This same study also demonstrated that
periodic treatment, rather than continual dosing, delayed progress to drug-resistant disease and
prevented drug-reliant subpopulation development (334). Several studies have run co-clinical
trials where the patient and matched PDX are treated with identical therapeutics, with PDX
sample analysis allowing clearer observation of patient tumor alterations that can potentially shift
clinical intervention for that individual (340–343). This represents an initial foray into personalized
or precision medicine where the genomic and proteomic tumor characteristics govern patient
care, rather than conventional therapy where clinicians rely upon gross tumor characteristics
including tumor size, grade, and stage to determine patient treatment (339,344,345).
While PDXs represent an advance in characterizing and in preclinical testing of human tumors,
there are several limitations to this model. Not every tumor sample engrafts in the animal to form
a tumor. Some tumors that do engraft grow too slowly to allow time for clinicians to practically
adjust patient care. Additionally, mouse stromal cells quickly replace their human stromal
counterparts within the tumor and do not always mimic behaviors found in patient tumor tissue.
Similarly, alterations in drug metabolism, targeting, and tumor vascularity can confound PDX drug
responses. On the practical side, one must account for the increased cost associated with
immunodeficient mouse cohorts along with the time commitment to implant tumors, monitor
progress, and passage tissue into subsequent mice. Newly developed models such as the NSGSGM3 can alleviate some biological deficiencies but come at increased expense and/or shortened
therapeutic window. Despite these short comings, PDX preclinical and co-clinical trials enhance
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translational robustness to patient care and pave the way towards enhanced precision medicine
care in oncology.
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Abstract
Malregulation of the actin cytoskeleton enhances tumor cell motility and invasion. The
actin-binding protein cortactin facilitates branched actin network formation through
activation of the actin-related protein (Arp) 2/3 complex. Increased cortactin
expression due to gene amplification is observed in head and neck squamous cell
carcinoma (HNSCC) and other cancers, corresponding with elevated tumor
progression and poor patient outcome. Arp2/3 complex activation is responsible for
driving increased migration and extracellular matrix (ECM) degradation by governing
invadopodia formation and activity. While cortactin-mediated activation of Arp2/3
complex and invadopodia regulation has been well established, signaling pathways
responsible for governing cortactin binding to Arp2/3 are unknown and potentially
present a new avenue for anti-invasive therapeutic targeting. Here we identify casein
kinase (CK) 2α phosphorylation of cortactin as a negative regulator of Arp2/3 binding.
CK2α directly phosphorylates cortactin at a conserved threonine (T24) adjacent to the
canonical Arp2/3 binding motif. Phosphorylation of cortactin T24 by CK2α impairs the
ability of cortactin to bind Arp2/3 and activate actin nucleation. Decreased invadopodia
activity is observed in HNSCC cells with expression of CK2α phosphorylation-null
cortactin mutants, shRNA-mediated CK2α knockdown, and with the CK2α inhibitor
Silmitasertib. Silmitasertib inhibits HNSCC collective invasion in tumor spheroids and
orthotopic tongue tumors in mice. Collectively these data suggest that CK2α-mediated
cortactin phosphorylation at T24 is critical in regulating cortactin binding to Arp2/3
complex and pro-invasive activity, identifying a potential targetable mechanism for
impairing HNSCC invasion.
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Implications: This study identifies a new signaling pathway that contributes to enhancing
cancer cell invasion.
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Introduction
Cell invasion from the primary tumor is responsible for initiating the metastatic cascade
and increasing cancer lethality (1,2). Invasion is initiated in part through the action of
invadopodia, actin-based membrane protrusions produced by tumor cells that mediate
dissemination by degrading restrictive extracellular matrix (ECM) proteins through
enzymatic matrix metalloproteinase (MMP) activity (3). Invadopodia contain a central
filamentous (F-) actin core surrounded by an integrin-based adhesion ring complex that
anchors the structure to allow focal matrix degradation and tumor cell protrusion through
the basement membrane (4). Cortactin and actin-related protein (Arp) 2/3 complex are
essential protein components involved in invadopodia precursor core formation required
for

subsequent

MMP

recruitment

and

membrane

protrusion

(5,6).

Cortactin

overexpression is common in several cancer types including head and neck squamous
cell carcinoma (HNSCC), resulting in enhanced motility, invasion, and invadopodia
activity (7,8). Cortactin binding to Arp2/3 complex activates Arp2/3 actin nucleation
activity, enhancing cellular actin polymerization to form branched F-actin networks (6,8–
10). Cortactin also directly binds F-actin and bundles newly-formed filaments, providing
an overall stabilizing effect on the Arp2/3-F-actin network required for invadopodia
formation (5,6,11). Previous work has shown that a DDW motif within the cortactin Nterminal acidic (NTA) domain is central in mediating Arp2/3 activation and branched actin
network formation (7,12–14). This region is similar to the Arp2/3 binding motif found in
the Acidic region of the Verprolin, Central, Acidic (VCA) domain of the Wiskott-Aldrich
Syndrome protein (WASp)-family of Arp2/3 nucleation promotion factors (NPFs). While
the cortactin DDW motif is well established as the region responsible for Arp2/3 binding,
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post-translational or other modifications of amino acids in the NTA region that regulate
binding have not been reported. Tyrosine and serine phosphorylation of cortactin residues
in the carboxyl-terminal region are essential for invadopodia formation, cellular invasion,
and tumor metastasis through multiple mechanisms ultimately involving activation of
WASp NPFs (6,7,15–18). In addition, comprehensive phosphorylation site mapping by
mass spectroscopy has identified NTA phosphorylation sites in close proximity to the
DDW motif (19). This raises the possibility that phosphorylation of one or more of these
residues may serve to govern Arp2/3 binding and invadopodia function in invasive cancer.
Casein kinase (CK) 2 is a ubiquitously expressed, constitutively active serine/threonine
kinase consisting of two catalytic subunits (α or α’) and two β regulatory subunits (20).
Increased CK2 expression correlates with cell cycle progression, apoptosis resistance
and tumor cell motility in various cancers (20). Overexpressed CK2 enhances HNSCC
tumor cell motility (20). CK2 phosphorylates the cortactin homologue HS1 at an
unidentified site(s) in the NTA region (21), as well as residues near the DDW region in
the NPFs N-WASp and WAVE2 (22–25). Here we show that CK2 phosphorylation of
threonine (T) 24 in the cortactin NTA impairs binding to and activation of Arp2/3 complex.
Cortactin T24 and CK2 are required for efficient invadopodia formation and ECM
degradation activity in HNSCC cell lines. Treatment of established and primary HNSCC
cells with the selective CK2 inhibitor Silmitasertib impairs invadopodia function and
regional HNSCC invasion. These results identify a new mechanism of invadopodia
regulation that can be targeted to impair HNSCC invasion.
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Materials and Methods
Cell culture, lentiviral infection and transfection, siRNA
HNSCC cell lines OSC19 and UMSCC1 were acquired and maintained as described (26).
MDA1586 cells were obtained in March 2014 from Barbara Frederick (University of
Colorado, Denver, CO). All HNSCC lines were authenticated by STR profiling at the
University of Arizona Genetics Core in June 2017. PCR-based mycoplasma testing
(13100-01, Southern Biotech) was conducted on OSC19 and UMSCC1 lines in March
2015 and were free of contamination. The MDA1586 line was not tested for mycoplasma.
HEK293T/17 cells were obtained in April 2013 from Robert Wysolmerski (West Virginia
University, Morgantown, WV). NIH3T3 cells were obtained in June 2017 from Ivan
Martinez (West Virginia University, Morgantown, WV) and maintained for ≤10 passages.
These lines were not authenticated or tested for mycoplasma. Cells were propagated in
DMEM supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin for ˂ 6
months. OSC19 and UMSCC1 cells stably infected with pLKO.1-puro cortactin shRNA or
CK2α shRNA were generated by clonal puromycin selection following standard methods
(CSNK2A1: TRCN0000380839, TRCN0000027627; CTTN: TRCN0000040275).
UMSCC1 cells stably infected with pLU-Luc2 expressing luciferase were generated
following standard methods. Murine cortactin rescue OSC19 and UMSCC1 cells
containing cortactin shRNA stably infected with pLenti CMV Hygro cortactin constructs
were generated by subsequent clonal hygromycin selection. Complete cortactin
knockdown in OSC19 and UMSCC1 cells was achieved by transfection of cortactin-
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targeting siRNA (ON-TARGETplus SMARTpool L-010508-00-0020, Dharmacon) using a
Nucleofector I (Amaxa Biosystems).
Western blotting, antibodies and immunoprecipitation
Western blotting was conducted as described (27) and visualized with autoradiography
film (E3012, Denville Scientific) or captured by an Amersham Imager 600 (GE Healthcare
Bio-Sciences). Antibodies used were: anti-cortactin clone 4F11 (1 μg/ml, (26)), antipS473 AKT (#4060, 1:1000; Cell Signaling Technology), anti-panAKT (#2920, 1:1000;
Cell Signaling Technology), anti-β-actin (#8457, 1:1000; Cell Signaling Technology), antiCK2α (#2656, 1:500, Cell Signaling Technology), anti-DYKDDDK (FLAG) clone 2EL1B11 (MAB3118, 1:500, Millipore) and anti-Arp3 (#07-272, 1:500, EMD Millipore).
Immunoprecipitation was conducted from cells lysed in 50mM Tris Buffer pH 8.0 with
10mM EDTA and 1% NP-40 (28). Clarified lysates (1 mg) were incubated with 50 μl of
FLAG M2 affinity resin (A2220, Sigma-Aldrich) for 2 hours at 4°C. Immune complexes
were collected by centrifugation, washed twice with Tris buffer, separated by SDS-PAGE,
and Western blotted with antibodies as described above.
Gelatin degradation assay, invadopodia characterization and microscopy
Cells were plated on Oregon Green 488-conjugated gelatin (G13186, Invitrogen) coated
coverslips (29). In cases of inhibitor treatment, cells were allowed to attach for 1 hour,
then incubated for 12 or 24 hours with Silmitasertib (S2248, Selleckchem) as indicated.
Cells were rinsed in PBS, fixed with 10% buffered formalin (SF100-4, Fisher) and labeled
as described (29). Antibodies used were 4F11 (1:500) or anti-FLAG (1:500). Primary
antibodies were visualized using Alexa Fluor 647 conjugated goat anti-mouse secondary
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antibody (A21235, 1:500, Invitrogen). F-actin was visualized with rhodamine-conjugated
phalloidin (R415, 1:1000, Invitrogen). Coverslips were mounted using ProLong Gold
antifade with DAPI (P36935, Invitrogen). Images for quantifying gelatin degradation and
knockdown/rescue expression were acquired with a Zeiss Axio Imager Z2 epifluorescent
microscope equipped with an AxioCam MRm CCD camera and AxioVision software using
LD Plan-Neofluar 40X/0.6 Corr and Plan-Apochromat 63X/1.4 oil objectives (Carl Zeiss
Microscopy). Acquisition parameters were held constant within comparison groups.
Confocal images were acquired using a Zeiss Axio Imager Z1 LSM510 confocal
microscope with EC Plan-Neofluar 40X/1.30 and Plan-Apochromat 63X/1.4 oil objectives
and Zen2009 software (Carl Zeiss Microcopy). All representative images were level
adjusted to enhance contrast and brightness as needed and resized using Photoshop CC
2018 (Adobe Systems). Gelatin images were corrected for uneven illumination via
bandpass filtering using ImageJ software (NIH). Degradation and invadopodia formation
was quantified as described previously (29), with n ≥ 70 lentiviral infected or ≥ 100
inhibitor-treated cells evaluated for each condition. FLAG-stained control images were
thresholded against non-specific staining using ImageJ software. Cells above threshold
values were considered positive for rescue construct expression and used for
quantitation. For therapeutic treatments and RNAi stable cell lines, degradation and cell
areas were determined by Image J (NIH) on an individual cell basis. Data represent the
mean values normalized to control degradation area per cell area from at least 3
independent experiments. Invadopodia precursors were determined by colocalization of
actin and cortactin at sites lacking gelatin degradation. Active invadopodia were
determined by colocalization of actin, cortactin, and gelatin degradation. Data represent
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the mean from at least 3 independent experiments. Phase contrast images were acquired
using a Zeiss Axiovert 200M microscope equipped with an AxioCamMR CCD camera
using a Plan-Neofluar 10X/0.30 objective and AxioVision software (Carl Zeiss
Microscopy).
CK2α kinase assay
In vitro kinase assays were performed as described (30). Briefly, 0.25, 0.5, or 1 μg of
purified GST-WT or T24A cortactin NTA fusion proteins were incubated with 8 ng CK2α
(#14-445, Millipore) and 10 μCi 32Pγ-ATP (#NEG002A500UC, PerkinElmer) at 30oC for
10 minutes. Reactions were terminated with hot SDS sample loading buffer. Proteins
were visualized by autoradiography. Purified N-WASp GST-VCA (0.5 μg) and GST (1 μg)
were used as respective positive and negative controls.
In vitro cortactin phosphorylation binding assay
Purified WT or T24A cortactin proteins (2.5 μg) were bound to 4F11-conjugated protein
G magnetic beads (#10003D, Life Technologies). Immune complexes were incubated in
the presence or absence of activated CK2α (75 ng; #V4482, Promega) and ATP (500
nmoles, #BP413-25, Fisher Scientific) at 30oC for 15 minutes. Reactions were washed
twice with 10mM Tris pH 7.4, 150mM NaCl, 0.5mM EDTA. Complexes were washed once
with 10mM Tris pH 7.4, 10mM EDTA and incubated with 50 ng Arp2/3 complex (#RP01A, Cytoskeleton) at 4oC for 30 minutes. Following incubation, binding complexes were
washed once with 10mM Tris Buffer pH 7.4 with 25 mM NaCl, 10mM EDTA, 1% NP-40,
then boiled and Western blotted with antibodies against cortactin and Arp3.
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Actin polymerization assay
Actin polymerization experiments were conducted as described previously (31).
Reactions contained 2 μM actin (10% pyrene-labeled), 75 nM Arp2/3 complex, 100 nM
cortactin or 50 nM GST-VCA (#VCG03, Cytoskeleton), and/or varying amounts of CK2α
(#14-445, Millipore) as indicated. For reactions with CK2α, GST-VCA or cortactin mutants
were preincubated with CK2α and 500 nmoles unlabeled ATP for 15 minutes at room
temperature prior to addition to the actin polymerization reaction.
PDX-derived cell lines
Patient-derived xenograft (PDX) tumors and cell lines were established as described (32).
WVUSCC-AR2 and WVUSCC-AR5 were derived from surgical specimens of alveolar
ridge HNSCC in compliance with West Virginia University Institutional Review Board
approved protocol #1310105737A033. PDXs were developed in compliance with West
Virginia University Institutional Animal Care and Use Committee approved protocol #150302.6 by placing approximately 1mm tumor fragments into subcutaneous pockets in the
flanks of anesthetized 8-10 week old NOD/SCID-γ (NSG) mice. Tumor fragments were
overlayed with Matrigel (354234, Corning) and incisions were closed using wound clips.
Mice were weighed and monitored for tumor growth on a weekly basis. PDX tumors were
passed into new NSG mice and/or used to generate cell lines once tumors reached ~1
cm in greatest dimension.
For cell line derivation, PDX tumors were minced and digested in DMEM supplemented
with 20% FBS and 1 mg/mL collagenase IV (17104019, Gibco). Digested tissues were
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plated onto NIH 3T3 fibroblasts senesced with 4μg/mL mitomycin C (BP2531, Fisher) and
cultured in DMEM:F12 1:1 supplemented with 10% FBS, 400 ng/mL hydrocortisone
(H0888, Sigma), 50 μg/mL gentamycin (15750060, Gibco), 5 μM ROCK inhibitor (S1049,
Selleckchem), 0.5 ng/mL recombinant human epidermal growth factor (EGF) (PHG0311,
Gibco), and 10 ng/mL cholera toxin (C8062, Sigma). Both WVUSCC-AR2 and -AR5 were
derived in August 2017 and maintained for ≤10 passages. Derived lines were verified
using cytokeratin 14 staining (ab15462, Abcam). Neither STR profiling nor mycoplasma
detection was performed on these cell lines. Prior to utilization in gelatin degradation or
spheroid invasion assays, PDX derived cell lines were plated directly onto cell culture
dishes for 1-2 passages to remove the fibroblast population. Gelatin degradation and
spheroid invasion assays were performed in DMEM supplemented with 10% FBS.
In vitro tumor spheroid invasion
3D spheroid invasion assays were performed as previously described (26). 1x104
(OSC19) or 2.5x104 (UMSCC1 and WVUSCC-AR5) cells were plated into individual wells
coated with 1.5% noble agar for 24 h (UMSCC1) or 48h (OSC19 and WVUSCC-AR5) to
form spheroids. For each line, spheroids were collected, resuspended in 500 µL of 2
mg/mL rat tail collagen I (354236, Corning), and plated into individual wells of a 24-well
plate pre-coated with 400 µL solidified 2 mg/mL collagen I. Plates were incubated for 1 h
at 37oC, then overlayed with 1 mL DMEM supplemented with 10% fetal bovine serum and
1% penicillin-streptomycin containing DMSO or 10µM Silmitasertib. Spheroid invasion
was visualized at the indicated time points by phase contrast microscopy using a Zeiss
Axiovert 200M microscope equipped with an AxioCamMR CCD camera using a Plan66

Neofluar 5X/0.15 objective and Axiovision software (Carl Zeiss Microscopy). Maximal
radial distances for invaded cells were calculated using Axiovision software, with invasive
distance determined as the difference between the initial and final maximum radius for
each invaded spheroid.
Orthotopic tongue tumors and invasion analysis
Tongue tumor establishment was adapted from previous work (33). 2.5X104 luciferase
expressing UMSCC1 cells were injected into the tongues of 8-10 week old NSG mice
(purchased from the West Virginia University Transgenic Animal Core Facility). Mice were
maintained using transgenic dough diet (S3472, Bioserve) and weighed every 2-3 days.
Tumor growth was monitored by bioluminescent imaging using 150 mg/kg D-luciferin
(122796, Caliper Life Sciences) injected intraperitoneally, followed by in vivo whole-body
bioluminescence imaging using an IVIS Lumina-II system and Living Image 4.0 software
(PerkinElmer). Tumors were allowed to establish for one week, then mice were divided
equally into two groups based on approximate tumor size. Mice were given 50 mg/kg
Silmitasertib in DMSO or DMSO alone by oval gavage twice daily for three weeks. Mice
were subsequently euthanized, tongues excised, processed and stained for histological
analysis.
To quantify invasion parameters, whole tongue histological images were cropped to
encompass the tumor invasive front and analyzed using ImageJ. Images were processed
with the colour deconvolution 1.5 plugin using H&E or H&E2 presets. Resultant colour_1
images were 25% contrast enhanced before conversion into binary images. ROIs were
selected for particles above 15,000 pixel units and manually verified by overlay onto the
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original H&E image to remove artifacts. Invasive protrusions were defined as projections
at the leading edge of the tumor surrounded by stroma on three sides and identified on
the binary image using the polygon selection tool. Invasive distance was determined as
the difference between the farthest edge of the protrusion and the protrusion base.
Statistical analysis
Differences in mean values between groups were evaluated using Student’s or Welch’s t
test. Significance was determined at p < 0.05 utilizing GraphPad Prism 7 software. Error
bars represent +/- S.E.M.
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Results
Cortactin threonine 24 is required for Arp2/3 complex binding and activation
Phosphorylation of serine (S) 11, T13, and T24 in the murine cortactin NTA domain has
been reported (19). The proximity of these residues to the canonical Arp2/3 binding motif
consisting of amino acids 20-22 (DDW) has the potential to regulate Arp2/3 binding (Fig.
1A). To determine if these residues influence cortactin binding to Arp2/3, FLAG-tagged
murine cortactin constructs were generated that contained serine to alanine (S11A) and
threonine to alanine (T24A) phosphorylation-null mutations. T13 was not evaluated since
it is not conserved in human cortactin. Co-immunoprecipitation studies indicate that S11A
cortactin bound endogenous Arp2/3 at levels similar to wild-type (WT) cortactin, while
T24A cortactin failed to effectively bind Arp2/3 despite retaining the DDW binding motif
(Fig. 1B). Threonine to aspartic acid (T24D) phosphomimetic cortactin bound Arp2/3 at
reduced levels compared to WT (Fig. 1B). These data demonstrate that both the DDW
motif and T24 are required for optimal Arp2/3 complex binding. Furthermore, reduced
Arp2/3 binding resultant from the addition of negative charge at amino acid 24 (T24D)
suggests that phosphorylation may play a negative-regulatory role.
To assess the impact of T24 on Arp2/3 actin nucleation, recombinant human WT, ΔDDW,
and T24A cortactin proteins were expressed in bacteria and purified (Fig. 1C). When
evaluated in pyrene-labeled actin assembly assays, WT cortactin displayed slower
polymerization kinetics compared to the neuronal (N)-WASp VCA domain, whereas the
ΔDDW mutant failed to activate Arp2/3 as previously reported (Fig. 1D, (16,34,35)). T24A
cortactin demonstrated intermediate activity, with reduced nucleation levels compared to
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WT cortactin and increased nucleation compared to ΔDDW (Fig. 1D). Taken together
these data identify T24 in the cortactin NTA as a critical residue required for optimal
cortactin-mediated Arp2/3 binding and activation regardless of phosphorylation status.
Cortactin T24 is required for invadopodia-mediated ECM degradation
Cortactin is essential for initiating invadopodia formation, maturation, and ECM
degradation in part due to NTA-mediated Arp2/3 binding (36,37). To determine the role
of cortactin T24 in invadopodia function, a panel of cortactin knockdown-rescue cell lines
stably expressing FLAG-cortactin mutant constructs were produced in invasive UMSCC1
(Fig. 2) and OSC19 (Supplementary Fig. S1) HNSCC cell lines. Both lines spontaneously
produce invadopodia and degrade ECM (26,38). While individual cortactin siRNA
(siCTTN) and shRNA (shCTTN) treatment resulted in decreased cortactin expression and
matrix degradation in each case (Fig. 2D, Supplementary Fig. S1B, Supplementary Fig.
S2), sequential exposure to cortactin siRNA in stable shRNA cells resulted in efficient and
reliable cortactin knockdown (KD; Fig. 2, Supplementary Fig. S1, Supplementary Fig. S2).
Cortactin KD cells were used for subsequent experimentation to minimize the possibility
of residual endogenous cortactin masking the effects of re-expressed FLAG-cortactin
mutants. FLAG-WT cortactin expression in KD cells partially restored the amount of active
invadopodia formation in UMSCC1 cells (Fig. 2A & C) and fully restored ECM degradation
in UMSCC1 (Fig. 2A & B) and OSC19 (Supplementary Fig. S1A & C) cell lines. FLAGΔDDW enhanced invadopodia precursor formation but failed to rescue active invadopodia
and ECM degradation (Fig. 2A-C, Supplementary Fig. 1A & C). Similarly, both FLAGT24A and FLAG-T24D cortactin restored invadopodia precursor formation while failing to
induce invadopodia maturation above KD levels, with active invadopodia and ECM
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degradation levels for both mutants similar to that of FLAG-ΔDDW cortactin (Fig. 2A-C,
Supplementary Fig. S1A, C, D). These results suggest that Arp2/3 binding and activation
facilitated by cortactin T24 is required for effective cortactin-mediated invadopodia
formation and ECM degradation in HNSCC cells.
CK2 phosphorylation of cortactin T24 regulates interaction with Arp2/3 complex
The importance of T24 in Arp2/3 activation and invadopodia function, along with prior
identification of T24 as a cortactin phosphorylation site, led us to identify the kinase(s)
responsible for phosphorylating T24. Computational analysis of the sequences flanking
T24 was performed by seven independent predictive algorithms, six of which suggested
that CK2α had the highest probability of phosphorylating cortactin T24 (Supplementary
Table S1). To test this, kinase assays were conducted using GST-tagged cortactin WT
and T24A NTA fusion proteins with purified active CK2α. The N-WASp VCA domain was
used as a positive control, since previous studies have shown this region to be a CK2α
substrate (23,25). Increasing amounts of GST-WT-NTA were efficiently phosphorylated
by CK2α, whereas no phosphorylation was evident in GST-T24A-NTA (Fig. 3A). These
data indicate that cortactin T24 can serve as a CK2α substrate, and that T24 is the only
residue targeted by CK2α in the NTA region.
To determine if CK2α phosphorylation of cortactin T24 effects binding to Arp2/3 complex,
recombinant human WT or T24A cortactin proteins were pre-incubated with or without
CK2α, then mixed with purified Arp2/3. Phosphorylation of WT cortactin by CK2α reduced
binding of Arp2/3 complex to background levels (beads alone) whereas no impact on
T24A was observed (Fig. 3B). To ascertain the impact of CK2α phosphorylation on
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cortactin-mediated Arp2/3 activation, actin assembly assays were conducted with CK2αphosphorylated cortactin and N-WASp VCA domain. As previously determined, CK2α
phosphorylation of N-WASp VCA results in a modest reduction of Arp2/3 NPF activity
(black vs. grey, Fig. 3C, (25)). Similarly, WT cortactin incubated with increasing amounts
of CK2α prior to inclusion in polymerization assays resulted in a dose dependent
suppression of actin assembly, suggesting that CK2α phosphorylation impairs the ability
of cortactin to activate Arp2/3 complex (Fig. 3C). Although Arp2/3 can be activated by
direct phosphorylation from multiple kinases (39–41), CK2α had no direct effect on Arp2/3
activation (orange vs. pale green, Fig. 3C), suggesting that the inhibitory effect on Arp2/3
activity is due to phosphorylated cortactin in these assays. To determine if the CK2αtargeted T24 residue is responsible for the observed inhibitory effect on Arp2/3 activity,
polymerization assays were conducted with WT and T24A cortactin proteins following
incubation with CK2α. While CK2α inhibited the ability of WT cortactin to activate Arp2/3
complex (blue vs. red, Fig. 3D), preincubation of CK2α with T24A cortactin exhibited no
additional inhibitory effect on Arp2/3 nucleation activity (green vs. purple, Fig. 3D).
Collectively these data indicate that cortactin phosphorylation at T24 by CK2α reduces
the ability of cortactin to bind and activate Arp2/3 complex-mediated branched actin
network formation.
CK2α is required for optimal HNSCC invadopodia function
To determine if CK2α impacts invadopodia function, CK2α expression was stably
knocked down in OSC19 and UMSCC1 cells using anti-CK2α shRNAs targeting two
different regions in the CK2α transcript. Both shRNAs reduced CK2α expression to nondetectable levels in each cell line (Fig. 4A). Neither line expressed the alternative CK2α’
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isoform in control or CK2α knockdown cells (data not shown). CK2α knockdown in OSC19
cells reduced the level of active invadopodia by 71-88% and ECM degradation by 6373%, whereas knockdown in UMSCC1 cells reduced active invadopodia formation by 6892% and ECM degradation by 36-60% (Fig. 4B-D). While these data indicate that CK2αis a key mediator of invadopodia maturation and function, neither invadopodia formation
nor matrix degradation was entirely abolished. This would indicate that alternative
signaling pathways impinging on cortactin and other invadopodia proteins remain active
in the absence of CK2α expression.
The CK2α inhibitor Silmitasertib suppresses invadopodia function in HNSCC cells
Silmitasertib (CX-4945) is an orally bioavailable small molecule ATP-competitive inhibitor
that targets CK2α kinase activity and is currently undergoing clinical trials in multiple
cancer types (20) (NCT01199718, NCT02128282, NCT00891280). To determine the
impact of Silmitasertib on HNSCC tumor cell-mediated invadopodia formation and ECM
degradation, established HNSCC cell lines were treated with increasing Silmitasertib
concentrations and evaluated for effects on invadopodia activity and ECM degradation.
Dose-dependent decreases in ECM degradation were observed at concentrations above
0.5 μM in all evaluated HNSCC lines (Fig. 5A & B). The greatest impairment of gelatin
degradation was seen at 10 μM (Fig. 5A & B), comparable to effective CK2 specific
growth-inhibitory doses in several cancer cell lines (20,42). At this concentration, active
invadopodia formation was significantly diminished in OSC19 and UMSCC1 cells,
whereas MDA1586 cells displayed non-significant decreases (Fig. 5C). To determine if
the invadopodia inhibitory effect of Silmitasertib was directly due to altering CK2αmediated cortactin T24 phosphorylation, antibodies against phosphorylated cortactin T24
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peptides (pT24) were designed and purified. Attempts by two different commercial
vendors failed to generate a pT24-specific antibody (not shown). Therefore, we evaluated
the phosphorylation status of S473 (pS473) in AKT following Silmitasertib treatment as a
surrogate marker for drug efficacy, as this site is known to be phosphorylated by CK2α
(20). MDA1586 cells treated with 1 or 10 μM Silmitasertib had decreased pS473 AKT
after 24 hours, the same timeframe used in ECM degradation assays (Supplementary
Fig. S3). OSC19 and UMSCC1 cells had decreased pS473 AKT after treatment with 10
μM Silmitasertib for 12 hours, the time used for matrix degradation assays in these lines
(Supplementary Fig. S3).
The fact that CK2α phosphorylates multiple targets aside from cortactin (20) raises the
possibility that the inhibitory effect of Silmitasertib may be due to impairing
phosphorylation of additional proteins involved in invadopodia function. To determine the
extent of cortactin-specific CK2α phosphorylation in invadopodia-mediated ECM
degradation, UMSCC1 cells expressing FLAG-WT, -T24A, and -T24D cortactin were
treated with 1 µM Silmitasertib and evaluated for additional suppressive effects on matrix
degradation (Fig. 5D & E). Silmitasertib diminished ECM degradation in cells expressing
FLAG-WT cortactin by 51%, similar to the reduction observed in non-transfected cells
(Fig 5D vs B). Neither FLAG-T24A or FLAG-T24D expressing cells treated with
Silmitasertib demonstrated reductions in ECM degradation levels from baseline vehicletreated controls (Fig. 5D & E). While these results do not entirely negate alternative CK2dependent signaling pathways in invadopodia regulation, it does suggest that cortactin
T24 is the primary CK2α target in governing HNSCC invadopodia function.
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To evaluate the anti-invadopodia effect of Silmitasertib in more translationally-relevant
models, patient-derived xenografts (PDXs) were derived from a well- and a moderatelydifferentiated HNSCC surgical sample. PDX tumors maintained original patient tumor
architecture, displaying collective invasion and keratin pearls characteristic of
differentiated HNSCC (Fig. 6A). Primary cell lines derived from these PDX tumors form
invadopodia and spontaneously degrade gelatin within 24 hours (Fig. 6B). Both lines
exhibit tight colony morphology under cell culture conditions consistent with HNSCC lines
derived from epithelial HNSCC (Fig. 6B, (32,43)). Treatment of WVUSCC-AR2 and
WVUSCC-AR5 with Silmitasertib yielded similar results to those observed in established
lines, with gelatin degradation impaired 38-62% in WVUSCC-AR2 cells and 56-66% in
WVUSCC-AR5 cells at and above 0.5 μM (Fig. 6C & D). Similarly, 10 μM Silmitasertib
treatment suppressed active invadopodia by 76% in WVUSCC-AR2 and 91% in
WVUSCC-AR5 (Fig. 6E). Collectively these data indicate that CK2α kinase activity is
essential for maximal ECM degradation ability in HNSCC.
Silmitasertib inhibits HNSCC invasion
To determine if Silmitasertib impacts HNSCC invasion, we initially utilized a 3D in vitro
assay designed to model collective invasion typically observed in differentiated HNSCC.
Tumor spheroids generated from OSC19, UMSCC1 and WVUSCC-AR5 PDX lines were
embedded between layers of collagen I. WVUSCC-AR2 cells failed to form spheroids and
could not be used in this assay. Spheroids were treated with 10 µM Silmitasertib or vehicle
(DMSO) for 48 h (Fig. 7A & B). Silmitasertib significantly reduced 3D collective invasion
in all assayed lines (Fig. 7B). We next evaluated the ability of Silmitasertib to control
invasion in the tongues of mice harboring orthotopic tumors. Luciferase-expressing
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UMSCC1 cells injected into the tongues of NSG mice formed detectable tumors within
one week (Fig. 7C). Mice were divided into two groups containing similar tumor size as
determined by in vivo bioluminescence, with one group treated with vehicle and one with
Silmitasertib. Mice dosed twice daily for three weeks displayed a non-significant reduction
in tumor growth compared to controls, similar to previous single agent xenograft studies
(Fig. 7C, (20)). To negate potential bias due to unequal tumor size, four equivalent tumors
from each group were selected for further assessment. In-depth evaluation of tumor
margins from tongues excised after four weeks revealed alterations in invasive
characteristics of Silmitasertib-treated mice (Fig. 7D-I). Tumors in drug-treated mice had
a less ragged appearance at the invasive front, exhibiting shorter and smaller collective
cell protrusions into the tongue stroma compared to control mice (Fig. 7D-G). In addition,
tongues from Silmitasertib-treated mice had reduced perineural invasion of nerves
adjacent to the invasive front (Fig. 7H & I). No difference was seen in the size or invasive
distance of detached collective groups within the invasive front (Supplementary Fig. S4).
Collectively these data support a role for CK2α signaling in driving several pro-invasive
behaviors associated with poor patient outcome in HNSCC (2,44).
Discussion
Proteolysis of restrictive tissue barriers is essential to all steps in the metastatic cascade,
and increasing evidence indicates that the proteolytic activity of invadopodia is required
for invasive breaching of ECM barriers (1). Signals that govern invadopodia are dynamic
and highly regulated, requiring coordinated activity of several oncogenic pathways in
parallel to achieve maximal efficiency (1). Active assembly and turnover of cellular F-actin
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networks is required for initiating invadopodia formation and subsequent maturation,
involving recruitment and activation of membrane-bound and secreted MMPs to mediate
ECM proteolysis (1). Breakdown of existing F-actin networks, in conjunction with Arp2/3
activation in invadopodia, is responsible for actin network turnover necessary for
productive branched F-actin formation that drives membrane protrusion. Early
recruitment of cortactin is necessary for invadopodia initiation, where phosphorylation of
C-terminal tyrosines 421, 470, and 486, along with serines 405 and 418, occurs
downstream of growth factor and integrin signaling (45). These phosphorylation events
create binding sites for scaffolding platforms that recruit N-WASp and WAS protein family
member 2 (WASF2; WAVE2, WASp family Verprolin-homologous protein 2), ensuring
that activation of Arp2/3 is maintained throughout the invadopodia cycle (6). Cortactin
also recruits the F-actin severing protein cofilin to invadopodia, providing the necessary
machinery for cyclic actin network breakdown and regrowth during invadopod extension
(16). In addition to these important C-terminal functions, the ability of the NTA region to
directly bind Arp2/3 is also essential for invadopodia formation and ECM degradation,
presumably through direct Arp2/3 activation and prolonged stabilization of Arp2/3-F-actin
networks (10,16).
Regarding the ability of the cortactin NTA to bind Arp2/3, this study reveals two distinct
findings. First, that T24 is required for Arp2/3 binding, since mutation of this residue
ablates (A) or reduces (D) the association of cortactin with Arp2/3 in coimmunoprecipitation assays. T24 is two residues C-terminal to the well-defined DDW
Arp2/3 interaction motif that is conserved in other Arp2/3 NPFs (6). This places T24 in
close proximity to contribute to Arp2/3 binding. While the crystal structure of the cortactin
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NTA bound to Arp2/3 complex has not been reported, previous chemical crosslinking and
three-dimensional reconstruction studies indicate that the NTA region primarily binds the
Arp3 subunit in the complex, with the most N-terminal residues spanning the Arp2-Arp3
interface to contact the Arp2 subunit (Graphical abstract, (9,34)). Thus, T24 may
contribute essential hydrogen bonding with recipient polar residues near the basic side
chains on Arp3 involved in electrostatic binding to the acidic NTA residues. This concept
is supported by the requirement of W22 in the DDW motif for Arp2/3 binding, along with
the lack of an equivalent threonine in the VCA region of WASp proteins (16,34,35). While
T24A cortactin appears incapable of binding Arp2/3, it can activate Arp2/3 actin
nucleation in conditions where ΔDDW cortactin remains inactive (Fig. 1D). This may be
due to T24 having a lower affinity for Arp3 than the DDW region and/or the high cortactin
molar levels required to stimulate NPF activity in vitro. Nonetheless, the requirement for
cortactin T24 in invadopodia-mediated ECM degradation supports an essential biological
role for this residue in a non-phosphorylated context.
Secondly, our study shows that T24 phosphorylation serves to negatively regulate
cortactin binding to and activation of Arp2/3 complex (Fig. 3B-D). Addition of the
phosphate group to T24 likely imparts a steric and electrostatic disruption, preventing the
DDW and other interacting residues in the NTA from initiating and/or maintaining binding
to Arp3. Steric interference may be the predominant mechanism, since T24D cortactin
can bind Arp2/3 at reduced levels (Fig. 1B), indicating that negative charge alone is
insufficient to completely prevent Arp2/3 association. Phosphorylation of T24 therefore
serves to block the ability of cortactin to bind Arp2/3, similar to the regulation of the Arp2/3F-actin regulatory proteins coronin 1B and cofilin (46,47). While we did not determine if
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phosphorylation of T24 serves to release cortactin from existing Arp2/3-F-actin
branchpoints, phosphorylation of Arp2/3-bound cortactin T24 may be an additional
mechanism to dissociate cortactin from these regions. Such a mechanism could function
in facilitating breakdown and recycling of invadopodia Arp2/3-F-actin networks.
The ability of CK2α to phosphorylate cortactin T24 supports a wider role for this kinase in
actin regulation. Previous work identified T23 as a putative but unconfirmed CK2α
phosphorylation site in the NTA region of myeloid-cell specific cortactin homolog HS1
(21). In addition, CK2α phosphorylates two adjacent sites in the A domain of WASp family
proteins (22–25). These studies report conflicting results on Arp2/3 activity, with
phosphorylation of WASp enhancing and in N-WASp and WAVE2 inhibiting VCAstimulated Arp2/3-mediated actin polymerization. Our results with CK2α-phosphorylated
N-WASp VCA domain also shows an inhibitory effect on Arp2/3 activation (Fig. 3C),
suggesting that CK2α effects may be differential to specific WASp family proteins.
Cortactin T24A and T24D expression in KD HNSCC lines impairs active invadopodia
formation and subsequent ECM degradation (Fig. 2A-C, Supplementary Fig. 1A & C),
supporting in vitro evidence that T24 phosphorylation prevents Arp2/3 binding and
activation necessary for invadopodia activity. The importance of CK2α-mediated cortactin
T24 phosphorylation is further supported by the inability of Silmitasertib to further
suppress ECM degradation in cortactin T24A or T24D expressing cells (Fig. 5D & E).
CK2α-specific knockdown or pharmacologic inhibition in cells would therefore be
expected to reduce phosphorylation of cortactin and WASp family proteins, resulting in
net increased Arp2/3 activity as observed from in vitro studies. The fact that CK2α
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knockdown or kinase blockade also impairs invadopodia formation and function is
paradoxical but can be explained by cyclic CK2α phosphorylation and dephosphorylation
to regulate cortactin binding to and activation of Arp2/3 in invadopodia during maturation
and elongation. Dephosphorylation of cortactin T24 and WASp NPFs by unknown
phosphatases would enable these NPFs to promote Arp2/3 activation, actin
polymerization, and invadopodia activity. Following network breakdown during actin
turnover, CK2α phosphorylation would return NPFs to the inactive state to await the next
cycle of actin assembly. While similar cyclic regulation of Src and cofilin has been shown
to be essential for invadopodia function and provides support for this model (38,46),
confirmation of T24 phosphorylation within invadopodia leading to altered actin dynamics
along with identification of the T24 phosphatase are necessary to fully confirm this
proposed mechanism.
Locoregional control of HNSCC dissemination is problematic, where perineural invasion
and invasive metastatic spread to cervical lymph nodes accelerates patient decline
(44,48,49). Cortactin and CK2α expression are elevated in HNSCC and individually
correspond with poorer patient outcomes (7,20). CK2 knockdown and Silmitasertib
treatment in HNSCC cells has anti-proliferative and anti-metastatic properties in vitro and
in mice, providing support for the utility of Silmitasertib in HNSCC (20). The anti-invasive
effect of Silmitasertib shown here is likely due in part to disruption of the invadopodia actin
assembly through combined inhibition of multiple Arp2/3 NPFs. We note that T24
cortactin mutants, CK2α knockdown, and Silmitasertib treatment in HNSCC cells does
not completely abolish invadopodia formation, degradation activity or invasion. Activation
of invadopodial Arp2/3 NPFs through alternative scaffolding or lipid-based signaling
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pathways that can bypass CK2 inhibition can account for this residual activity (1).
However, our results indicate that CK2α inhibition by a single agent does significantly
impair collective HNSCC invasion. Given the current paucity of treatment options for
invasive HNSCC, combining Silmitasertib with additional drugs known to impair
invadopodia function by blocking additional invadopodia and motility pathways (8) has the
potential to provide novel treatment options for controlling invasive spread of late-stage
HNSCC harboring elevated cortactin and/or CK2 expression.
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Figure 1. Cortactin T24 is required for binding and activation of Arp2/3 complex.
A. Diagram representing cortactin functional domains. NTA, N-terminal acidic domain;
R1-R6, repeats regions with F-actin binding site indicated; Helix, alpha helical domain,
PRR, proline rich region; SH3, Src homology 3 domain. NTA domain with position of S11
and T24 in context of the DDW region is shown. B. Immunoprecipitation analysis of Arp2/3
binding to cortactin NTA mutants. HEK 293T/17 cells transfected with FLAG-empty vector
(EV), FLAG-wild-type cortactin (WT) or the indicated FLAG-cortactin mutants. Immune
complexes were Western blotted with antibodies against cortactin (top) and Arp3
(bottom). 1:10 diluted total cell lysates were Western blotted as indicated. C. Coomassie
blue staining of the indicated purified recombinant human cortactin proteins. D. Effect of
cortactin T24A on Arp2/3 complex activation. Fluorometric evaluation of actin
polymerization over time with the indicated cortactin mutants incubated with Arp2/3
complex and pyrene-labeled actin. Polymerization curves: WT cortactin (blue); T24A
cortactin (dark green) and ΔDDW cortactin (purple). N-WASp VCA domain (black) was
used as a positive control; negative controls include Arp2/3 complex plus actin (pale
green) and actin alone (red). Polymerization curves are representative from three
independent experiments.
Figure 2. T24 is required for cortactin-mediated invadopodia formation and ECM
degradation in HNSCC cells.
A. UMSCC1 cells with stable shRNA scramble control (Ctl) or anti-cortactin shRNA
combined with siRNA knockdown (KD) were transduced with murine FLAG-WT, -ΔDDW,
-T24A and -T24D cortactin lentiviruses. Cells were plated on Oregon Green (OG)-488
gelatin coated coverslips for 12 hours, fixed, and labeled with anti-FLAG and rhodamine
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phalloidin (Actin). Gelatin panels are pseudo-colored white; degradation is evident as
black areas indicating loss of fluorescence. Scale bar represents 20 μm. Insets in WT
Cttn panel display invadopodia precursors (top right, yellow arrows) and active
invadopodia (bottom left, yellow arrowheads). Inset scale bar represents 1 μm. B.
Quantification of gelatin matrix degradation for control (Ctl), cortactin KD and FLAGcortactin expressing UMSCC1 cells. C. Quantification of invadopodia precursors (left) and
active invadopodia (right) numbers from the lines assayed in (B). Data represents the
mean + S.E.M. of n ≥ 100 cells for each line analyzed from at least three independent
experiments. All gelatin degradation conditions were normalized to Ctl UMSCC1 cells.
n.s., not significant; *, P ˂ 0.05, Welch’s or Student’s t test vs. Ctl (B & C), †, P <0.05,
Student’s t test vs. wild type cortactin rescue (WT) (C). D. Total cell lysates from (A)
evaluated for endogenous and FLAG-cortactin expression by immunoblotting with
antibodies against cortactin (top) and β-actin (bottom).
Figure 3. CK2α phosphorylation of cortactin T24 inhibits Arp2/3 complex binding
and activation.
A. Cortactin T24 is a CK2α phosphorylation site. Autoradiogram of active CK2α incubated
with the increasing amounts (0, 0.25, 0.5, and 1 μg) of GST-WT-NTA or GST-T24A-NTA
cortactin fusion proteins. GST (1 μg) and the GST-VCA domain of N-WASp (0.25 μg)
were used as respective negative and positive phosphorylation controls. Positions of
autophosphorylated CK2α, GST-VCA and cortactin NTA proteins are indicated on the left;
autoradiogram is representative of three independent experiments. B. CK2α
phosphorylation at cortactin T24 ablates binding to Arp2/3 complex. Purified recombinant
human WT and T24A cortactin proteins (2.5 μg) were bound with an anti-cortactin
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antibody to protein G beads. Immune complexes were preincubated with or without 75 ng
active CK2α, washed and incubated with 50 ng purified Arp2/3 complex. Coimmunoprecipitated complexes were Western blotted for cortactin (top) and Arp3
(bottom). 4F11-bound protein G beads were used as a negative control for non-specific
binding (Beads). Arp2/3 complex (5 ng) was used as positive control for Arp3
immunoblotting. Blot is representative of two independent experiments. C. Cortactin
phosphorylation by CK2α inhibits cortactin-mediated Arp2/3 actin polymerization. WT
human cortactin or GST-VCA proteins were preincubated with the indicated amounts of
active CK2α and evaluated for effects on Arp2/3 activity. Polymerization curves are
representative from three independent experiments. D. Phosphorylation of T24 is
responsible for the inhibitory effect of CK2α on cortactin-mediated Arp2/3 activation.
Human WT and T24A cortactin proteins were preincubated with or without 30 ng active
CK2α and evaluated for effects on Arp2/3-mediated actin assembly. Polymerization
curves are representative from three independent experiments.
Figure 4. CK2α is required for optimal HNSCC invadopodia function.
A. Evaluation of CK2α expression in stable scramble control (Ctl) and CK2α shRNA
HNSCC cells. Cells were lysed and Western blotted with antibodies against CK2α (top)
and β-actin (bottom). B. Representative confocal images of OSC19 and UMSCC1 cells
with Ctl shRNA and with each anti-CK2α shRNA (shCK2α #1 and #2). Cells were plated
on OG-488 gelatin coverslips for 12 h then labeled with an anti-cortactin antibody and
rhodamine phalloidin (Actin). Gelatin is pseudo-colored white. Scale bar represents 20
μm. C. CK2α knockdown decreases invadopodia-mediated ECM degradation.
Quantification of matrix degradation area per cell area for Ctl and each anti-CK2α shRNA
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in the indicated cell lines. Degradation data was normalized to Ctl condition for each cell
line. D. CK2α knockdown decreases invadopodia numbers. Amount of invadopodia
precursors (left) and active invadopodia (right) per cell is shown for control and shCK2α
OSC19 and UMSCC1 cells. Data in C and D represents the mean + S.E.M. of n ≥ 100
cells analyzed from at least three independent experiments. n.s., not significant; *, P ˂
0.05, Welch’s t test vs Ctl.
Figure 5. Silmitasertib-mediated CK2 inhibition reduces invadopodia function in
established HNSCC cell lines.
A. Representative confocal images of MDA1586, OSC19, and UMSCC1 cells plated on
OG-488 gelatin coverslips for 1 hour before treatment with vehicle (DMSO) or 10 µM
Silmitasertib for 24 hours (MDA1586) or 12 hours (OSC19 & UMSCC1) (optimal ECM
degradation times for each line). Cells were fixed and labeled with an anti-cortactin
antibody and rhodamine phalloidin (Actin). Gelatin is pseudo-colored white. Scale bar
represents 20 μm. B. CK2α inhibition decreases invadopodia-mediated ECM
degradation. Quantification of gelatin matrix degradation area per cell area in HNSCC cell
lines treated with the indicated Silmitasertib concentrations. C. CK2α inhibition decreases
invadopodia numbers. Amount of invadopodia precursors (left) and active invadopodia
(right) per cell is shown for Silmitasertib treated HNSCC cell lines. Degradation data was
normalized to DMSO-treated (0) cells for each cell line. Data in B and C represents the
mean + S.E.M. of n ≥ 100 cells analyzed from at least three independent experiments.
n.s., not significant; *, P ˂ 0.05, Welch’s or Student’s t test vs DMSO for each cell line. D.
Quantitation of gelatin matrix degradation area per cell area for UMSCC1 cells expressing
FLAG-WT, T24A or T24D cortactin treated with DMSO or 1μM Silmitasertib. Data
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represents the mean + S.E.M of n ≥ 75 cells analyzed from at least three independent
experiments. n.s., not significant; *, P ˂ 0.05, Welch’s or Student’s t test vs DMSO for
each condition. E. Representative confocal images of UMSCC1 cells expressing FLAGWT, T24A, or T24D cortactin plated on OG-488 gelatin coverslips for 1 hour before
treatment with vehicle (DMSO) or 1 µM Silmitasertib for 12 hours. Cells were fixed and
labeled with an anti-FLAG antibody and rhodamine phalloidin (Actin). Gelatin is pseudocolored white. Scale bar represents 20 μm.
Figure 6. Silmitasertib inhibits invadopodia function in HNSCC PDX cells.
A. Establishment of HNSCC patient-derived xenograft (PDX) tumors. Hematoxylin and
eosin stained patient tumor tissue and PDXs. Patient tumors were from the alveolar ridge
(AR). Scale bar represents 200 μm. B. Invadopodia formation in HNSCC PDX cells.
Representative confocal images of WVUSCC-AR2 (AR2) and WVUSCC-AR5 (AR5) PDX
cell lines. Cells were plated on OG-488 gelatin coverslips for 24 hours and labeled with
an anti-cortactin antibody and rhodamine phalloidin (Actin). Gelatin is pseudo-colored
white. Scale bar represents 20 μm. 10X representative phase contrast images (Phase) of
each line are shown on the right. Scale bar represents 100 μm. C. Confocal images of
WVUSCC-AR2 and WVUSCC-AR5 cells plated on OG-488 gelatin coverslips, allowed to
attach for 1 hour, then treated with vehicle (DMSO) or 10 µM Silmitasertib for 24 hours.
Cells were labeled with an anti-cortactin antibody and rhodamine phalloidin (Actin).
Gelatin is pseudo-colored white. Scale bar represents 20 μm. D. CK2α inhibition
decreases invadopodia-mediated ECM degradation in PDX derived cell lines.
Quantification of matrix degradation area per cell area for WVUSCC-AR2 and WVUSCCAR5 PDX cell lines treated with the indicated Silmitasertib concentrations. Degradation
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data was normalized to DMSO-treated cells for each cell line. E. CK2α inhibition
decreases invadopodia numbers in PDX derived cell lines. Determination of amount of
invadopodia precursors (left) and active invadopodia (right) in WVUSCC-AR2 and
WVUSCC-AR5 cells. Data represents the mean + S.E.M. of n ≥ 100 cells analyzed from
at least three independent experiments. *, P ˂ 0.05, Welch’s t test vs DMSO for each cell
line.
Figure 7. Silmitasertib impairs collective invasion in HNSCC.
A. Representative phase contrast microscopy images of OSC19, UMSCC1 and
WVUSCC-AR5 tumor cell spheroids embedded in collagen I (0 h) then incubated in
complete media containing 10 μM Silmitasertib or vehicle (DMSO) for 48 h. Red circles
indicate the maximum radial distance at indicated time points. Scale bar represents 100
μm. B. Quantitation of maximal collective invasive distance of each cell line at 48 h with
vehicle (0) or Silmitasertib (10 μM). Data represents the mean + S.E.M. of n ≥ 10
spheroids per cell line and condition analyzed from at least three independent
experiments. *, P ˂ 0.05, Welch’s or Student’s t test vs DMSO. C. Effect of Silmitasertib
on HNSCC orthotopic tumor growth. Bioluminescent monitoring of UMSCC1 cells
orthotopically injected into tongues of NSG mice. Tumors were allowed to establish for
one week prior to administration of Silmitasertib or equal volume vehicle (DMSO). Data
represent means +/- S.E.M. from two independent experiments. DMSO, n = 9 mice;
Silmitasertib, n = 7 mice. n.s., not significant; Student’s t test vs DMSO. D. Silmitasertib
inhibits orthotopic HNSCC invasion. Representative hematoxylin and eosin stained
invasive front of orthotopic UMSCC1 tongue tumors from mice receiving Silmitasertib or
vehicle (DMSO) for three weeks. Black lines show tumor-encompassing RIO borders
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determined by software analysis. Black box in DMSO tumor indicates the invasive
protrusion shown in F. White box in DMSO tumor denotes region containing perineural
invasion (PNI) shown in I. Black arrow indicates direction of invasion toward tongue base.
M, skeletal muscle; T, tumor. Scale bar represents 100 μm. E. Invasive distance of tumor
protrusions from mice treated with Silmitasertib or vehicle (DMSO). Data represent the
mean + S.E.M. of two serial sections from N = 4 tumors; n = 34 protrusions per condition.
*, P ˂ 0.05, Student’s t test vs DMSO. F. Representative image of an invasive protrusion
from vehicle-treated mice shown in the black box in D. The protrusive region was traced
in black to denote the tumor protrusion from surrounding muscle-containing stroma. M,
skeletal muscle; T, tumor protrusion. Scale bar represents 100 μm. G. Area of invasive
protrusions from mice treated with Silmitasertib or vehicle (DMSO). Data represent the
mean + S.E.M. of two serial sections from N = 4 tumors; n = 34 protrusions per condition.
*, P ˂ 0.05, Welch’s t test vs DMSO. H. Percentage of lingual nerves displaying PNI in
tumors from mice treated with Silmitasertib or vehicle (DMSO). Data represent the mean
+ S.E.M. of two serial sections from N = 4 tumors; n ≥ 60 nerves per condition. *, P ˂
0.05, Student’s t test vs DMSO. I. Representative image of PNI shown in the white box in
the DMSO-treated mouse in D. N, nerve; T, tumor cells. Scale bar represents 50 μm.
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Supplementary Materials
Supplementary Figure S1. T24 is required for optimal OSC19 invadopodia function.
A. Representative epifluorescent images of OSC19 cells with stable shRNA scramble
control (Ctl) or anti-cortactin shRNA combined with siRNA knockdown (KD) transduced
with murine FLAG-WT, -ΔDDW, -T24A and -T24D cortactin lentiviruses. Cells were plated
on Oregon Green(OG)-488 gelatin coated coverslips for 12 hours, fixed, and labeled with
anti-FLAG and rhodamine phalloidin (Actin). Gelatin panels are pseudo-colored white;
degradation is evident as black areas indicating loss of fluorescence. Scale bar
represents 20 μm. B. Total cell lysates from (A) evaluated for endogenous and FLAGcortactin expression by immunoblotting with antibodies against cortactin (top) and β-actin
(bottom). C. Quantification of gelatin matrix degradation for cortactin KD and FLAGcortactin expressing OSC19 cells. Data represents the mean + S.E.M. of n ≥ 100 cells for
each line analyzed from at least three independent experiments. All conditions were
normalized to control (Ctl) OSC19 cells. n.s., not significant; *, P ˂ 0.05, Welch’s t test vs.
Ctl. D. Representative epifluorescent images of UMSCC1 cells stably expressing shRNA
scramble control (Ctl) or murine FLAG-WT, -ΔDDW, -T24A and -T24D cortactin
lentiviruses plated on Oregon Green(OG)-488 gelatin coated coverslips for 12 hours,
fixed, and labeled with anti-cortactin or anti-FLAG and rhodamine phalloidin (Actin), as
indicated. Gelatin panels are pseudo-colored white; degradation is evident as black areas
indicating loss of fluorescence. Scale bar represents 20 μm. Insets denote invadopodia
precursors (yellow; top right corners) and active invadopodia (magenta; bottom left
corners). Invadopodia precursors comprise cortactin and actin puncta lacking associated
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gelatin degradation (yellow arrowheads). Active invadopodia contain cortactin and actin
with associated gelatin degradation (magenta arrowheads). Inset scale bar represents 2
μm.
Supplementary Figure S2. Effects of stable and transient cortactin knockdown on
HNSCC invadopodia function.
A. Representative epifluorescent images of OSC19 cells with stable scramble shRNA
control (Ctl), anti-cortactin siRNA knockdown (siCTTN), anti-cortactin shRNA knockdown
(shCTTN), or both shRNA and siRNA cortactin treatment (KD). Cells were plated on OG488 gelatin coverslips for 12 hours and labeled with an anti-cortactin antibody and
rhodamine phalloidin (Actin). Gelatin is pseudo-colored white. Scale bar represents 20
μm. Effects of each knockdown condition on cortactin expression are found in the
indicated RNAi lanes of the Western blot in Supplemental Figure S1B. B. Quantification
of matrix degradation area per cell area for the indicated OSC19 cell lines. All conditions
were normalized to control OSC19 gelatin degradation (Ctl). Data represents the mean +
S.E.M. of n ≥ 100 cells per condition analyzed from at least three independent
experiments. Ctl and KD conditions are identical to those displayed in Supplemental
Figure S1. C. Representative epifluorescent images of UMSCC1 cells with stable
scramble control (Ctl), cortactin siRNA knockdown (siCTTN), cortactin shRNA knockdown
(shCTTN), or both RNAi conditions (KD). Cells plated on OG-488 gelatin for 12 hours
were labeled with an anti-cortactin antibody and rhodamine phalloidin (Actin). Gelatin is
pseudo-colored white. Scale bar represents 20 μm. Cortactin expression for the indicated
RNAi lanes of the Western blot are shown in Figure 2D. D. Quantification of matrix
degradation area per cell area for the indicated UMSCC1 cell lines. Conditions were
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normalized to control (Ctl). Data represents the mean + S.E.M. of n ≥ 100 cells per
condition analyzed from at least three independent experiments. Ctl and KD conditions
are identical to those displayed in Figure 2.
Supplementary Figure 3. Silmitasertib inhibits CK2-dependent phosphorylation.
HNSCC cells incubated with 0, 1 or 10 μM Silmitasertib for 24 hours (MDA1586) or 12
hours (OSC19 and UMSCC1) were lysed and evaluated for CK2α inhibition by Western
blotting with antibodies against phospho-serine 473 AKT (pS473; top), pan AKT (middle),
and β-actin (bottom).
Supplementary Figure 4. Silmitasertib treatment does not impact collective
invasive groups at the tumor invasive front.
A. Quantitation of invasive distance and B. area of collective invasive group in tumors
from mice treated with Silmitasertib or vehicle (DMSO). Data represent the mean + S.E.M.
of two serial sections from N = 4 tumors, n ≥ 54 collective groups per condition. n.s., not
significant; Welch’s t test vs DMSO.
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Supplemental Materials and Methods
Plasmid constructs
FLAG-tagged murine cortactin expression constructs were generated as described (1).
Briefly, murine cortactin cDNAs were PCR amplified as XbaI-SalI fragments and
subcloned into XbaI-SalI digested pLenti CMV GFP Hygro (#17446, Addgene). GSTtagged full length and NTA human cortactin and N-WASp VCA expression constructs
were generated as before (2). Full length human cortactin cDNAs were PCR amplified as
ClaI-BglII fragments and subcloned into ClaI-BglII digested pGST-parallel2. Purification
of recombinant proteins were performed as before (3), with GST tags removed by AcTEV
protease (#12575015, Invitrogen). The pLU-Luc2 lentiviral vector was obtained from
Elena Pugacheva (West Virginia University, Morgantown, WV).
Tissue sectioning, staining and microscopy
HNSCC patient and PDX tissue samples were fixed in 10% neutral-buffered formalin and
paraffin embedded (FFPE). Extracted orthotopic tongue tumors were frozen in O.C.T.
media (4583, Scigen) using a HM 525 cryostat (Thermo Scientific). For patient tissue
blocks, five micron sections were cut and dried onto charged glass slides at 60-65oC for
30 minutes. Slides were washed three times in xylene (#8400-1, Statlabs) for two minutes
each, rinsed in 100%, 95%, and 80% ethanol (#7100-1, Statlabs) sequentially for 20
seconds each, rinsed with distilled water twice for 10 seconds each, then incubated in
hematoxylin (#7211, Richard Allan Scientific) for 90 seconds. Slides were washed twice
in distilled water for 20 seconds each, then incubated with bluing solution (0.3%
ammonium hydroxide, A669-212, Fisher Scientific) for 10 seconds and rinsed twice in
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distilled water for 20 seconds. Slides were washed with acid alcohol solution (0.1%
hydrochloric acid in 70% ethanol, A144-212, Fisher Scientific), twice with distilled water
for 1 minute, then with 80% ethanol for 10 seconds. Slides were incubated in eosin
(#3801600, Lieca Biosystems) for 15 seconds, washed twice with 95% ethanol, three
times with 100% ethanol, then three times with xylene for 20 seconds. Slides were
mounted using a Tissue-Tek SCA coverslipper (Model 4764, Sakura).
For PDX tumors, FFPE sections were incubated three times in microwave-heated xylene
for 3 minutes each. PDX tumor and orthotopic tongue tumor sections were washed thrice
in 100% ethanol, then once in 96% ethanol for 1 minute. Samples were washed with
distilled water, incubated with hematoxylin for 30 seconds, rinsed with water for 1 minute,
then with 96% ethanol. Slides were subsequently incubated with eosin for 2 minutes,
washed with water for 10 seconds, then rinsed in 96% ethanol. Slides were washed with
100% ethanol, followed by three 1 minute xylene washes. Slides were dried and mounted
with glass coverslips using Permount (SP15-500, Fisher). Histological images were
acquired with an Olympus VS120 Virtual Slide microscope with a UPlanSApo 20X/0.75
objective using VS-ASW-S6 software (Olympus Corporation).
Predictive analysis of human cortactin T24 phosphorylating kinases
The 84 amino acid sequence containing the entire human cortactin NTA domain was
evaluated for potential phosphorylating kinases targeting the T24 site using the publicly
available web-based programs ScanSite 2.0 (4), Minimotif Miner (5), PhosphoMotif finder
(6), NetPhosK 1.0 (7), GPS 2.0 (8), PPSP (9) and KinasePhos (10). Potential kinases
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were ranked by frequency based on the number of different programs identifying the
same kinase and are displayed in Supplementary Table S1.
Tumor invasive group characterization and quantitation
Collective groups were defined as independent groups of tumor cells that were
discontinuous with the main tumor mass and progressed towards the base of tongue.
Invasive distance represents the difference between the farthest edge of the collective
group and the nearest border of the primary tumor mass. Quantitation of these groups
was carried out as described for tumor invasive protrusions in the Materials and Methods.
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Supplemental Table S1. Predictive analysis of human cortactin T24 phosphorylating
kinases
Phospho
Minimotif
Kinase
ScanSite
Motif
NetPhosK
GPS
PPSP
KinasePhos
Miner
finder
CK2
X
X
X
X
X
X
CK1
X
X
GRK
X
X
X
DNA-PK
X
PKB
X
Protein
Sequence:
MWKASAGHAVSIAQDDAGADDWETDPDFVNDVSEKEQRWGAKTVQGSG
HQEHINIHKLRENVFQEHQTLKEKELETGPKASHGY
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Abstract
Although overall cancer incidence rates are declining across the United States, the incidence of
head and neck squamous cell carcinoma (HNSCC) continues to increase within the Appalachian
region. West Virginia is the only state entirely within Appalachia, with the population having
increased HNSCC incidence and mortality. This underscores the need for improved
understanding of Appalachian HNSCC in WV and the rest of the region in order to ultimately
devise improved patient treatment. To better understand the underlying factors leading to these
disproportionate outcomes, our group has established an Appalachian-specific HNSCC patient
tissue cohort from surgically-resected tumors. This cohort represents all HNSCC stages, lesion
types and morphologies, as well as cases that contain human papillomavirus (HPV) and/or from
patients with histories of tobacco and alcohol use. Moreover, we have generated several patient
derived xenografts (PDXs) from these tissues, allowing further cellular, biochemical and
preclinical therapeutic evaluation. Utilization of PDX tumors from this cohort will allow examination
of critical steps in the development and potential treatment of invasive, metastatic, and recurrent
Appalachian-associated disease. Matched patient and PDX sample availability enables
personalized medicine and co-clinical trials aimed at reversing this Appalachian cancer health
disparity and ultimately improving regional HNSCC patient care.
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Introduction
Tumors of the epithelium lining the upper aerodigestive tract, termed head and neck squamous
cell carcinoma (HNSCC), can form in the lips, oral cavity, nasopharynx, hypopharynx, and larynx
(1–3). Anatomical location subdivides these tumors into oral cavity and pharynx or laryngeal
disease, which clinically display differences in progression, response to therapy, and patient
survival (1–3). Clinically HNSCC is subdivided based on human papilloma virus (HPV) infection
(1–3). HPV associated HNSCC results a significantly less aggressive disease with much
improved prognosis, leading the American Joint Committee on Cancer (AJCC) to down-stage all
HPV-positive tumors effective January 1st, 2017 (4). Clinical trials have shown that less
aggressive therapy can still garner efficacious patient outcomes in HPV-positive HNSCC (5). In
contrast, prolonged tobacco and alcohol exposure is associated with HPV-negative HNSCC (1,2).
With diminishing tobacco consumption in the United States the number of HPV-negative HNSCC
cases have decreased over time (6). Unfortunately, increasing HPV-positive incidence within this
same time period has resulted in no significant change in the total number HNSCC cases during
the past decade (6). Recent projections predict HPV-related HNSCC will become the predominant
form of this cancer as early as 2020 (6).
Present reports indicate that HPV-positive HNSCC accounts for approximately 20% of all HNSCC
incidence, but is significantly enriched in oropharyngeal tumors (60-80% of cases) (6–8). HPVpositive HNSCC is due in large part to infection of the high-risk HPV subtypes 16 and 18 (7–9).
HPV is a circular double stranded DNA virus encoding 7 “early” stage proteins (E1-7) and 2 “late”
stage proteins (L1 and L2) (8,9). The critical early proteins E6 and E7 primarily target tumor
suppressor genes p53 and Rb in host cells, promoting transformation of the infected epithelium
and predisposing cells to subsequent genomic damage (8,9). Surprisingly, HPV-positive tumors
harbor similar chromosomal mutational burdens but unique mutational signatures when
compared with HPV-negative tumors (10–12). Other HPV encoded genes bias these tumors
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towards a poorly differentiated and highly metastatic phenotype (13). Conversely, HPV-negative
HNSCC tumors are typically well- to moderately-differentiated and undergo collective invasion
causing vast loco-regional devastation resulting in decreased overall patient survival (13).
Loco-regional disease remains the focus HNSCC progression, yet metastasis to distant organs
such as the lungs, bone, brain, and liver do occur (14,15). More commonly, tumors spread along
tissue-specific drainage pathways into the lymphatic system or follow neural pathways from the
oral cavity (14–17). Both perineural invasion (PNI) and lymph node involvement result in
decreased patient survival, emphasizing the necessity to control local disease prior to distal
dissemination (14–17).
Utilizing 2D culture or subcutaneous and orthotopic xenograft models to model human cancer
and develop pharmaceuticals has largely been ineffective, as few preclinical trial drugs duplicate
their success when evaluated in the clinic (18–21). Traditional cell culture models select for highly
proliferative, pro-survival subclonal cell populations presenting far greater homogeneity than
found in patient tumors (21). Established cell line-based xenograft models often lack physiological
tumor microenvironment interactions, displaying limited resemblance to the human disease (22).
These limitations necessitate the use of more sophisticated tumor models to enhance the
translatability of preclinical findings in informing patient treatment.
Genetically engineered mouse models (GEMMs) can model tumorigenesis and progression as
well as serve to evaluate tumor-stroma interactions and immune surveillance of the tumor,
enabling broader biological insights (23–25). These models allow researchers to address tissuespecific and temporal changes regulating key steps in tumor onset and progression that cannot
be recapitulated in cell line-based xenografts (23,24). GEMM studies can be used to validate
novel oncogenes, evaluate new drugs and/or treatment combinations, and assess drugresistance and disease recurrence mechanisms that closely mimic the human disease (23,25–
28). There are some practical and biological limitations to GEMMs in that they can be time
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consuming to generate, often display decreased tumor heterogeneity due to reliance on specific
oncogenic drives rather than chromosomal instability and de novo DNA damage, and rarely
capture the magnitude of alterations seen heavily pretreated patients (27,29–31). While GEMMs
represent marked improvement towards mimicking human disease, certain genetic abnormalities
found in human patients cannot be recreated in any mouse model due to differences between
species (26,31). This is particularly true for large chromosomal amplification events common in
human patients which have no genetic equivalent in rodents.
Patient-derived xenograft (PDX) models maintain greater tumor heterogeneity and preserve
genetic landscapes found in patient tumors (30–37). Directly culturing tumors in vivo conserves
several critical tumor microenvironmental facets, including reduced oxygen levels, nutrient and
hormone delivery, and tumor-stromal interactions (22,23,34).
PDX development begins by directly implanting patient tumor samples into immunodeficient mice,
maintaining many primary patient tumor histological and genetic characteristics (32,33,35–38).
Patient samples are obtained as either fine needle aspirates (FNAs) or following surgical resection
(34). The host mice receive either small pieces of tumor or a single-cell suspension typically mixed
with pseudo-extracellular matrix (ECM) cocktail such as collagen I or Matrigel (29,32–36,39–41).
Tumor cells are separated into suspension through chemical digestion with ECM cleaving
proteases and/or mechanical tissue mincing (29,34,40–42). These suspension techniques
expose tumor cells to harsh chemical and mechanical challenges that can reduce cell viability,
leading to decreased tumor engraftment and/or heterogeneity in mice (29). PDXs are inserted
into heterotopic (typically subcutaneous flank or subretinal space) or orthotopic sites (34,39,43).
Site selection varies based on tissue sample size, orthotopic organ (both size and accessibility),
and the individual PDX model purpose (tissue expansion vs. tumor phenomenon observation vs.
therapeutic assessment, etc.) (34,42).
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PDX engraftment success varies based on intrinsic tumor characteristics such as tumor
aggressiveness, histological grade, tumor composition, sample size, resistance to anoikis and
apoptosis (29,37,38,40,43). Other factors that influence engraftment include time (from surgical
removal from the patient to implantation in the mouse), tissue temperature, exposure to nutrients
while outside of the body, and implantation location (29,41).
PDX nomenclature varies but is typically denoted using either F0, G0, or P0 for initial implantation
of patient tissue into the mouse (29,34,43). Subsequent implantations following P0 tumor growth
increase the associated passage number, indicating rounds of growth occurring within the animal
model (ex. P1, P2, P3). A particular PDX sample is commonly considered established and reliable
around P3, assuming the tumor characteristics still resemble the primary patient sample
(29,34,43,44). From this passage forward, PDX models are utilized in drug or tumor progression
studies rather than the initial rounds of PDX establishment and tissue expansion (29,34,43).
Criteria for PDX tumor passaging are variable due to differing Institutional Animal Care and Use
Committee (IACUC) standards and tumor monitoring techniques. Generally, once the tumor
exceeds 1 cm in the largest dimension, the tissue is harvested, processed, then reimplanted (43).
During tissue processing the tumor mass is broken down into small pieces, which can then be
evaluated for tumor drift by genomic sequencing or derived into novel primary cell lines.
Several HNSCC PDX models have been developed, covering both HPV+ and HPV- subtypes.
However these models represent a limited selection of HNSCC patients (41,42,44–48). As seen
in other tumor PDX models, engraftment rates vary based on the tissue of origin (42,44).
Surprisingly, while neither recurrence nor HPV status impact the success of HNSCC PDX
establishment, these PDXs still recapitulate overall survival differences seen in patients (41,42).
The sole factor seems to influence PDX engraftment thus far is whether the patient developed
metastatic disease prior to surgical resection, but this finding is inconsistent across published
cohorts (41,45–47). Epigenetic analysis determined that, unlike tumor cell lines, PDXs maintain
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an identical methylation signature to their primary human tumor, indicating consistent genetic
regulation between the PDX and patient tumor (49). Several studies sought to identify a HNSCC
cancer stem cell (CSC) subpopulation enriched for tumor initiating capacity and drug resistance
(36,40,50). Establishing treatment modalities to identify and target distinct subpopulations is
critical to developing novel therapeutics and preventing disease progression and recurrence.
In many cases, PDX models respond to clinical therapeutics similarly to patient tumors (37,51,52).
Successful translation of PDX treatment to clinical efficacy enabled the National Cancer Institute
(NCI) drug screening program to replace their panel of established cell lines, known as the NCI60, with a comprehensive PDX cohort (53). Recently, the Novartis Institutes for BioMedical
Research unveiled a robust drug screening study utilizing its 1,075 PDX library (54). The
increasing availability of large PDX cohorts should improve drug optimization and translation
efforts that have largely been unsuccessful using prior methodologies. Advantageously, PDX
samples can be evaluated post-treatment, identifying shifts in tumor cell protein expression that
can influence secondary treatment options (42,55). For instance, identifying drug resistant and
susceptible subpopulations undetectable in the untreated sample provides beneficial insight
towards selecting subsequent clinical interventions (42,51,55,56). One study found that the drugresistant tumor subpopulation was addicted to the drug itself and regressed following treatment
cessation (51). This study went on to show that periodic treatment rather than continual dosing
delayed onset of drug resistance and abolished drug-reliant subpopulation development (51).
Several studies have run co-clinical trials where the patient and their matched PDX are treated
with identical therapeutics. Subsequent PDX sample analysis is then used to advise therapeutic
selection tailored to that specific tumor (57–60). These studies utilize personalized or precision
medicine, employing genomic and proteomic tumor characteristics to customize patient care
rather than conventional chemotherapy, where clinicians rely upon gross tumor characteristics
involving tumor size, grade, and stage to determine the optimal clinical intervention (56,61,62).
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While PDXs represent advances in characterizing and preclinical testing of human tumors, there
are limitations to this model. Not every tumor sample engrafts in mice. Some that do engraft can
grow too slow to be practical for clinicians to adjust patient care. Additionally, mouse stromal cells
replace human stromal components within the first two passages and do not always mimic
behaviors found in the patient tumor microenvironment. Additionally, alterations in drug
metabolism, targeting, and tumor vascularity in the mouse can weaken PDX translation to the
clinical setting. More practically, PDXs come at the increased cost associated with
immunodeficient mice along with a large time commitment for implanting tumors, monitoring
progress, and passaging tissue. Despite these short comings, PDX preclinical and co-clinical trials
enhance translational effectiveness to patient care, paving the way towards precision medicine.
West Virginia resides entirely within the Appalachian region, an area with a majority Caucasian
rural population and a history of economic depression (63). While Appalachia has made
remarkable strides towards attaining national averages in health care, it remains an underserved
region (63). When compared to regions outside Appalachia, multiple studies indicate an increased
cancer incidence and mortality within the Appalachian population (63,64). West Virginia in
particular shows higher total cancer incidence and a lower relative survival ratio than the national
average (64,65). A recent study found that while overall cancer incidence is decreasing both
nationally and within Appalachia, cancers of the oral cavity/pharynx and larynx, show increasing
incidence compared to the rest of the nation (63,64). Specifically, there was a 20% increase in
Appalachian oral cavity and pharynx cancer incidence from 2004-2011 compared to national
averages (63,64). This increased burden on the local and regional population necessitates a
focused approach to combating this growing cancer health disparity. As a first step towards further
understanding the underlying biological factors that drive Appalachian oral cavity and pharyngeal
cancers, the present study details the collection and establishment of an Appalachian specific
HNSCC and PDX cohort. Characterization and analysis of this cohort will begin to unravel the
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molecular and genetic mechanisms driving the disproportionate incidence in our state, enabling
improved clinical treatment to reverse these trends.

Materials and Methods
PDX establishment
Patient-derived xenograft (PDX) tumors were established as described (36,66). WVUSCC PDXs
were derived from surgical specimens of HNSCC in compliance with the West Virginia University
Institutional Review Board. PDX models were developed in compliance with the West Virginia
University Institutional Animal Care and Use Committee by placing approximately 1 mm tumor
fragments into subcutaneous pockets in the flanks of anesthetized 8-10 week-old NOD/SCID-γ
(NSG) mice. Tumor fragments were overlayed with Matrigel (354234, Corning) and incisions were
closed using wound clips. Mice were weighed and monitored for tumor growth on a weekly basis.
PDX tumors were passaged into new NSG mice and/or used to generate cell lines once tumors
reached ~1 cm in greatest dimension.
PDX-derived cell lines
For cell line derivation, PDX tumors were minced and digested in DMEM supplemented with 20%
FBS and 1 mg/mL collagenase IV (17104019, Gibco). Digested tissues were plated onto NIH 3T3
fibroblasts senesced with 4 μg/mL mitomycin C (BP2531, Fisher) and cultured in DMEM:F12 1:1
supplemented with 10% FBS, 400 ng/mL hydrocortisone (H0888, Sigma), 50 μg/mL gentamycin
(15750060, Gibco), 5 μM ROCK inhibitor (S1049, Selleckchem), 0.5 ng/mL recombinant human
epidermal growth factor (EGF) (PHG0311, Gibco), and 10 ng/mL cholera toxin (C8062, Sigma).
Prior to utilization in gelatin degradation assays, PDX derived cell lines were plated directly onto
cell culture dishes for 1-2 passages to remove the fibroblast population. Gelatin degradation
assays were performed in DMEM supplemented with 10% FBS.
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Tissue sectioning, staining and microscopy
HNSCC patient and PDX tissue samples were fixed in 10% neutral-buffered formalin and paraffin
embedded (FFPE).
For patient tissue blocks, five micron sections were cut and dried onto charged glass slides at 6065 oC for 30 minutes. Slides were washed three times in xylene (#8400-1, Statlabs) for two
minutes each, rinsed in 100%, 95%, and 80% ethanol (#7100-1, Statlabs) sequentially for 20
seconds each, rinsed with distilled water twice for 10 seconds each, then incubated in hematoxylin
(#7211, Richard Allan Scientific) for 90 seconds. Slides were washed twice in distilled water for
20 seconds each, then incubated with bluing solution (0.3% ammonium hydroxide, A669-212,
Fisher Scientific) for 10 seconds and rinsed twice in distilled water for 20 seconds. Slides were
washed with acid alcohol solution (0.1% hydrochloric acid in 70% ethanol, A144-212, Fisher
Scientific), twice with distilled water for 1 minute, then with 80% ethanol for 10 seconds. Slides
were incubated in eosin (#3801600, Lieca Biosystems) for 15 seconds, washed twice with 95%
ethanol, three times with 100% ethanol, then three times with xylene for 20 seconds. Slides were
mounted using a Tissue-Tek SCA coverslipper (Model 4764, Sakura).
For H&E stained PDX tumors, FFPE sections were incubated three times in microwave-heated
xylene for 3 minutes each. Tumor sections were washed thrice in 100% ethanol, then once in
96% ethanol for 1 minute. Samples were washed with distilled water, incubated with hematoxylin
for 30 seconds, rinsed with water for 1 minute, then with 96% ethanol. Slides were subsequently
incubated with eosin for 2 minutes, washed with water for 10 seconds, then rinsed in 96% ethanol.
Slides were washed with 100% ethanol, followed by three 1 minute xylene washes. Slides were
dried and mounted with glass coverslips using Permount (SP15-500, Fisher).
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Histological images were acquired with an Olympus VS120 Virtual Slide microscope with a
UPlanSApo 20X/0.75 objective using VS-ASW-S6 software (Olympus Corporation).
For immunofluorescent stained PDX tumors, FFPE sections were incubated three times in
microwave-heated xylene for 3 minutes each. Tumor sections were washed thrice in microwaveheated 100% ethanol for 2 minutes each. Sections were then washed in 95%, 80%, and 70%
ethanol for 2 minutes each. Next sections were incubated in 11 mM citrate buffer pH 6.0 with
0.05% Tween 20 at 98 oC for 20 minutes then cooled to room temperature. Slides were incubated
in 1X PBS with 0.1% Triton X-100 for 20 minutes followed by incubation in 1X PBS with 0.01%
Tween 20 for 5 minutes. Tissue samples were encircled using a hydrophobic PAP pen. Antibodies
used were p16 (ab2301980, 1:250, Abcam). Primary antibodies were visualized using Alexa Fluor
647 conjugated goat anti-mouse secondary antibody (A21235, 1:500, Invitrogen). F-actin was
visualized with rhodamine-conjugated phalloidin (R415, 1:1000, Invitrogen). Slides were mounted
using ProLong Gold antifade with DAPI (P36935, Invitrogen). Fluorescent images were acquired
using a Zeiss Axiovert 200M microscope equipped with an AxioCamMR CCD camera using a
Plan-Neofluar 20X/0.40 Corr objective and AxioVision software (Carl Zeiss Microscopy).
Phase contrast and gelatin degradation microscopy
Phase contrast images were acquired using a Zeiss Axiovert 200M microscope equipped with an
AxioCamMR CCD camera using a Plan-Neofluar 20X/0.40 Corr objective and AxioVision software
(Carl Zeiss Microscopy).
For gelatin degradation, cells were plated on Oregon Green 488-conjugated gelatin (G13186,
Invitrogen) coated coverslips for 24 h (67). Cells were rinsed in PBS, fixed with 10% buffered
formalin (SF100-4, Fisher) and labeled as described (67). Antibodies used were 4F11 (1:500).
Primary antibodies were visualized using Alexa Fluor 647 conjugated goat anti-mouse secondary
antibody (A21235, 1:500, Invitrogen). F-actin was visualized with rhodamine-conjugated
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phalloidin (R415, 1:1000, Invitrogen). Coverslips were mounted using ProLong Gold antifade with
DAPI (P36935, Invitrogen). Gelatin degradation images were acquired with a Zeiss Axiovert 200M
microscope equipped with an AxioCamMR CCD camera using a Plan-Apochromat 63X/1.4
objective and AxioVision software (Carl Zeiss Microscopy).
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Results
Establishing a WVUSCC patient cohort
In order to investigate underlying biological factors that contribute to increased HNSCC lethality
in West Virginia and other Appalachia regions, a collective patient tissue repository was
constructed. 63 tumor samples from different individuals encompassing the majority of HNSCC
subsites were accrued from WVU Department of Pathology Laboratory for Translational Medicine.
Patient consent was provided in all cases prior to surgery by the Department of OtolaryngologyHead and Neck Surgery. The cohort displays a biased occurrence towards male patients similar
to that found in HNSCC cohorts from other institutions (Table 1, (11,44,68)). The vast majority of
these patients present with advanced disease (Stage IV) at initial diagnosis (Table 1, (11,44,68)).
Within the oropharyngeal subtype, the majority of samples came from a primary tumor, with some
recurrent and metastatic patient samples (Table 1). The laryngeal subtype presented an even
distribution between primary and recurrent tumors and lacked any metastatic samples (Table 1).
Well differentiated tumors show clear distinction between tumor cells and the surrounding stroma
at the tumor leading edge, while poorly differentiated tumors display intermixed tumor and stromal
cells (69). Tumors that either fall in between those two extremes or display both morphologies
across areas along the tumor leading edge are considered moderately differentiated (69). The
overall WVUSCC histology matches the rank order distribution published for similar HNSCC
cohorts, with the majority of patient tumors are moderately differentiated, followed by well
differentiated and poorly differentiated morphology (Table 1, (68,70)). While HPV status is an
important clinical parameter for patient care, HPV status for any HNSCC tumor was not routinely
tested at our institution until 2017. As a result, the majority of tumors in our cohort do not have
HPV status determined either by p16 immunostaining or PCR (Table 1). Importantly, over 70%
of all cohort patients use tobacco in some form, with 11% having smoked with concurrent
smokeless tobacco use (Table 1). Alcohol consumption is present in over 50% of cases,
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correlating with high occurrence in other studies (11,70). Due to the self-reporting nature of these
data, it is possible that figures for tobacco and alcohol underrepresent the number of individuals
with such exposure. Overall our WVUSCC cohort contains similar representation of clinical,
biological and social factors that are common to other HNSCC population groups from a highsmoking demographic.
While HNSCC represents an assortment tumors arising from various tissues, not all tissues give
rise to tumors that behave uniformly in the clinic (3). Differences in outcomes and response to
therapy have already been taken into account for oral cavity and pharynx vs. laryngeal disease
as well as the enrichment for HPV positivity among tumors of the oropharynx (1–3,6–8). To
establish clarity and allow for future assessment of unique features that may arise from other
tissue sites, we designated our PDX samples based on tissue of origin as defined in Cumming’s
Otolaryngology, 5th edition (Table 2, (3)). HNSCC is made up of five major anatomic sites: 1) oral
cavity (OC), 2) oropharynx (OX), 3) hypopharynx (HX), 4) larynx (LX), 5) nasal cavity (NC); each
of which can be further subdivided into specific tissue locations. The oral cavity comprises the lip
(LP), buccal mucosa (BM), alveolar ridge (AR), floor of mouth (FM), oral tongue (OT), retromolar
trigone (RT), hard palate (HP), and soft palate (SP). The oropharynx contains the base of tongue
(BT), vallecula (VL), posterior pharyngeal wall (PPW), tonsil (TS), and lateral pharyngeal wall
(LPW). The hypopharynx contains the pyriform sinus (PS) and post cricoid area (PC) (3). The
larynx contains the supraglottis (SG), arytenoid (AT), epiglottis (EG), vocal cords (VC), and
subglottis/infraglottis (IG). The nasal cavity contains the ethmoid sinus (ET), maxillary sinus (MS),
frontal sinus (FS) and sphenoid sinus (SS). The nasopharynx (NX) contains only one subsite.
Additionally, we designated associated lymph nodes as LN. Care was taken to attempt to discern
the tissue of origin for each tissue collected in order to accurately account for any trends
discovered from analysis of these samples. This nomenclature allows rapid determination of the
specific HNSCC subsite for each patient tumor and associated PDX.
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PDX Development from WVUSCC patient samples
Detailed analysis of the genomic and proteomic landscape contributing to aggressive HNSCC in
the WVUSCC cohort requires a robust tissue resource. As clinical presentation and prioritization
towards pathological diagnosis limit tissue availability for further detailed analysis, tissue
expansion becomes a critical step in generating sufficient tumor material for subsequent study.
Sample collection begins with surgical resection where a tumor mass is excised from the patient
(Fig. 1A-D). These samples undergo histological staining and pathological confirmation, with
many tumors consisting of moderately differentiated cancer associated with keratin pearl
formation (Fig. 1E). Keratin pearls (large pink-stained oval areas lacking cells within the tumor)
are a hallmark of classical HNSCC, exhibiting the epithelial nature common to the originating
tissue (Fig. 1E). Following resection, a small portion of the patient tumor is implanted into an
anesthetized NSG mouse flank (Fig. 2A). Mice are monitored biweekly until tumors reach ~1 cm
in greatest diameter, at which point the mouse is sacrificed and tumor tissue is collected (Fig. 3AC). Despite the heterotopic location, established PDX tumors maintain the histological
characteristics of the patient tumor from which they are derived (Fig. 4A). Clearly, the PDX tumor
(Fig. 4A, left) resembles the patient tumor (Fig. 1E, left), displaying a more well differentiated
morphology against the mouse stroma and continuing to present keratin pearls. Similarly, the
oropharyngeal PDX tumor maintains its well differentiated status (Fig. 4A, right). While histological
resemblance suggests similarities between the patient and PDX tumors, biochemical
characterization is required to understand oncogenic, recurrent, and metastatic drivers within
each tumor. Thus verifying expression of pathologically identified characteristics such as p16
expression is crucial to the reliability of this PDX cohort. Immunofluorescent staining of a
previously pathologically identified HPV positive tumor shows sustained p16 expression in the
PDX tumor, specifically staining tumor cells within the tumor mass (Fig. 4B). Together these initial
indicators suggest that the PDX cohort strongly represents the WVUSCC patient cohort from
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which these samples have been established. Further genomic and proteomic examination are
necessary to validate these PDX samples and will allow for insight into the causative factors
driving this disease.
In addition to tumor characterization, preclinical modeling is frequently used to establish novel
therapeutic approaches and paradigms aimed at improving patient outcome. To expand cell and
tumor-based model availability for Appalachian HNSCC patients, PDX derived cell lines have
been generated from six PDX tumors. Ongoing work will increase the number and variety of PDX
derived cell lines from new tumors, enabling a more comprehensive investigation of the disease
spectrum observed in the WVUSCC cohort.
For primary cell line generation, tumors excised from mice were dissociated and plated on
senesced NIH 3T3 fibroblasts to generate novel cell lines. Example cell lines are shown in Fig.
5A. The WVUSCC-AR3 line, derived from a recurrent stage IV alveolar ridge tumor displays tight
colony morphology in 2D co-culture typical of epithelial HNSCC cell lines (Fig. 5A left, (71)). The
WVUSCC-BT4 line, derived from a recurrent stage II base of tongue tumor displays very tight
colony morphology (Fig. 5A right, (71)).
As a way to measure retention of tumor behavior in the PDX cell lines, select lines were evaluated
for invadopodia activity. The WVUSCC-AR3 cell line exhibits large numbers of active invadopodia
(colocalization of actin and cortactin puncta at black dots within the gelatin) degrading the
surrounding pseudo-ECM (Fig. 5B, top). Capturing this invasive phenomenon indicates retention
of the aggressive nature of advanced stage HNSCC. The WVUSCC-BT4 cell line displays fewer
invadopodia and less degradation over the same time course (Fig. 5B, bottom), suggesting lower
aggressiveness as seen in p16-positive, HPV-harboring tumors.
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Discussion
The health disparity in West Virginia and other Appalachian regions for various cancers including
HNSCC necessitates further investigation into the molecular and genetic drivers in this disease
(65). Characterizing these patient tumors will help identify potential unique factors within
Appalachia contributing to the increased incidence and mortality in this region, potentially
identifying novel targets and increased information to better inform rational clinical intervention.
Once the genomic and proteomic landscape for Appalachian HNSCC is known, appropriate
combination therapies or novel drug development can be employed. In order to perform these
detailed analysis, we generated the first Appalachian HNSCC live tissue cohort to capture the
spectrum of the disease as it presents in the clinic. From there, tumor and cell-based models
allow for preclinical experimentation and validation of novel approaches, tailoring patient care to
the individual. This study demonstrates the creation of this cohort through the WVUCI, including
a matched HNSCC PDX cohort for downstream applications. The generation of this critical
resource will allow better insight into this health disparity with the end goal of resolving the
Appalachian HNSCC cancer disparity through more suitable therapeutic interventions.
While the diversity within the WVUSCC cohort captures a broad spectrum within the disease, it is
not representative of the total patient population treated at the WVUCI, nor does it completely
extend to the local or regional population (Table 1, (65)). Patient accrual and tissue sample
collection was limited to patients undergoing surgical resection whose tumors were sufficiently
large enough to provide diagnostic and research samples. Even if surgical patients had adequate
tumors, some patients refused consent or underwent lengthy resections which precluded tissue
collection. Despite these limitations, the WVUSCC cohort captures a myriad of tumor stages,
types and sublocations. There is also preferential selection for cofactors associated with poor
patient outcome including advanced stage, recurrence, and metastatic disease (Table 1).
Additional value of this specific HNSCC cohort lies in the unique ability to allow direct molecular,

129

biological and pharmacological interrogation of tumors from patients that represent an escalating
health issue among the patient population seen at the WVUCI. In addition, this cohort enables
comparison between HNSCC sub-locations (oropharynx vs. larynx), stage, and differentiation
status. It also encompasses the currently acknowledged extrinsic disease contributions from HPV,
tobacco, and alcohol. Combining these factors allows for identification of biomarkers for
oncogenesis and aggressive disease. Once these factors have been identified, preclinical
experimentation aimed at combatting this disease can begin.
The successful translation of many co-clinical and preclinical drug studies carried out utilizing
PDX models lends this cohort the potential for changing disease outcomes (41,42,46–49). This
study demonstrates PDX model reliability in maintaining hallmarks identified in patient tumors.
We have shown that our PDX tumors continue to display histological characteristics (Fig. 1B vs.
E) and genetic abnormalities (Fig. 1F) found in the matched patient tumor. The PDX derived cell
lines enable further characterization of tumor and stromal based contributions to disease
progression and recurrence. Initial novel drug compound validation in these PDX derived cell lines
and tumors can assure target specificity and efficacy prior to clinical trials. Our previous work
demonstrates this utility in preclinical Silmitasertib evaluation in HNSCC, a drug which other
studies have concluded was ineffective (66,72). Although Silmitasertib is currently ongoing clinical
trials, it has yet to be evaluated in this disease as an anti-invasive therapeutic (66). Given the
current paucity of targeted therapeutic options, recognition of other clinical trials or FDA approved
therapies as potentially advantageous for HNSCC patients would rapidly benefit patients. Novel
drug target identification will facilitate partnership with pharmaceutical research and development
in order to broaden the spectrum of available treatments specifically aimed at combatting this
disease. The high translatability and decreased cost of PDX preclinical studies as compared to
human clinical trials can continue to lessen the burden on drug developers while at the same time
enhancing the successful implementation of promising lead compounds. The continued
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expansion of this WVUSCC cohort will allow us to make more rapid advances in HNSCC
treatment designed to ablate the current rising trend in HNSCC incident and mortality seen in the
Appalachian patient population.
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Figure Legends
Figure 1. Representative examples of WVUSCC patient tumor anatomy and histology
A. Gross images of a recurrent stage IV laryngeal tumor involving the supraglottis, glottis, and
subglottis. Scale bar represents 2.5 cm. B. Stage IV alveolar ridge tumor exhibiting mandibular
invasion. Scale bar represents 1 cm. C. Neck mass metastasis from a stage IV oral tongue tumor.
Ruler displays cm distance. D. Stage IV oral tongue tumor cross section. Ruler displays cm
distance. E. Histological architecture of HNSCC patient tumors. Hematoxylin and eosin (H & E)
stained stage IV patient tumor (left) and a stage III tumor (right), both arising from the alveolar
ridge. Keratin pearls are denoted with black arrows. Scale bar represents 100 μm (left) and
200 μm (right).
Figure 2. Representative example of WVUSCC PDX implantation
A. Image of an anesthetized NSG mouse following surgical implantation of HNSCC patient tumor
tissue. Tissue that has been implanted into a subcutaneous flank pocked of a shaved/depilated
mouse was covered with Matrigel and wound closed with metal surgical wound clips.
Figure 3. WVUSCC PDX tumor monitoring and tissue passaging
A. Established (P0) flank PDX tumor protruding from the mouse flank. Calipers show largest
tumor dimension (1 cm) prior to passaging. B. WVUSCC-AR2R PDX tumors derived from
recurrent stage IV patient tumor of the alveolar ridge. Two tumors are evident; one tumor mass
adherent to the skin flap on either flank. C. Gross images of multiple resected PDX tumors in
sterile PBS prior to mincing for reimplantation or dissociation for cell line derivation. Ruler displays
cm distance.
Figure 4. Histological validation of WVUSCC PDX tumors
A. PDX tumor tissue maintains patient tumor histological architecture. H & E stained WVUSCCAR3 P2 (left) and WVUSCC-OX3 P0 (right) PDX tumor tissue. Keratin pearls are denoted with
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black arrows. Scale bar represents 100 μm (left) and 200 μm (right). B. Immunofluorescent
labeling of WVUSCC-BT4 PDX tissue with an anti-p16 antibody. p16 (green) expression is
maintain in the PDX tumor and exclusively stains tumor cells. Merged image shows p16 along
with F-actin (red) and nuclei (blue). Scale bar represents 50 µm.
Figure 5. WVUSCC PDX-derived cell lines and gelatin degradation
A. Phase contrast images of PDX derived cell lines grown on senesced fibroblast “feeder” cell
layers. Images of the indicated WVUSCC lines are from alveolar ridge (AR, left) and base of
tongue (BT, right) tumor tissue. Tumor cells display tight colony epithelial morphology indicative
of moderate-well differentiated HNSCC. Scale bar represents 50 µm. B. Invadopodia formation
and matrix degradation activity in PDX derived cell lines. Representative epifluorescent images
of PDX cell lines derived from tumor tissue shown in (A). Cells were plated on OG-488 gelatin
coverslips for 24 hours and labeled with an anti-cortactin antibody and rhodamine phalloidin
(Actin). Gelatin is pseudo-colored white. Scale bar represents 20 μm.
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Table 1. WVUSCC patient cohort

Characteristic
Sex
Male
Female
AJCC Stage
I / II
III
IV
Type of Lesion
Primary
Recurrence
Metastasis
Differentiation Status
Well
Moderate
Poor
Unknown
HPV Status
Positive
Negative
Missing
Tobacco Usage
Smoking
Smokeless
Both
Neither
Alcohol Usage
Yes
Never
Unknown

All
n = 63
(100%)
n (%)

Oropharynx
n = 53
(100%)
n (%)

Larynx
n = 10
(100%)
n (%)

43 (68.25)
20 (31.75)

36 (67.92)
17 (32.08)

7 (70)
3 (30)

13 (20.63)
8 (12.7)
42 (66.67)

12 (22.64)
5 (9.43)
36 (67.92)

1 (10)
3 (30)
6 (60)

40 (63.49)
21 (33.33)
2 (3.17)

35 (66.04)
16 (30.19)
2 (3.77)

5 (50)
5 (50)
-

15 (23.81)
38 (60.32)
7 (11.11)
2 (3.17)

12 (22.64)
32 (60.38)
6 (11.32)
2 (3.77)

3 (30)
6 (60)
1 (10)
-

9 (14.29)
16 (25.4)
38 (60.32)

9 (16.98)
15 (28.3)
29 (54.72)

1 (10)
9 (90)

45 (71.43)
14 (22.22)
7 (11.11)
6 (9.52)

35 (66.04)
14 (26.42)
7 (13.21)
6 (11.32)

10 (100)
-

36 (57.14)
25 (39.68)
2 (3.17)

31 (58.49)
20 (37.74)
2 (3.77)

5 (50)
5 (50)
-

Markwell et al. Table 1
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Table 2. WVUSCC tissue naming convention
Subsite
Lip
Buccal mucosa
Alveolar ridge
Floor of mouth
Oral tongue
Retromolar trigone
Hard palate
Soft palate
Lymph node
Oropharynx
Base of tongue
Vallecula
Posterior pharyngeal wall
Tonsil
Lateral pharyngeal wall
Nasopharynx
Hypopharynx
Pyriform sinus
Post cricoid area
Larynx
Supraglottis
Arytenoid
Epiglottis
Vocal cord
Subglottis
Nasal cavity
Ethmoid sinus
Maxillary sinus
Frontal sinus
Sphenoid sinus

Abbreviation
LP
BM
AR
FM
OT
RT
HP
SP
LN
OX
BT
VL
PPW
TS
LPW
NX
HX
PS
PC
LX
SG
AT
EG
VC
IG
NC
ET
MS
FS
SS

Anatomic Site
Oral Cavity

Oropharynx

Hypopharynx

Larynx

for Infraglottis
Nasal Cavity

Markwell et al. Table 2
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GENERAL DISCUSSION
This dissertation describes studies that elucidate a novel phospho-regulatory pathway that
modulates tumor cell invasiveness and the development of a unique Appalachian HNSCC patient
cohort with matched PDX samples. The first study details a druggable target that regulates the
initial steps of cellular invasion which controls tumor invasion in an orthotopic setting. The second
study establishes a comprehensive tissue collection allowing investigation of significant steps in
the development and potential treatment of invasive, metastatic, and recurrent Appalachianassociated HNSCC. Collectively, these studies expand potential treatment options for HNSCC
patients and position us to uncover unique facets driving higher HNSCC incidence and poor
outcome among Appalachian patients as initial steps to combat this cancer health disparity.
While HNSCC loco-regional and distal spread has long been shown to coincide with decreased
patient survival, we are just beginning to understand the various modes of invasion enabling
lymphatic and metastatic dissemination (1–5). Tumor cell invasion occurs across a spectrum,
ranging from single-cell modalities to large multi-cellular structures (6,7). These collective invasive
groups often contain stromal cells alongside tumor cells, leading to greater appreciation for the
contributions of the tumor microenvironment toward tumor progression (7,8). Currently, there are
promising new therapeutic interventions targeting tumor stromal components that target
endothelial cells, CAFs, and TAMs along with various immunotherapies aimed at reinitiating
immune surveillance (9–12). As future studies expand our understanding of stromal contributions
to tumorigenesis, progression and recurrence, it seems likely that combination therapies will soon
include components aimed at combating multiple facets of the tumor microenvironment.
At the cellular level, many studies have focused on tumor cell-based motility and invasion, much
of which relies on actin cytoskeletal dynamics allowing for concerted cell migration. The
interaction between Arp2/3 complex and associate NPFs, mainly N-WASp and cortactin, are
critical to producing the F-actin network at the center of migratory and invasive cellular
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substructures such as lamellipodia, filapodia, podosomes and invadopodia (13–15). These
structures require tightly regulated actin dynamics achieved through specific interactions among
various ABPs (13–15). Cortactin plays a key role maintaining the integrity of the F-actin network
through its ability to stabilize actin branch point through interactions in the NTA domain and RR
(16). Much of the current literature focuses on cortactin as a central integrator for multiple
upstream signaling pathways that converge on actin cytoskeletal regulation. Post-translational
modifications to the cortactin C-terminal end have been established for Src, Erk1/2, PAK family
kinases, PKD, and Arg/Abl family kinases (17). All of these modifications are suggested to release
cortactin from an auto-inhibited state, opening the protein up to become a scaffold for other ABPs
(17). Less is known regarding signaling events that modulate the ability of cortactin to interact
with other binding partners. Several studies have demonstrated that removal of the DDW motif in
the cortactin NTA domain dramatically reduces binding to Arp2/3 complex and subsequently
blunts invadopodia formation and maturation in multiple cell lines (18–25). Data presented in
Study 1 demonstrate a novel CK2-cortactin signaling mechanism which is required for efficient
invadopodia formation and function leading to tumor cell invasion in 3D and in vivo. We observed
that CK2-mediated cortactin NTA phosphorylation proximal to the DDW motif is sufficient to
diminish binding to and/or activation of Arp2/3 complex. This is in agreement with the majority of
the literature that indicates CK2 phosphorylation plays an inhibitory role with respect to other
NPFs (26–29).
Despite significant reductions in HNSCC tumor cell invadopodia and invasion due to modification
of cortactin T24 and CK2 inhibition, invadopodia or tumor cell invasion were not completely
abolished (Study 1). The incomplete ability of cortactin removal or CK2 inhibition to block invasion
has not been emphasized in other work (30–36). Unlike CK2 inhibition, which has mainly been
studied with a focus on anti-proliferative effects, cortactin inhibition resulting in reduced
invasiveness has been extensively documented in many tumor cell types. Results from across
148

these studies have shown significant reduction in invadopodia and invasion following reduced
cortactin expression, yet some cells still retain the ability to form functional invadopodia (16,30–
33). Evaluation of this work indicates that ~20% of cells still make invadopodia and degrade matrix
when cortactin is directly targeted. While it is possible that this residual activity results from
incomplete cortactin reduction through limitations of RNAi, the consistent lower limit achieved
among multiple laboratories (including our own) using a variety of cell lines suggests that tumor
cells also possess cortactin-independent invasion mechanism(s) to ensure invadopodia are
produced. Studies utilizing CRISPR-Cas9 technologies or cortactin null GEMM models can be
used to verify the existence of such a mechanism. Presuming that such a mechanism does exist,
there are several ways to elucidate the compensatory pathways allowing cortactin-independent
invasion. Following the creation of cortactin-null cell lines, RNA sequencing and proteomic
analysis may reveal compensatory upregulation of proteins able to stabilize actin networks in the
absence of cortactin. We have already tested our cortactin KD cell lines for expression of the
cortactin homologue HS1 and found that all HNSCC cell lines tested failed to upregulate HS1.
Upregulation or a change in the phosphorylation status of other ABPs will generate a list of targets
for subsequent investigation. Utilizing an RNA or CRISP-mediated reduction in those target
proteins in cortactin-null cells will be helpful in further validating the comprehensive network
involved in compensatory cortactin-independent invasive processes. Such targets can serve as
the basis for additional anti-invasive therapeutic development in order to generate a combination
therapy capable of fully inhibiting tumor invasion. It is also possible, if not likely, that there are
tumor cell independent compensatory mechanisms in vivo that can facilitate tumor cell invasion
in the absence of cortactin. This is supported by the fact that cortactin amplification and
overexpression only occurs in a subset of tumors, indicating that tumors can progress without
relying on cortactin driven enhancements (1,30,33,37–45). The most likely compensation in this
case would arise from recruitment of various stromal cells to the tumor border, followed by
stromal-cell directed invasion. This can already be seen in certain tumors undergoing collective
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invasion mediated through the proteolytic action of CAFs on the ECM to generate permissive
trails for tumor cells for migration independent of tumor cell-driven ECM proteolysis (6,7). In
addition to CAFs, other immune infiltrating cells such as TAMs are capable of remodeling the
ECM and can similarly contribute to generating a permissive environment for cortactinindependent tumor cell invasion. Further stromal cell contributions to tumor cell invasion are
detailed in Markwell and Weed 2015 which can be found under Appendix items attached to end
of this dissertation (p.172-196).
CK2 has been established as a pro-oncogenic gene involved in cell survival, proliferation and
resistance to apoptosis (46). In agreement with a pro-invasive role, CK2 is enriched at the tumor
border and correlates with enhanced tumor cell invasion and metastatic progression in various
tumor types (47,48). Many signaling pathways require CK2 activity for optimal signal transduction
including mitogenic signals, inflammatory cytokines, apoptosis, cell survival and angiogenesis
(49–54). The central role of CK2 in multiple important oncogenic process spurred the
development of many pharmacological inhibitors, though only a select few have shown promise
as true clinical interventions (55). Data from Study 1 demonstrate efficacy for Silmitasertib in
blunting HNSCC invasion in 3D and in vivo models. While insufficient as a single agent, CK2
inhibition may be a useful component of a multi-drug regimen for treating aggressive tumors.
Several preclinical and early clinical studies have already demonstrated a synergistic role for CK2
inhibition when in combination with other standard chemotherapeutic agents, mainly through
sensitizing cells to apoptosis (56–58). Targeting the CK2-cortactin signal pathway with
Silmitasertib presents a new potential anti-invasion therapeutic option for HNSCC patients.
Preclinical efficacy in PDX-derived cell lines further suggests the likelihood of clinical benefit
resultant from Silmitasertib administration, since PDXs have been shown to exhibit similar
response to patient tumors when treated with the same agents (59–61).
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While data presented in Study 1 identify CK2α as the T24 phosphorylating kinase, future efforts
are needed to discover the pT24 phosphatase capable of regenerating T24 cortactin that is
required for optimal interaction with Arp2/3 complex. The Slingshot family phosphatases are
potential candidates for this role, since they localize to actin-rich structures and are capable of
dephosphorylating other ABPs including cofilin and coronin (62–64). The close proximity
Slingshot phosphatases to sites of cortactin activity suggest that it may be capable of acting upon
pT24 in the cortactin NTA domain. Alternatively, CK2α has been shown to bind to and enhance
the activity of protein phosphatase 2A (PP2A) in fibroblasts and glioma cell lines (65,66). PP2A
directly binds to the CK2 catalytic subunit and blocks its association with the regulatory β subunit,
preventing CK2 holoenzyme formation (66). The feasibility of this interaction at invadopodia
warrants further investigation, as the CK2β subunit localizes the holoenzyme to the plasma
membrane and may be critical for CK2 association at areas of actin network formation in
invadopodia (67,68). It is possible that both interactions with CK2α are coordinated to enhance
CK2 signal cycling. One interaction allowing for CK2α substrate phosphorylation is through proper
localization of the kinase domain, while a second enhances substrate dephosphorylation. These
two events combine to form a CK2 phosphoregulatory cycle at the plasma membrane.
Additionally, RNA sequencing or proteomic analysis of CK2 overexpressing cell lines and patient
tumors could generate an unbiased approach to identifying likely CK2 phosphatase candidates.
These candidate genes could then be verified through biochemical, RNAi, or phosphatase
inhibitor studies in order to identify candidate phosphatases that contribute to the CK2-cortactin
phosphoregulatory cycle described herein.
PDX models maintain greater tumor heterogeneity and preserve genetic landscapes found in
patient tumors (59,69–75). Directly culturing tumors in vivo conserves several critical tumor
microenvironmental facets, including reduced oxygen levels, nutrient and hormone delivery, and
tumor-stromal interactions (71,76,77). Despite some failures of PDX-based treatment outcomes
151

to recapitulate their results in the clinical setting, PDX models have far superior success rates
when compared to cell culture and animal-based studies (78). Not only do PDX models allow for
repurposing current FDA approved drugs and the generation of novel combinational therapies
with those drugs, but PDX tissue analysis post treatment allows for discovery of new druggable
targets for further research and development (79,80). The success of a small handful of co-clinical
trials has already altered the way that innovative oncologists approach patient care. The current
shift toward rapid, reliable sequencing utilizing personalized or precision medicine through
genomic and proteomic tumor analysis will allow customized patient care to become more
frequently utilized in clinical practice in the future.
Although PDX models are becoming increasingly popular tools for studying tumor behavior, this
model still does not fully recapitulate the human disease. Rapid depletion of human stromal cells
with their mouse stromal counterparts that do not entirely mimic behaviors found in the patient
tumor microenvironment limits the utility of PDX models. Furthermore, the immune compromised
nature of these animals prevents observation of tumor-immune cell interactions. The inability to
observe stromal and immune cell compensation in the tumor microenvironment is the greatest
limitation to PDX-based discoveries. Additionally, differences in drug metabolism, targeting, and
tumor vascularity in the mouse diminishes PDX translation to the clinical setting. Development of
better immune-compromised mouse hosts such as humanized mice and more sophisticated de
novo tumorigenesis models will enable researchers to recapitulate disease development,
progression, response to therapy and recurrence.
The Appalachian population displays increased cancer incidence and mortality when compared
to the rest of the United States (81,82). West Virginia specifically exhibits higher total cancer
incidence and a lower relative survival ratio than the national average (81,83). Despite a decrease
in overall cancer incidence at the national level and within Appalachia, cancers of the oral
cavity/pharynx and larynx, continue to have higher incidence in Appalachia (81,82). The
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enhanced tumor burden on the local and regional population warrants directed efforts to reverse
this cancer health disparity. Our group has begun such an effort towards further understanding
biological factors that drive Appalachian oral cavity and pharyngeal cancers through the collection
and establishment of an Appalachian specific HNSCC and PDX cohort. We have amassed 63
tumor samples covering the majority of HNSCC subsites across all stages, histologic subtypes
and known causative factors including HPV, tobacco and alcohol exposure. The established PDX
tissues maintain histological and functional similarities to the patient samples from which they are
derived (Study 2). Characterization and future investigation of this cohort seeks to reveal the
molecular and genetic mechanisms driving the disproportionate incidence and mortality in West
Virginia and neighboring Appalachian regions. Successful analysis will enable informed clinical
care to combat this health disparity. Additional investigation into the genomic and proteomic
topography within Appalachian HNSCC combined with current array of PDXs will allow for rapid
evaluation of novel treatments directed towards improving HNSCC patient survival. With the
limited targeted therapeutic agents available in HNSCC, any novel interventions will provide
meaningful advances in patient care.
As noted in the discussion section of Study 1, there are several subsequent studies required to
further confirm these findings. Successful pT24 antibody development would enable direct
detection of CK2-mediated cortactin regulation. This would confirm that CK2 acts directly on
cortactin in cell lines and tumor tissues. It would also allow analysis of cortactin amplified and
overexpressing tumors to determine if pT24 levels correlate with enhanced invasiveness,
metastasis, and poor outcome as predicted by this dissertation. Additional analysis directed at
observing invadopodia dynamics in real time could determine whether the T24 phosphoregulatory cycle alters invadopodia initiation or maturation. This can be partially achieved through
actin incorporation assays aimed at labeling actin barded ends in areas of invadopodia
development. A complementary method involves live cell imaging of de novo invadopodia
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formation and maturation utilizing 2D or 3D invasion models. Combined these data would
elucidate the exact step(s) of invadopodia formation and function that CK2 phosphorylation
regulate.
Further validation of Silmitasertib in blunting tumor invasiveness can be achieved through
additional animal modeling. PDX tumor treatment either at heterotopic or orthotopic sites would
confirm its utility in treating advanced human HNSCC tumors. However, PDX models and the
orthotopic tumor injection model shown in Study 1 all start treatment following significant tumor
establishment. Further studies involving spontaneous tumor development combined with
Silmitasertib treatment would determine the extent to which CK2 inhibition can blunt tumor
progression from the point of tumor initiation. Focusing solely on CK2-dependent processes,
additional studies carried on patients or animals with post-surgical tumor resection may
demonstrate Silmitasertib efficacy towards delaying or even preventing disease recurrence. As
has been revealed with CK2 inhibition in other tumor types, Silmitasertib would be expected to
enhance HNSCC tumor sensitivity to cytotoxic chemotherapies. Thus, Silmitasertib could be a
component of first-line therapeutic combinations. In the case of HNSCC, it has yet to be
determined if CK2 inhibition enhances EGFR inhibition. As EGFR blockade is the only tumor
targeted therapy in HNSCC that shows efficacy in the metastatic setting (84), it would be
interesting to evaluate any potential synergistic overlap between these two major signaling
pathways through combined Silmitasertib and Erbitux treatment in the neoadjuvant or postoperative settings.

154

References
1.

Martin CL, Reshmi SC, Ried T, Gottberg W, Wilson JW, Reddy JK, et al. Chromosomal
imbalances in oral squamous cell carcinoma: examination of 31 cell lines and review of
the literature. Oral Oncol. 2008;44:369–82.

2.

Kurtz KA, Hoffman HT, Bridget Zimmerman M, Robinson RA, Carver LA. Perineural and
Vascular Invasion in Oral Cavity Squamous Carcinoma Increased Incidence on Rereview of Slides and by Using Immunohistochemical Enhancement. Arch Pathol Lab
Med. 2005.

3.

Fagan JJ, Collins B, Barnes L, D’Amico F, Myers EN, Johnson JT. Perineural Invasion in
Squamous Cell Carcinoma of the Head and Neck. Arch Otolaryngol Neck Surg. American
Medical Association; 1998;124:637.

4.

Takes RP, Rinaldo A, Silver CE, Haigentz M, Woolgar JA, Triantafyllou A, et al. Distant
metastases from head and neck squamous cell carcinoma. Part I. Basic aspects. Oral
Oncol. 2012;48:775–9.

5.

López F, Rodrigo JP, Silver CE, Haigentz M, Bishop JA, Strojan P, et al. Cervical lymph
node metastases from remote primary tumor sites. Eisele D, editor. Head Neck.
2016;38:E2374–85.

6.

Friedl P, Locker J, Sahai E, Segall JE. Classifying collective cancer cell invasion. Nat Cell
Biol. 2012;14:777–83.

7.

Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and
reciprocity. Cell. Elsevier Inc.; 2011;147:992–1009.

8.

Markwell S, Weed S. Tumor and Stromal-Based Contributions to Head and Neck
Squamous Cell Carcinoma Invasion. Cancers (Basel). 2015;7:382–406.

9.

Kosoff D, Lang JM. Development and translation of novel therapeutics targeting tumorassociated macrophages. Urol Oncol Semin Orig Investig. 2018;

10.

Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev
Drug Discov. 2018;

11.

Vassilakopoulou M, Psyrri A, Argiris A. Targeting angiogenesis in head and neck cancer.
Oral Oncol. 2015;

12.

Jie H-B, Srivastava RM, Argiris A, Bauman JE, Kane LP, Ferris RL. Increased PD-1+ and
TIM-3+ TILs during cetuximab therapy inversely correlates with response in head and
neck cancer patients. Cancer Immunol Res. 2017;canimm.0333.2016.

13.

Rottner K, Faix J, Bogdan S, Linder S, Kerkhoff E. Actin assembly mechanisms at a
glance. J Cell Sci. 2017;130:3427–35.

14.

Yamaguchi H, Condeelis J. Regulation of the actin cytoskeleton in cancer migration and
invasion. Biochem Biophys Acta. 2007;1773:642–52.

15.

Siton-Mendelson O, Bernheim-Groswasser A. Functional Actin Networks under
Construction: The Cooperative Action of Actin Nucleation and Elongation Factors. Trends
Biochem Sci. 2017;42:414–30.

16.

Markwell SM, Ammer AG, Interval ET, Allen JL, Papenberg RA, Castano JE, et al.
155

Cortactin Phosphorylation by Casein Kinase 2 Regulates Actin-Related Protein 2/3
Complex Activity, Invadopodia Function and Tumor Cell Invasion. Mol cancer Res.
2019;in press.
17.

Ayala I, Baldassarre M, Giacchetti G, Caldieri G, Tete S, Luini A, et al. Multiple regulatory
inputs converge on cortactin to control invadopodia biogenesis and extracellular matrix
degradation. J Cell Sci. 2008;121:369–78.

18.

Weaver AM, Heuser JE, Karginov A V., Lee W, Parsons JT, Cooper JA. Interaction of
cortactin and N-WASp with Arp2/3 complex. Curr Biol. 2002;12:1270–8.

19.

Pollard TD. Regulation of Actin Filament Assembly by Arp2/3 Complex and Formins.
Annu Rev Biophys Biomol Struct. Annual Reviews; 2007;36:451–77.

20.

Miglarese MR, Mannion-Henderson J, Wu H, Parsons JT, Bender TP. The protein
tyrosine kinase substrate cortactin is differentially expressed in murine B lymphoid
tumors. Oncogene. 1994;9:1989–97.

21.

Du Y, Weed SA, Xiong WC, Marshall TD, Parsons JT. Identification of a novel cortactin
SH3 domain-binding protein and its localization to growth cones of cultured neurons. Mol
Cell Biol. 1998;18:5838–51.

22.

Weed S a, Du Y, Parsons JT. Translocation of cortactin to the cell periphery is mediated
by the small GTPase Rac1. J Cell Sci. 1998;111 ( Pt 1:2433–43.

23.

Daly RJ. Cortactin signalling and dynamic actin networks. Biochem J. 2004;382:13–25.

24.

Weed SA, Karginov A V., Schafer DA, Weaver AM, Kinley AW, Cooper JA, et al.
Cortactin localization to sites of actin assembly in lamellipodia requires interactions with
F-actin and the Arp2/3 complex. J Cell Biol. 2000;151:29–40.

25.

Galletta BJ, Chuang DY, Cooper JA. Distinct roles for Arp2/3 regulators in actin assembly
and endocytosis. Kirschner MW, editor. PLoS Biol. 2008;6:e1.

26.

Mendoza MC. Phosphoregulation of the WAVE regulatory complex and signal integration.
Semin Cell Dev Biol. Elsevier Ltd; 2013;24:272–9.

27.

Pocha SM, Cory GO. WAVE2 is regulated by multiple phosphorylation events within its
VCA domain. Cell Motil Cytoskeleton. 2009;66:36–47.

28.

Cory GOC, Cramer R, Blanchoin L, Ridley AJ. Phosphorylation of the WASP-VCA
domain increases its affinity for the Arp2/3 complex and enhances actin polymerization by
WASP. Mol Cell. 2003;11:1229–39.

29.

Galovic M, Xu D, Areces LB, van der Kammen R, Innocenti M. Interplay between NWASP and CK2 optimizes clathrin-mediated endocytosis of EGFR. J Cell Sci.
2011;124:2001–12.

30.

Clark ES, Brown B, Whigham AS, Kochaishvili a, Yarbrough WG, Weaver a M.
Aggressiveness of HNSCC tumors depends on expression levels of cortactin, a gene in
the 11q13 amplicon. Oncogene. 2009;28:431–44.

31.

Clark ES, Whigham AS, Yarbrough WG, Weaver AM. Cortactin is an essential regulator
of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia.
Cancer Res. 2007;67:4227–35.

32.

Oser M, Yamaguchi H, Mader CC, Bravo-Cordero JJ, Arias M, Chen X, et al. Cortactin
156

regulates cofilin and N-WASp activities to control the stages of invadopodium assembly
and maturation. J Cell Biol. 2009;186:571–87.
33.

Chuma M, Sakamoto M, Yasuda J, Fujii G, Nakanishi K, Tsuchiya A, et al.
Overexpression of cortactin is involved in motility and metastasis of hepatocellular
carcinoma. J Hepatol. 2004;41:629–36.

34.

Zhang H-X, Jiang S-S, Zhang X-F, Zhou Z-Q, Pan Q-Z, Chen C-L, et al. Protein kinase
CK2α catalytic subunit is overexpressed and serves as an unfavorable prognostic marker
in primary hepatocellular carcinoma. Oncotarget. 2015;

35.

Ku MJ, Park JW, Ryu BJ, Son Y-J, Kim SH, Lee SY. CK2 inhibitor CX4945 induces
sequential inactivation of proteins in the signaling pathways related with cell migration
and suppresses metastasis of A549 human lung cancer cells. Bioorg Med Chem Lett.
Elsevier Ltd; 2013;23:5609–13.

36.

Benavent Acero F, Capobianco CS, Garona J, Cirigliano SM, Perera Y, Urtreger AJ, et al.
CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis
in lung cancer models. Lung Cancer. 2017;107:14–21.

37.

Luo M-L, Shen X-M, Zhang Y, Wei F, Xu X, Cai Y, et al. Amplification and overexpression
of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by
promoting cell migration and anoikis resistance. Cancer Res. 2006;66:11690–9.

38.

Gibcus JH, Mastik MF, Menkema L, de Bock GH, Kluin PM, Schuuring E, et al. Cortactin
expression predicts poor survival in laryngeal carcinoma. Br J Cancer. 2008;98:950–5.

39.

Rodrigo JP, Garcı LA, Ramos S, Lazo PS, Sua C, García LA, et al. EMS1 Gene
Amplification Correlates with Poor Prognosis in Squamous Cell Carcinomas of the Head
and Neck. Clin cancer Res. 2000;6:3177–82.

40.

Weaver AM. Cortactin in tumor invasiveness. Cancer Lett. 2008;265:157–66.

41.

Dedes KJ, Lopez-Garcia M-A, Geyer FC, Lambros MBK, Savage K, Vatcheva R, et al.
Cortactin gene amplification and expression in breast cancer: a chromogenic in situ
hybridisation and immunohistochemical study. Breast Cancer Res Treat. 2010;124:653–
66.

42.

Rodrigo JP, García-Carracedo D, García LA, Menéndez S, Allonca E, González M V, et
al. Distinctive clinicopathological associations of amplification of the cortactin gene at
11q13 in head and neck squamous cell carcinomas. J Pathol. 2009;217:516–23.

43.

Yuan B-Z, Zhou X, Zimonjic DB, Durkin ME, Popescu NC. Amplification and
Overexpression of the EMS 1 Oncogene, a Possible Prognostic Marker, in Human
Hepatocellular Carcinoma. J Mol Diagnostics. 2003;5:48–53.

44.

Rothschild BL, Shim AH, Ammer AG, Kelley LC, Irby KB, Head J a, et al. Cortactin
overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion
in carcinomas with chromosome 11q13 amplification. Cancer Res. 2006;66:8017–25.

45.

Hui R, Campbell DH, Lee CS, McCaul K, Horsfall DJ, Musgrove EA, et al. EMS1
amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may
identify different phenotypes in primary breast cancer. Oncogene. 1997;15:1617–23.

46.

Chua MMJ, Ortega CE, Sheikh A, Lee M, Abdul-Rassoul H, Hartshorn KL, et al. CK2 in
Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target.
157

Pharmaceuticals (Basel). Multidisciplinary Digital Publishing Institute (MDPI); 2017;10.
47.

Faust RA, Niehans G, Gapany M, Hoistad D, Knapp D, Cherwitz D, et al. Subcellular
immunolocalization of protein kinase CK2 in normal and carcinoma cells. Int J Biochem
Cell Biol. 1999;31:941–9.

48.

Yenice S, Davis AT, Goueli SA, Akdas A, Limas C, Ahmed K. Nuclear casein kinase 2
(CK-2) activity in human normal, benign hyperplastic, and cancerous prostate. Prostate.
1994;24:11–6.

49.

Trembley JH, Chen Z, Unger G, Slaton J, Kren BT, Van Waes C, et al. Emergence of
protein kinase CK2 as a key target in cancer therapy. Biofactors. NIH Public Access;
2010;36:187–95.

50.

Di Maira G, Brustolon F, Bertacchini J, Tosoni K, Marmiroli S, Pinna LA, et al.
Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance
phenotype of a CEM cell line characterized by high CK2 level. Oncogene. 2007;26:6915–
26.

51.

Landesman-Bollag E, Song DH, Romieu-Mourez R, Sussman DJ, Cardiff RD,
Sonenshein GE, et al. Protein kinase CK2: signaling and tumorigenesis in the mammary
gland. Mol Cell Biochem. 2001;227:153–65.

52.

Kramerov AA, Saghizadeh M, Caballero S, Shaw LC, Li Calzi S, Bretner M, et al.
Inhibition of protein kinase CK2 suppresses angiogenesis and hematopoietic stem cell
recruitment to retinal neovascularization sites. Mol Cell Biochem. 2008;316:177–86.

53.

Brown MS, Diallo OT, Hu M, Ehsanian R, Yang X, Arun P, et al. CK2 Modulation of
NF- B, TP53, and the Malignant Phenotype in Head and Neck Cancer by Anti-CK2
Oligonucleotides In vitro or In vivo via Sub-50-nm Nanocapsules. Clin Cancer Res.
2010;16:2295–307.

54.

Duncan JS, Litchfield DW. Too much of a good thing: the role of protein kinase CK2 in
tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta.
2008;1784:33–47.

55.

Ahmad KA, Wang G, Slaton J, Unger G, Ahmed K. Targeting CK2 for cancer therapy.
Anticancer Drugs. 2005;16:1037–43.

56.

Mishra S, Pertz V, Zhang B, Kaur P, Shimada H, Groffen J, et al. Treatment of P190
Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2.
Leukemia. 2007;21:178–80.

57.

Sandholt IS, Olsen BB, Guerra B, Issinger O-G. Resorufin: a lead for a new protein
kinase CK2 inhibitor. Anticancer Drugs. 2009;20:238–48.

58.

Yamane K, Kinsella TJ. CK2 inhibits apoptosis and changes its cellular localization
following ionizing radiation. Cancer Res. 2005;65:4362–7.

59.

Sivanand S, Peña-Llopis S, Zhao H, Kucejova B, Spence P, Pavia-Jimenez A, et al. A
validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci
Transl Med. 2012;4:137ra75.

60.

Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, et al.
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug
resistance. Nature. 2013;494:251–5.
158

61.

Merk J, Rolff J, Becker M, Leschber G, Fichtner I. Patient-derived xenografts of nonsmall-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy? Eur J
Cardiothorac Surg. 2009;36:454–9.

62.

Konotop G, Bausch E, Nagai T, Turchinovich A, Becker N, Benner A, et al.
Pharmacological inhibition of centrosome clustering by slingshot-mediated cofilin
activation and actin cortex destabilization. Cancer Res. 2016;

63.

Liu L, Li J, Zhang L, Zhang F, Zhang R, Chen X, et al. Cofilin phosphorylation is elevated
after F-actin disassembly induced by Rac1 depletion. Biofactors. 2015;41:352–9.

64.

Cai L, Makhov AM, Schafer D a, Bear JE. Coronin 1B antagonizes cortactin and
remodels Arp2/3-containing actin branches in lamellipodia. Cell. 2008;134:828–42.

65.

Mandal T, Bhowmik A, Chatterjee A, Chatterjee U, Chatterjee S, Ghosh MK. Reduced
phosphorylation of Stat3 at Ser-727 mediated by casein kinase 2 — Protein phosphatase
2A enhances Stat3 Tyr-705 induced tumorigenic potential of glioma cells. Cell Signal.
2014;26:1725–34.

66.

Hériché JK, Lebrin F, Rabilloud T, Leroy D, Chambaz EM, Goldberg Y. Regulation of
protein phosphatase 2A by direct interaction with casein kinase 2alpha. Science.
1997;276:952–5.

67.

Sarrouilhe D, Filhol O, Leroy D, Bonello G, Baudry M, Chambaz EM, et al. The tight
association of protein kinase CK2 with plasma membranes is mediated by a specific
domain of its regulatory beta-subunit. Biochim Biophys Acta. 1998;1403:199–210.

68.

Wei T, Tao M. Human erythrocyte casein kinase II: characterization and phosphorylation
of membrane cytoskeletal proteins. Arch Biochem Biophys. 1993;307:206–16.

69.

van Weerden WM, de Ridder CM, Verdaasdonk CL, Romijn JC, van der Kwast TH,
Schröder FH, et al. Development of seven new human prostate tumor xenograft models
and their histopathological characterization. Am J Pathol. 1996;149:1055–62.

70.

Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, et al. Molecular
profiling of patient-derived breast cancer xenografts. Breast Cancer Res. 2012;14:R11.

71.

Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived
tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol.
2012;9:338–50.

72.

Jung J, Lee CH, Seol HS, Choi YS, Kim E, Lee EJ, et al. Generation and molecular
characterization of pancreatic cancer patient-derived xenografts reveals their
heterologous nature. Oncotarget. 2016;7:62533–46.

73.

Basu D, Nguyen T-TK, Montone KT, Zhang G, Wang L-P, Diehl JA, et al. Evidence for
mesenchymal-like sub-populations within squamous cell carcinomas possessing
chemoresistance and phenotypic plasticity. Oncogene. 2010;29:4170–82.

74.

Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, Borowski C, et al. Toward
understanding and exploiting tumor heterogeneity. Nat Med. 2015;21:846–53.

75.

Tabassum DP, Polyak K. Tumorigenesis: It takes a village. Nat Rev Cancer. Nature
Publishing Group; 2015;15:473–83.

76.

De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol.
159

2003;200:429–47.
77.

Gengenbacher N, Singhal M, Augustin HG. Preclinical mouse solid tumour models:
status quo, challenges and perspectives. Nat Rev Cancer. Nature Publishing Group;
2017;17:751–65.

78.

Day C-P, Merlino G, Van Dyke T. Preclinical mouse cancer models: a maze of
opportunities and challenges. Cell. NIH Public Access; 2015;163:39–53.

79.

Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, et al. Inhibition of MEK
and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in
patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res.
2012;18:2515–25.

80.

Keysar SB, Astling DP, Anderson RT, Vogler BW, Bowles DW, Morton JJ, et al. A patient
tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate
therapeutics in defined molecular bins. Mol Oncol. 2013;7:776–90.

81.

Cancer in North America: 2011-2015. 2018.

82.

Wilson RJ, Ryerson AB, Singh SD, King JB. Cancer Incidence in Appalachia, 2004-2011.
Cancer Epidemiol Biomarkers Prev. 2016;25:250–8.

83.

2017 West Virginia Cancer Burden Report. Morgantown; 2017.

84.

Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinumbased chemotherapy plus cetuximab in head and neck cancer. N Engl J Med.
2008;359:1116–27.

160

APPENDIX

161

Journal of Visualized Experiments

www.jove.com

Video Article

Quantitative Measurement of Invadopodia-mediated Extracellular Matrix
Proteolysis in Single and Multicellular Contexts
Karen H. Martin, Karen E. Hayes, Elyse L. Walk, Amanda Gatesman Ammer, Steven M. Markwell, Scott A. Weed
Department of Neurobiology and Anatomy, Program in Cancer Cell Biology, Mary Babb Randolph Cancer Center, West Virginia University

Correspondence to: Scott A. Weed at scweed@hsc.wvu.edu
URL: http://www.jove.com/video/4119/
DOI: 10.3791/4119
Keywords: Cellular Biology, Issue 66, Cancer Biology, Anatomy, Molecular Biology, Biochemistry, invadopodia, extracellular matrix, gelatin, confocal
microscopy, quantification, oregon green
Date Published: 8/27/2012
Citation: Martin, K.H., Hayes, K.E., Walk, E.L., Ammer, A.G., Markwell, S.M., Weed, S.A. Quantitative Measurement of Invadopodia-mediated
Extracellular Matrix Proteolysis in Single and Multicellular Contexts. J. Vis. Exp. (66), e4119 10.3791/4119, DOI : 10.3791/4119 (2012).

Abstract
Cellular invasion into local tissues is a process important in development and homeostasis. Malregulated invasion and subsequent cell
1
movement is characteristic of multiple pathological processes, including inflammation, cardiovascular disease and tumor cell metastasis .
Focalized proteolytic degradation of extracellular matrix (ECM) components in the epithelial or endothelial basement membrane is a critical step
in initiating cellular invasion. In tumor cells, extensive in vitro analysis has determined that ECM degradation is accomplished by ventral actin-rich
2,3
membrane protrusive structures termed invadopodia . Invadopodia form in close apposition to the ECM, where they moderate ECM breakdown
through the action of matrix metalloproteinases (MMPs). The ability of tumor cells to form invadopodia directly correlates with the ability to invade
3
into local stroma and associated vascular components .
Visualization of invadopodia-mediated ECM degradation of cells by fluorescent microscopy using dye-labeled matrix proteins coated onto glass
4,5
coverslips has emerged as the most prevalent technique for evaluating the degree of matrix proteolysis and cellular invasive potential . Here
we describe a version of the standard method for generating fluorescently-labeled glass coverslips utilizing a commercially available Oregon
Green-488 gelatin conjugate. This method is easily scaled to rapidly produce large numbers of coated coverslips. We show some of the common
microscopic artifacts that are often encountered during this procedure and how these can be avoided. Finally, we describe standardized methods
using readily available computer software to allow quantification of labeled gelatin matrix degradation mediated by individual cells and by entire
cellular populations. The described procedures provide the ability to accurately and reproducibly monitor invadopodia activity, and can also
serve as a platform for evaluating the efficacy of modulating protein expression or testing of anti-invasive compounds on extracellular matrix
degradation in single and multicellular settings.

Video Link
The video component of this article can be found at http://www.jove.com/video/4119/

Protocol

1. Production of Oregon Green 488-gelatin Coated Coverslips
1. Prepare an unlabeled 5% (w/w) stock gelatin/sucrose solution by adding 1.25 g gelatin and 1.25 g sucrose in PBS to a final volume of 50 ml.
Warm the stock gelatin solution to 37 °C and ensure it is entirely melted before use. Store the final mixture at 4 °C.
2. Clean 13 mm diameter #1 glass coverslips by placing an individual coverslip into each well of a 24 well plastic tissue culture plate. Add 500 μl
of 20% nitric acid to each well and incubate for 30 min. Aspirate the nitric acid solution and wash coverslips three times with deionized water.
3. Coat coverslips with 500 μl of 50 μg/ml poly-L-lysine (prepared from 0.1% stock solution and diluted in deionized water) to each well for 20
min at room temperature. Aspirate the solution and wash three times with PBS. Poly-L-lysine coating facilitates even coating and bonding of
the overlying labeled gelatin.
4. Add 500 μl of 0.5% glutaraldehyde (made fresh before use) to each well and incubate the 24 well plates on ice for 15 min. Aspirate and wash
three times with cold PBS. Be sure to remove all traces of PBS prior to gelatin coating. Keep plates on ice during all washes until gelatin is
added.
5. Reconstitute the Oregon Green 488-conjugated gelatin as per manufacturer's protocol and warm it and the unlabeled 5% gelatin/sucrose
solution from (1.1) to 37 °C. Dilute one part Oregon Green 488 gelatin into eight parts of unlabeled gelatin/sucrose (i.e.; 500 μl of Oregon
Green 488 gelatin into 4 ml of 5% gelatin mixture). Pipet 100 μl of the diluted 488-gelatin mixture (kept at 37 °C) onto each coverslip, using
enough gelatin to coat the coverslip without manual spreading (which can lead to uneven coverslip coating as shown in Figure 3B). It is
important to keep the diluted 488-gelatin mixture at 37 °C during the coating procedure to prevent premature solidification. From this step
forward the coverslips should be kept in the dark as much as possible to avoid potential photobleaching. Other ECM proteins conjugated to
different fluorophores can be substituted for Oregon Green 488 gelatin (see Discussion).
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6. Once all coverslips are coated in a single plate, hold the 24 well plate at an angle and remove excess gelatin from each well by vacuum
aspiration. Incubate coated coverslips in the dark for 10 min at room temperature.
7. Wash the coverslips three times with PBS, then add 500 μl of freshly made 5 mg/ml sodium borohydride (NaBH4) for 15 min at room
temperature to reduce and inactivate residual glutaraldehyde. Sodium borohydride is effervescent, and small bubbles will be evident on and
around each coverslip.
8. Remove the NaBH4 solution by vacuum aspiration with a quick sweeping motion around the outside of each well. Take care not to pick up any
floating coverslips that became detached from the bottom of the tissue culture plate during NaBH4 treatment. Detached coverslips that float to
the top may be gently pushed back down to the well bottom, but care must be taken to avoid damaging the protein coating. Wash each well
three times with PBS and then incubate coverslips in 70% ethanol for 30 min at room temperature.
9. Using sterile technique, transfer the coverslip-containing plates to a type IIA/B cell culture laminar flow hood and rinse coverslips three times
with sterile PBS. At this point coverslips can be stored in PBS protected from light at 4 °C for at least two months.
10. Transfer coverslips to be used for degradation assays to an empty well of a new 24 well plate by careful removal using a sterile needle and
forceps. Equilibrate coverslips for 1-24 hr with complete media appropriate to the specific cell type being assayed. Care must be taken not to
invert the coverslip or scratch the gelatin coating (see Figure 3B).

2. Plating and Processing of Cells on Oregon Green 488-gelatin Coated Coverslips to Assay
ECM Degradation
1. Seed 3-5x104 cells onto a coverslip within each well of the 24 well plate.
2. Conduct a time course study to determine optimal times required for invadopodia degradation activity for the particular cell line/type of
interest. Most invasive cells require a time between 4-24 h for degradation to become apparent, although this range can vary widely and
should be empirically determined. To synchronize invadopodia activity, cells can be treated with MMP inhibitors (e.g., GM 6001) for a desired
6
time period, then wash out the inhibitor to allow invadopodia activity to proceed (for example, see ).
3. Rinse coverslips three times with PBS, then fix cells with 500 μl of 10% buffered formalin phosphate for 15 min. Rinse three times with PBS
and permeabilize for 4 min with 0.4% Triton X-100 in PBS. Rinse three times with PBS to remove the Triton X-100.
4. Label cells using any standard protocol for immunofluorescence staining (see 7 for example) by co-labeling cells with fluorescent conjugated
5
8
phalloidin to visualize actin filaments (F-actin) and for a known marker protein that localizes to invadopodia (e.g; cortactin , TKS5 , or N9
WASp ).Remember to avoid using 488-labeled secondary antibodies or GFP-labeled proteins if using Oregon Green 488 or FITC-labeled
gelatin to prevent signal interference.
5. Mount stained coverslips onto glass microscope slides by carefully inverting the coverslip and placing it on a drop of ProLong Gold antifade or
similar reagent.
6. To assess matrix degradation, image cells in appropriate channels using a conventional fluorescent or confocal microscope. Gelatin
degradation is visualized as darker areas on the coverslip due to proteolytic removal of the fluorescent gelatin (Figure 4A). Labeling of cells
for actin and an invadopodia marker protein allows for confirmation of invadopodia at sites of matrix degradation in merged images (Figure
4A).
7. Degradation activity can also be monitored in real time by live cell imaging with fluorescent-tagged recombinant proteins to track invadopodia
5,10,11
formation and matrix degradation
.

3. Quantification of Fluorescent Gelatin Degradation by Measuring Normalized Matrix
Degradation
This analysis provides the normalized area of matrix degradation relative to the area of the cells or the number of cells. It is useful for analyzing
entire microscopic fields of view where multiple cells are present that have been collectively treated with siRNA, growth factors or therapeutic
agents. For this analysis, images collected at lower magnification are sufficient to efficiently collect information about populations of cells.
1. Open the images in ImageJ12. ImageJ for microscopy can be downloaded from http://www.macbiophotonics.ca/imagej/.
2. Check the scale information by choosing the menu command "Analyze/Set Scale." This information will import automatically with many file
formats, but can be entered manually if required. Proper scaling is necessary to report measurements in microns rather than pixels.
3. Select the appropriate measurements to track by choosing "Analyze/Set Measurements." Check Area and Limit to Threshold.
4. Calculate the area of degradation using the fluorescent gelatin image (Figure 5A).
5. Threshold the image ("Image/Adjust/Threshold") to set the upper and lower pixel intensity values to select the areas of degradation
(highlighted in red; Figure 5B). In subsequent images, use the Set button in the Threshold window to set the same threshold for all images as
an objective means to select degradation area.
6. In some cases, the coverslip may not be perfectly flat when images are acquired. This causes the intensity of the gelatin to change across the
image. If this variation creates problems when thresholding the image, correct for uneven illumination across the gelatin by subtracting the
background ("Process/Subtract Background") or by filtering with a bandpass filter ("Process/FFT/Bandpass Filter") or a pseudo flatfield filter
("Process/Filters/Pseudo Flatfield") until the background intensity is uniform.
7. Measure the area of matrix degradation ("Analyze/Analyze Particles"). In the Analyze Particles window, choose a particle size > 0 to remove
noise from the selection. Show Outlines to identify regions of interest (ROIs). Check Display Results and Summarize to show measurements.
If the drawing has specifically outlined all of the areas of degradation (Figure 5C), copy the Total Area measurement into a spreadsheet. If
other objects were selected (such as debris), record only the areas of the relevant ROIs.
8. Calculate the cell area using the phalloidin stained (F-actin) image (Figure 5D).
9. Threshold the image ("Image/Adjust/Threshold") to set the upper and lower pixel intensity values so that the edges of the cells are selected
(highlighted in red; Figure 5E). In subsequent images, use the Set button in the Threshold window to set the same threshold for all images as
an objective means to select cell area.
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10. 10 Measure the area of the cells ("Analyze/Analyze Particles"). In the Analyze Particles window, choose a particle size > 0 to remove
noise from the selection. Show Outlines to identify regions for analysis (Figure 5F). Check Display Results and Summarize to show area
measurements. Do not check Include Holes if there are spaces between cells in a cluster so the non-selected pixels within the cluster will not
be included in the cell area calculation. Choose OK.
11. Copy the Area results for relevant ROIs into a spreadsheet.
12. Calculate the area of gelatin degradation per total area of cells13.
13. An alternative approach would be to report the area of degradation per number of cells from counting nuclei (Figure 5G). This is necessary
if manipulations alter the cell area between different compared treatment groups. Automatic counting works best if nuclei are well separated,
uniform in intensity and round. Automatically count nuclei ("Plugins/Particle Analysis/Nucleus Counter"). Choose Smallest and Largest
Particle Size, a Threshold Method and a Smoothing Method. Check Subtract Background, Watershed Filter, Add Particles to ROI Manager
and Show Summary (Figure 5H).
14. If nuclei overlap extensively or have an irregular shape or texture, automatic counting may not produce an accurate count (Figure 5H, arrows
on right). In this case, manual counting can be facilitated using the cell counter tool ("Plugins/Particle Analysis/Cell Counter"). This will keep
count as cells are marked during a manual count (Figure 5I).
15. Copy the number of cells (nuclei) into a spreadsheet. Calculate the area of gelatin degradation per total number of cells.

4. Quantification of Fluorescent Gelatin Degradation by Individual Cells in a Mixed Cellular
Population
To evaluate matrix degradation resulting from specific cells in a population apart from other cells within the field (e.g., transfected versus nontransfected cells), the procedure in section 3 can be modified to measure the area of degradation under individual cells. An additional fluorescent
channel is needed to mark transfected cells. In this instance, higher magnification images and well-separated cells are easier to quantitate.
1. Check the scale information by choosing the menu command "Analyze/Set Scale." Select the appropriate measurements to track by choosing
"Analyze/Set Measurements." Check Area and Limit to Threshold.
2. For individual cells that are not touching, identify each cell using the F-actin image (Figure 6A). Threshold the image (see 3.9) (Figure 6B).
It is important to capture the edges of the cells, but there can be holes inside that are not included in the threshold. Use the same intensity
values across images to select cell boundaries.
3. To measure the area of the cells, use "Analyze/Analyze Particles." In the Analyze Particles window, choose a Size >0 (to eliminate noise),
Show Outlines, and check Display Results, Add to Manager and Include Holes (to record the entire area inside the outline). Choose OK and
record the Area for each cell from the Results window.
4. Identify which cells are transfected (Figure 6C).
5. Identify the areas of degradation using the fluorescent gelatin image (Figure 6D). If needed, filter the gelatin image to even background
intensity (see 3.6). Threshold to select the areas of degradation, making note of the threshold settings (Figure 6E). On subsequent images,
use these same upper and lower intensity values (using the Set button in the Threshold window) for an objective selection of areas of
degradation.
6. Measure the areas of degradation under the cells. On the thresholded fluorescent gelatin image, show an outline of the cells by selecting
ROIs in the ROI Manager window and selecting Measure (Figure 6F). Record the results and calculate the normalized area of degradation/
cell or cell area.

5. Representative Results
The overall schematic for the procedure is shown in Figure 1. The procedure entails preparation of glass coverslips and coating with
fluorescently-conjugated gelatin, plating of cells onto the coated coverslips to allow cells to degrade the gelatin, fixing and labeling of cells for
fluorescence microscopic analysis, imaging the fluorescent matrix to assess the matrix integrity, and objectively quantifying the degree of gelatin
matrix degradation using computer software.
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Figure 1. Overall schematic highlighting the key steps involved in fluorescent gelatin coating, cell plating, fixing and immunolabeling, and
evaluating matrix proteolysis.
The key procedural steps involved in preparing and coating glass coverslips are outlined in Figure 2.

Figure 2. Schematic demonstrating the individual steps involved in preparing glass coverslips for gelatin matrix coating. Steps conducted
in the light (lit bulb), on ice (cubes) and in the dark (non-illuminated bulb) are cartoon indicated. Steps conducted in the dark help prevent
photobleaching of the fluorescent matrices.
When properly performed, coverslips are evenly coated with Oregon Green 488-conjugated gelatin, displaying homogenous fluorescence when
visualized by microscopy (Figure 3A). Typical artifacts that can arise due to improper coating, handling, storage and usage of coated coverslips
are shown in Figure 3B.
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Figure 3. Examples of artifacts encountered during gelatin coated coverslip preparation and handling. A. Orthogonal view of a confocal z-stack
showing the typical color and consistency of an Oregon Green 488-conjugated gelatin coated coverslip produced using the prescribed protocol.
Coverslips should have a homogenous coating ~1-2 μm thick as shown in the X-Z (bottom) and Y-Z (right) confocal planes. B. Artifacts that
can occur during the coating and processing of gelatin-coated coverslips include: Improper covering of the coverslip during the coating process
due to poor mixing, manual spreading or partial solidification of the gelatin mixture (uneven coating), removal of the coated matrix by scoring
with needles or forceps during handling (scrape), drying of the coverslip surface during prolonged storage periods, resulting in a "cobblestone"
appearance (dehydrated) and photobleaching of the fluorescent gelatin surface during imaging due to prolonged or high intensity light exposure
(bleaching). White arrow indicates bleached area encompassing a plated OSC19 head and neck squamous carcinoma cell. The Oregon Green
488-conjugated gelatin is pseudocolored white to enhance image contrast. Bar, 10 μm.
The resulting thin matrices produced during this procedure provide a sensitive means to evaluate the ability of cells to degrade ECM. Figure 4
demonstrates an example of invadopodia activity from an OSC19 cell plated on an Oregon Green-488 conjugated gelatin coverslip and imaged
by conventional confocal microscopy as well as by volume-fill image rendering following three dimensional deconvolution.
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Figure 4. Representative examples of invadopodia matrix degradation activity. A. Visualization of invadopodia and corresponding gelatin matrix
proteolysis. OSC19 cells plated on Oregon Green 488-conjugated gelatin coverslips for 10 hr were fixed and labeled with rhodamine-conjugated
phalloidin (F-actin) and anti-cortactin antibodies (visualized with an Alexa Fluor 647 secondary antibody and pseudocolored green). Invadopodia
are evident as focal cytoplasmic concentrations of F-actin and cortactin that overlap with areas of gelatin clearing (dark holes in the matrix) within
the merged image. Boxed regions containing arrowheads indicate individual invadopodia and areas of focal matrix proteolysis as shown in the
enlarged regions below. Bar, 10 μm. B. Volume fill visualization of invadopodia penetration into the ECM. OSC19 cells plated and stained as in
(A) were visually rendered by obtaining 23 successive 0.32 μm optical z-slices totaling 7.04 μm for rhodamine-conjugated phalloidin and Oregon
Green 488-conjugated gelatin. The native LSM file set for each channel was opened in AutoQuant X2.2 software and a 3D blind deconvolution
of each image stack was performed using the recommended settings (10 iterations, medium noise). The processed images were saved as TIFF
stacks that were then opened in NIS Elements and rendered as a volume view with alpha blending. The LUTs were adjusted, and a subvolume
was created to show an edge inside the cell where invadopodia are present. Dorsal-edge view demonstrates invadopodia (red, arrows) inserted
into the underlying gelatin (green). Ventral-edge view shows protrusive invadopodia and areas of gelatin degradation underneath the coverslip as
regions of red present in the green matrix (arrowheads). The total image field presented is cropped to 77 x 65 μm; the cell is~ 60 x 40 μm.
Figure 5 shows some of the important steps for quantification of normalized gelatin matrix degradation as described in step 3 of the protocol.
This procedure is designed to allow for unbiased quantitation of gelatin degradation in an entire field of view, and is suitable for matrix
degradation attributed to many cells within the field.
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Figure 5. Screen capture images demonstrating key steps in computational-assisted quantification of normalized gelatin degradation for cells
within an entire microscopic image as described in protocol step 3. All fluorescent images have been converted to grayscale to better display
the red thresholding and ROI markings. A. Image of Oregon Green 488-conjugated gelatin, showing dark areas ("holes") where degradation has
occurred (step 3.4). B. Thresholded gelatin image highlighting areas of degradation in red (step 3.5). C. Drawing showing ROIs measured for
area of degradation (step 3.7). D. Rhodamine phalloidin staining of F-actin (step 3.8). E. Thresholded actin image highlighting total cell area in
red (step 3.9). F. Drawing showing cell areas to be measured (step 3.10). G. Image of DAPI-stained cell nuclei (step 3.13). H. Red outlines show
results from automatic nuclei counting (step 3.13). The Watershed filter has the potential to separate nuclei that are touching (white arrow). If
nuclei overlap extensively, they may not be separated into individual objects (red arrow). If a nucleus has an irregular shape, it may be separated
into multiple objects (yellow arrow). I. Results from marking nuclei during a manual count using the cell counter tool (step 3.14).
Figure 6. demonstrates select steps involved in quantifying fluorescent gelatin degradation by individual cells within a mixed cellular population
as described in protocol step 4. Here, matrix degradation by transfected cells can be analyzed within a mixed population of transfected and nontransfected cells.
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Figure 6. Screen capture images of steps involved in quantifying gelatin degradation from individual transfected cells within a cell population.
Quantification of a single transfected OSC19 cell overexpressing recombinant cortactin fused to the FLAG epitope tag is shown as an example.
All fluorescent images have been converted to grayscale to better display the red thresholding and yellow ROI markings. A. Confocal image
of three cells labeled with rhodamine-phalloidin (step 4.2). B. Drawing of total cell area based on F-actin staining following application of the
Threshold and Analyze Particles functions (step 4.2-3). C. Confocal image of anti-FLAG immunolabeling of the cell population demonstrating a
single cell expressing FLAG-tagged cortactin (marked with *) (step 4.4). D. Image of Oregon Green 488-conjugated gelatin, showing dark areas
("holes") where degradation has occurred (step 4.5) E. Thresholded gelatin image highlighting dark areas of degradation in red (step 4.5). F.
Thresholded gelatin image overlaid with cell outlines from panel B (step 4.6). Note that only the thresholded pixels within the cell outlines are
counted in the analysis. Areas of degradation outside the current cell location (white arrow) result from cell migration across the gelatin over time
and are not included in the analysis.

Discussion
The ability to visualize cells degrading the extracellular matrix has aided in discovering the molecular mechanisms employed in the early steps
4,14,15
of cell invasion. Pioneered by Wen-Tien Chen in the early 1980's
, coating fluorescently labeled extracellular proteins on glass coverslips for
subsequent microscopic analysis has emerged as the primary technique in evaluating invadopodia function across a wide range of cell types.
The prescribed protocol demonstrates the basic method used for preparing gelatin-coated coverslips that form a collagenous layer less than
11,16-18
2 μm thick suitable for detection of extracellular matrix degradation by cells in most conventional fluorescent and confocal microscopes
,
19-21
similar to what has been previously described
. These properties allow for rapid production of coated coverslips capable of detecting the
initial onset of matrix degradation. The sensitivity afforded by the resulting thin gelatin matrix on the underlying hard glass surface likely aids in
22
promoting invadopodia formation as a response to the high inherent stiffness of the overall matrix environment . However, these matrices are
not well suited for analysis of invadopodia elongation or additional morphological evaluation that has been achieved using thicker (30-100 μm)
20,23,24
gelatin layers with similar methodology, coated transwells or electron microscopy
.
We have found that pre-conjugated commercially produced Oregon Green 488 gelatin allows for rapid experimental set up and consistent,
reproducible results. However, alkaline borate conjugation of fluorescein isothiocyanate (FITC) to unlabeled gelatin remains a popular and
20
inexpensive method for producing fluorescent gelatin conjugates . Fibronectin is also used as an alternative matrix protein for labeling and
4,9
coverslip coating , and in some cases investigators have used labeled fibronectin layered onto unlabeled gelatin coated coverslips to create
11,25
denser matrices
. Other matrices could be used, depending on the specifics of the cell type. In addition to dyes in the green 488 nm spectrum,
a wide range of fluorophores have also been used with manual coupling methods to generate coverslips with different fluorescence spectra,
21,26
24
21
5,11
27
5
including rhodamine
, Alexa Fluor 350 , 546 , 568 , 594 and 647 dyes. Such conjugates are easily adaptable for use in the prescribed
protocol, providing the flexibility for utilizing specific ECM protein-dye combinations suitable for most any imaging filter set.
The techniques described herein provide the necessary detailed steps for utilizing ImageJ to quantify gelatin matrix degradation attributed to
6,28
individual cells in a heterogeneous population or to entire cell groups as published previously . Proprietary software has also been successfully
5,25
employed for the same purpose . In this protocol, the area of matrix degradation is normalized to either the total area of the cells or the
total number of cells (nuclei) in the field. Generally, both options for normalization will give the same result (ELW, data not shown). However, if
different cell lines having different sized cells are being compared or if the experimental treatment causes cells to change size, then it may be
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more accurate to normalize to cell number. On the other hand, many cancer cell lines have a high percentage of multi-nucleated cells, in which
case total cell area may be a more accurate parameter for normalization. Also, if only part of a cell is captured in an image (Figure 6), it may
be better to normalize to cell area rather than underestimate the degradation potential for an individual cell. It is important to optimize the image
analysis to best suit the characteristics and nuances of the specific experimental setup.
For determining cell numbers in a crowded field, counting nuclei is often the method of choice. ImageJ has a nucleus counter plugin for
automatic counting. One option in this tool is the Watershed filter. This filter will help separate nuclei that are touching by segregating them into
individual objects (Figure 5H, white arrow). However, this filter may not be able to separate nuclei that overlap extensively (Figure 5H, red
arrow). In addition, if a nucleus has an irregular shape and large variations in intensity, the filter may separate a single nucleus into multiple
objects (Figure 5H, yellow arrow). Therefore, it is important to try different thresholding and smoothing methods in this plugin to determine the
best parameters for analysis. If the automatic counting does not produce accurate numbers, the cell counter plugin can facilitate manual counting
of cells or nuclei.
In cases utilizing transient transfection, images will often contain a mixture of cells expressing or not expressing a protein of interest (Figure
6). In this scenario, it is not always apparent which cells were responsible for creating areas of matrix degradation. This is especially true if the
cells are migrating across the gelatin. To be consistent in the analysis, it is important to only measure the degraded areas directly underneath
each cell. By thresholding to select the dark areas in the matrix and using the actin to generate cell outlines, only the degraded areas under the
cells will be quantitated. This procedure will exclude degraded areas outside of cell boundaries from analysis (Figure 6F, arrow). The assay may
require optimization to select a time point that allows sufficient time for degradation before the cells have had a chance to move.
Numerous methods have been developed to quantitate invadopodia formation and function. In addition to matrix degradation, other frequently
reported parameters include determining the number of invadopodia per cell, the percentage of cells displaying invadopodia within a given
population, and the number of "immature" or "pre" non-degrading invadopodia compared to "mature" invadopodia capable of degrading the
11,13,25,26
ECM
. The method(s) of choice for invadopodia evaluation depend on inherent characteristics of each cell type. For instance, counting
the number of invadopodia per cell or determining the percentage of cells containing invadopodia is a straightforward approach that works well
if the analyzed cells contain just a few prominent invadopodia, but becomes more difficult in cells that have dozens of invadopodia or where
invadopodia may be small and difficult to detect. Using the degradation assay makes it possible to calculate the percentage of pre-invadopodia
vs. mature invadopodia in single cells or in a population by comparing the total number of cells with invadopodia to the percentage that are
degrading matrix. If there is a discrepancy where fewer cells are degrading matrix compared to cells displaying invadopodia, it may indicate that
these cells are forming pre-invadopodia that were incapable of matrix degradation at the time the cells were fixed.
Whatever method combination is chosen for analysis, it is important to quantify the desired invadopodia characteristics as objectively as
possible. When collecting images on the microscope, choose fields by looking at cells (actin), rather than the fluorescent matrix, to avoid bias
from preferentially selecting areas with high levels of degradation. Multiple images should be acquired to ensure a fair representation of the
cell population. Images should also be acquired at an appropriate magnification. For uniform populations of cells, lower magnification can be
used to collect more cells as long as the areas of degradation can still be resolved. Higher magnification images are preferred to measure
areas under individual cells and to resolve individual invadopodia. When areas are being quantitated, thresholding images based on intensity
is more objective than manually choosing the area of the matrix to measure. In all cases, a sufficient number of cells from multiple independent
experiments should be analyzed to give statistically meaningful, reproducible results.
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Abstract: Head and neck squamous cell carcinoma (HNSCC) is typically diagnosed at
advanced stages with evident loco-regional and/or distal metastases. The prevalence of
metastatic lesions directly correlates with poor patient outcome, resulting in high patient
mortality rates following metastatic development. The progression to metastatic disease
requires changes not only in the carcinoma cells, but also in the surrounding stromal cells
and tumor microenvironment. Within the microenvironment, acellular contributions from
the surrounding extracellular matrix, along with contributions from various infiltrating
immune cells, tumor associated fibroblasts, and endothelial cells facilitate the spread of
tumor cells from the primary site to the rest of the body. Thus far, most attempts to limit
metastatic spread through therapeutic intervention have failed to show patient benefit in
clinic trails. The goal of this review is highlight the complexity of invasion-promoting
interactions in the HNSCC tumor microenvironment, focusing on contributions from tumor
and stromal cells in order to assist future therapeutic development and patient treatment.
Keywords: invasion; HNSCC; tumor microenvironment; metastasis
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1. Introduction
Head and neck squamous cell carcinoma (HNSCC) is one of the most aggressive and invasive cancer
types [1]. A common HNSCC hallmark is loco-regional invasion and metastasis to cervical lymph nodes,
accounting for an 88% patient mortality rate in the two years following metastatic disease development [1].
Despite the long-held notion of genomic instability in advanced disease stages, recent studies have found
no difference in the accumulation of mutations in tumors from patients with and without lymph node
involvement [2]. This indicates that alterations other than mutations in signaling pathways likely account
for progression from primary tumor to invasive and metastatic disease. The contributions towards
metastatic disease arise both from changes in the behavior of tumor cells and interactions with various
stromal components in the tumor microenvironment. The purpose of this review is to highlight the molecular
and cellular mechanisms utilized by tumor cells and the associated microenvironment in promoting
HNSCC invasiveness.
2. Tumor Cell Contributions
In HNSCC patients, two out of three individuals exhibit locoregional or distal metastasis at diagnosis,
correlating with poor patient survival [3,4]. As in other carcinomas, HNSCC invasion involves a multi-step
process that entails initial breaching of the basement membrane, tumor cell migration through the stromal
extracellular matrix (ECM), intravasation into regional vasculature, and extravasation at the metastatic
site. These stages frequently utilize proteolytic-mediated degradation of ECM proteins to facilitate tumor
cell spreading [5–9].
2.1. Cell-ECM Interactions
The activity of several actin cytoskeletal-modulating proteins has been demonstrated to alter
the invasive nature of HNSCC. The basement membrane and ECM are barriers that tumor cells must
bypass in order to move into the surrounding stroma [6,10,11]. Tumor cell mediated proteolytic
degradation of ECM components, globally or at focalized points termed invadopodia, is essential to
the invasive process [6,10–12]. Invadopodia are actin-based membrane protrusions that mediate tumor
cell dissemination by degrading restrictive ECM proteins through the action of matrix metalloproteinases
(MMPs) [5,10–12]. Many MMPs are overexpressed in HNSCC, including the invadopodia-associated
MMPs MMP-2, MMP-9, and MMP-14 [9,12,13]. Invadopodia comprise a central filamentous (F)-actin
core surrounded by an integrin-based adhesion complex ring [6,10,11]. Cortactin and Arp2/3 complex
are essential protein components involved in formation of the F-actin invadopodia core [14–17].
Cortactin is overexpressed in several cancer types including HNSCC, resulting in enhanced tumor cell
motility and invasion [18–25]. Cortactin stabilizes actin branch points, binding to both the F-actin “mother”
filament and Arp2/3 complex on the “daughter” filament [22,25–27]. The end result of this activity is
enhanced invadopodia formation and maturation, leading to robust localized ECM degradation [22,25–27].
Further evidence indicates that cortactin overexpression correlates with lymph node involvement and
metastases [28–30]. In addition to modulating cytoskeletal dynamics, cortactin facilitates localization
and activation of MMP-14 (also termed membrane type 1—matrix metalloproteinase (MT1-MMP)) to
invadopodia along with the secretion of MMP-2 and MMP-9 at sites of focalized degradation of ECM
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proteins [13,31,32]. The activity of MMP-14, MMP-2, and MMP-9 is significantly elevated in HNSCC
cell lines with high metastatic potential and well as oral cancer patient samples with lymph node
involvement [12,33,34].
Several studies have demonstrated increased localization of the actin bundling protein fascin at
the tumor invasive front [35,36]. Facin functions by bundling F-actin, which facilitates the formation of
cellular protrusions necessary for cell-ECM interactions and cell motility [35–37]. Bundling of F-actin
into parallel strands stabilizes filopodia and invadopodia, resulting in enhanced cell motility and localized
ECM degradation [35–37]. Re-expression of fascin in facin-null SW1222 human colonic epithelial cells
results in relocalization of integrin β1 and vinculin to the leading edge of motile cells [38]. Overexpression
of fascin in various tumors, including HNSCC, correlates with aggressive disease, high metastatic potential,
and poor prognosis [35,36].
Similarly, the serine/threonine kinase p21 protein (Cdc42/Rac)-activated kinase (PAK1) is enriched
at the invasive boarder of HNSCC tumors, and is essential for HNSCC invasion in vitro [39,40]. PAK1
resides in the cytoplasm, but can be detected at the leading edge of motile cells, focal adhesions, cell-cell
junctions, and cortical actin structures [41–44]. PAKs phosphorylate several cytoskeletal protein targets,
including vimentin, desmin, LIM kinase (LIMK), myosin light chain (MLC), and myosin light chain
kinase (MLCK), where phosphorylation directly correlates with enhanced cellular motility [39,40].
PAK1-mediated MLCK phosphorylation reduces stress fiber formation, while PAK-1-mediated MLC
phosphorylation induces contractility [41,45,46]. LIMK activation facilitates LIMK binding to the F-actin
severing protein ADF/cofilin, inhibiting ADF/cofilin activity via phosphorylation to stabilize the F-actin
network [41,47,48]. The p41-ARC subunit of Arp2/3 complex can be directly phosphorylated by PAK1,
activating Arp2/3 actin nucleation activity to enhance F-actin formation and increase cell motility [49,50].
This effect on actin network formation can also be accomplished through PAK1 phosphorylation of
cortactin [49,51]. In addition to altering cytoskeletal dynamics, PAK1 has been implicated in the
downregulation of cell-cell contacts. PAK1-mediated phosphorylation of the transcription factor Snail
results in reduced expression of the epithelial cell-cell adhesion molecule epithelial (E)-cadherin [41,52].
Secretion of MMP-1, MMP-3, and MMP-9 correlates directly with PAK1 expression, suggesting that
the activity of PAK1 may enhance proteolytic degradation of ECM [53,54]. Overexpression of PAK1 in
various tumors, including HNSCC, correlates with aggressive disease and poor prognosis [39,40].
The calcium binding proteins S100A8 and S100A9 belong to a family of low-molecular-weight
cytoplasmic proteins primarily detected as a S100A8/A9 heterodimer termed calprotectin [55–58].
Expression and secretion of S100A8/A9 is associated with chronic inflammation and is released from
tumor cells in response to hypoxic stress [55]. While S100A8 and S100A9 are overexpressed in a
multitude of cancers, their expression is suppressed in HNSCC [55,59,60]. Certain studies have
demonstrated a pro-apoptotic role of S100A8/A9, inducing pro-caspase-3 cleavage and downregulating
expression of anti-apoptotic members of the Bcl family, Bcl2 and Bcl-XL [55,61]. The ability of
S100A8/A9 to induce an apoptotic response, rather than the role in inflammatory signaling, is the most
likely reason that expression of these proteins is lost in HNSCC. In addition to inflammatory signaling
and apoptotic response, S100A8/A9 regulates the expression and secretion of MMP-2, representing a
potential upstream therapeutic target [59,60]. Thus, calprotectin may serve a dual role in HNSCC by
preventing apoptosis while facilitating MMP-2-driven metastatic dissemination.
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In order to monitor the surrounding ECM, cells form actin-rich protrusions that in a migratory cell
contact the ECM to form structures known as focal adhesions. Focal adhesions contain the
well-characterized cytoskeletal proteins talin, paxillin, α-actinin, vinculin and focal adhesion kinase
(FAK) [62–64]. Focal adhesions serve as intermediary structures by linking the actin cytoskeleton within
the cell to the ECM surrounding the cell by interacting with the cytoplasmic domains of the integrin
class of transmembrane ECM receptors [62,65–68]. Integrin extracellular domains directly bind ECM
proteins, including fibronectin, laminin, collagen I and collagen IV. [62,65–68]. FAK activation precedes
focal contact formation and facilitates focal adhesion maturation through phosphorylation of Rho
guanine nucleotide exchange factors and phosphatidylinositol phosphate kinase isoform γ, which
enhances talin binding to integrin cytoplasmic domains [66,69]. Regulation of focal adhesion
disassembly at the trailing edge by FAK dramatically alters cellular motility [66,70,71]. FAK overexpression
occurs early in HNSCC development, correlating with increased tumor cell invasion and lymph node
metastasis, partially through an increase in MMP-2 and MMP-9 secretion [67–69]. As such, FAK has
become a therapeutic target in many tumor types, where pharmacological inhibition of FAK tyrosine
kinase activity results in decreased tumor cell invasion [72–75].
Phospholipase D (PLD1), mediates the hydrolysis of phosphatidyl choline into choline and the second
messenger phosphatidic acid [49,76,77]. Phosphatidic acid is further hydrolyzed by phosphatidic acid
phosphohydrolases to generate diacylglycerol and lysophosphatidic acid (LPA), the latter being a key
mediator of inflammatory response and has been implicated in oncogenesis and metastatic progression [10,76].
In addition, LPA activates the Rho family of cytoskeletal regulatory GTPases, facilitating the formation
of filopodia, lamellipodia, and stress fibers essential for cell movement [49,76]. PLD1 has been shown
to drive stress fiber and focal adhesion formation in HeLa cells [78]. PLD1 is overexpressed in several
cancers including HNSCC, where it activates Src kinase and mitogen activated protein kinase (MAPK),
driving invadopodia formation, maturation, and tumor cell invasion [79–82]. Due to the numerous
migratory and invasive signaling networks stimulated by PLD1 and PLD1 substrates, PLD1 represents a
viable upstream target for limiting tumor spread and metastatic progression. To this end, the PLD1 inhibitors
quercetin, ML298, and ML299 decrease U87 glioblastoma cell invasion in in vitro assays [83,84]. These
data support further investigation into PLD1 inhibitor efficacy in suppressing HNSCC invasion.
The phosphoinsositide-3-kinase (PI3K) family of kinases are among the most frequently altered
oncongenic drivers in cancer [85,86]. Genomic alteration of PI3K occurs in approximately 31% of
HNSCC tumors [85,86]. The PI3K class IA isoforms, p110α, p110β, and p110δ lie directly downstream
of many oncogenic receptor tyrosine kinases, including epidermal growth factor receptor (EGFR),
human epidermal growth factor receptor 3 (HER3), Met, platelet-derived growth factor receptor
(PDGFR), vascular endothelial growth factor receptor (VEGFR), and insulin-like growth factor receptor 1
(IGF-1R) [85,87]. The PI3K isoform p110α is the most commonly overexpressed family member in
HNSCC, acting upstream of Cdc42, Rac, and Rho kinases, to enhance filopodia and lamellipodia
formation resulting in increased cellular motility [85,86,88–90].
Despite the expression of several fibroblast growth factor (FGF) receptors in HNSCC, surprisingly
little investigation has focused on secretion of the FGF gene products FGF-3, FGF-4, and FGF-19
located within the 11q13 amplified region found in nearly a third of HNSCC patient samples [91,92].
Studies have focused on FGF-2 and FGF-binding protein, identifying autocrine loops with these FGF
receptors that correlate with enhanced HNSCC invasion [92,93]. Given the establishment of these
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autocrine loops and the potential for these secreted FGFs to attract fibroblasts into proximity with
HNSCC cells (see below), further investigation into the 11q13 amplified FGFs is warranted to determine
if these proteins contribute to HNSCC metastatic progression.
2.2. Cell-Cell Interactions
In addition to enhanced motility at the individual cellular level, the mode of tumor cell migration also
impacts local invasion and metastasis. Tumor cells can invade as individual cells, displaying either
mesenchymal or amoeboid migration depending on intercellular signaling events, which result in poorly
differentiated tumors due to the intermingling of individual invasive tumor cells with the stromal
tissue [94,95]. Other tumor cells utilize multicellular or collective invasion, maintaining tumor cell-cell
junctions, resulting in moderately to well differentiated tumors as the invasive tumor cells can be
distinguished from the surrounding tissue [94,95]. In histological HNSCC samples displaying a broad
invasive front, tumors remain well-to moderately-differentiated due the tumor cells being easily
distinguished from the surrounding tissue by retaining membranous E-cadherin staining. These
characteristics indicate that such tumors undergo collective invasion. In addition, cases where tumors
display individual finger-like invasive fronts, tumors are poorly differentiated as individual tumor cells
are intermingled with stromal cells. These invasive tumor cells show reduced E-cadherin staining,
with notable increases in both phospho-Src and vimentin that represent a more mesenchymal invasion
modality [96]. Patients with elevated phospho-Src and vimentin have direct correlation with greater
lymph node involvement and advanced tumor stage [96]. Although E-cadherin is not essential to
collective invasion, maintenance of cell-cell adhesions and an epithelial phenotype allow for multicellular
invasive clusters to migrate simultaneously [94,95].
In addition to direct cell-cell contact, tumor cells interact through autocrine and paracrine signaling
networks. EGFR is overexpressed in greater than 95% of HNSCC patient samples, and phosphorylation
of the downstream effector Src kinase correlates with poorly differentiated HNSCC, lymph node
involvement, and poor patient outcome [97–99]. Recent studies indicate that there are two distinct
subpopulations within most HNSCC tumors, in which E-cadherin and vimentin are inversely
expressed [100–102]. These two subpopulations demonstrate plasticity in regenerating heterogeneity in
culture and xenograft tumors derived from single subpopulations, but respond differentially to various
chemotherapeutic agents [100–102]. Expression of EGFR is variable in these subpopulations, correlating
inversely with vimentin expression, suggesting a potential mechanism for acquired EGFR inhibitor
resistance that is observed in the clinic [100–102]. Another receptor tyrosine kinase, tyrosine receptor
kinase B (TrkB), is expressed in more than half of HNSCC patient tumors. TrkB activates the transcription
factors Snail and Twist, driving the epithelial to mesenchymal transition (EMT) and enhancing tumor
cell invasion [103]. These data collectively support the idea that deterioration of cell-cell contacts drives
a drug resistant and more invasive phenotype in HNSCC.
2.3. Angiogenesis and Neo-Vascularization
Angiogenesis not only supplies growing tumors with requisite nutrition, but also provides cells at
the tumor periphery a route to disseminate into surrounding tissues and the rest of the body. In addition
to MMPs, HNSCC cells secrete a variety of pro-angiogenic factors that recruit endothelial cells into
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the local tumor microenvironment, resulting in formation of a leaky capillary bed that facilitates tumor
cell intra- and extravasation. Two key angiogenic paracrine signaling profiles have been proposed for
HNSCC cells. The first utilizes excess secreted VEGF, FGF-2, with small amounts of interleukin (IL)-8.
The second mainly consists of IL-8, with lesser amounts of VEGF and FGF-2 [104–106]. In addition,
primary HNSCC tumor cell cultures, tissue specimens, and established cells lines have enhanced
secretion of VEGF and/or PDGF-AB, with lesser, yet still elevated, secretion of granulocyte colony
stimulating factor (G-CSF) and granulocyte macrophage (GM)-CSF [105,107]. Increased secretion of
these cytokines drives HNSCC tumor angiogenesis and corresponds with decreased patient survival [105].
Furthermore, oral SCC tissue samples display enhanced lymphatic microvessel density in the presence
of VEGF, PDGF, basic FGF, hepatocyte growth factor (HGF) and IGF-1 [108,109]. Enhanced primary
tumor lymphatic and blood microvessel density in response to these secreted factors correlates with
lymph node metastasis and invasive tumor margins [110,111]. Endothelial cell recruitment and
formation of an immature vascular network around the tumor in response to HNSCC cell angiogenic
secretions are therefore prime contributors for providing essential routes for primary tumor cell invasion
and metastatic dissemination.
2.4. Metastasis to Distant Sites
Once tumor cells reach the blood or lymphatic vasculature, they must survive in circulation until they
reach lymph nodes or other metastatic sites. While little has been elucidated about such circulating tumor
cells (CTCs) in HNSCC, the amount of HNSCC CTCs rises significantly in stage IV tumors, correlating
directly with increased metastasis and inversely with therapeutic response [112,113]. HNSCC CTCs are
not well defined, and are typically characterized as cells expressing epidermal cell adhesion molecule
(EpCAM) or cytokeratin (CK) 8, CK18, or CK19 in blood samples [112,113]. One study found that IL-6
enhanced survival and self-renewal of the aldehyde dehydrogenase (ALDH)highCD44high cell population,
representing a potential cancer stem cell (CSC) subpopulation sufficient to reconstitute a tumor when
transplanted into a mouse xenograft model [114]. This same CSC subpopulation is resistant to cisplatininduced cell death [115]. There is evidence that indicates EGFR, TrkB, and IL-1β are essential to maintaining
a mesenchymal subpopulation associated with chemotherapeutic resistance in HNSCC [103,116,117].
Other studies suggest that these mesenchymal-like cells can recapitulate the epithelial population of a
tumor following chemotherapeutic therapy, potentially representing the HNSCC tumor equivalent to the
CD44+/CD24− stem-like subpopulation in breast carcinomas [100–102]. It remains unclear if these
mesenchymal-like cells, CSCs and CTCs are the same or unique HNSCC subpopulations, but all show
tumor initiating capacity that can be utilized to form metastases [101–103,114,115,117]. Once these
tumor initiating cells (TICs) reach the metastatic site, they must first extravasate, a process aided by the
local endothelial cells [114]. Following extravasation, some TICs differentiate back into the more epithelial
phenotype that makes up the majority of the tumor mass, while other TICs undergo self-renewal to
maintain the subpopulation [100–102,114]. Reconstituting the entire tumor mass allows the tumor to
grow rapidly, taking advantage of the hospitable metastatic niche since the epithelial cell phenotype
shows enhanced proliferation rates as compared to TICs [101,117]. While CTCs, CSCs, and
mesenchymal-like cells represent resistant subpopulations potentially capable of initiating recurrence
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and correlates with invasive and metastatic disease, investigation into this aspect of HNSCC progression
for therapeutic targeting has become an important newly emerging field [100,103,112,113,116].
3. Stromal Cell Contributions
In addition to carcinoma cells, various cellular and acellular stromal components contribute to promoting
and maintaining HNSCC invasion. Deposition of specific ECM proteins (collagen IV, collagen XVII,
fibronectin, and laminin) is enhanced in HNSCC tumors and serve as a chemo-attractant for HNSCC
cells in various in vitro invasion assays [118–120]. As HNSCC tumors progress towards metastatic
disease, non-tumor cell types from the associated stroma have been shown to have direct and indirect
roles in facilitating HNSCC invasion.
3.1. Mast Cells
Mast cells are part of the immune myeloid lineage that mediate innate and acquired immune responses
through granule exocyctosis, releasing histamine, serine proteases, carboxypeptidase A (CPA1),
proteoglycans, prostaglandin D2 (PGD2), leukotriene C4 (LTC4), tumor necrosis factor (TNF)-α, GM-CSF,
IL-3, IL-4, IL-5, IL-6, IL-8, and IL-16 [121]. During advanced HNSCC stages, where the tumor has
spread to loco-regional or distal lymph nodes, mast cells accumulate in the tumor stroma, with their
presence directly correlating with increased angiogenesis [104,122,123]. How HNSCC tumors suppress
rapid mast cell activation in response to immunoglobulin E or CD32 binding to FcεRI or FCγRIIb
respectively remains to be elucidated, but may occur by blocking FcεRI activation on mast cells [121].
Additionally, heparanase, an enzyme involved in cleavage and remodeling heparin sulfate proteoglycans
in the ECM, accumulates at the HNSCC invasive front, and is a marker of poor prognosis for lymph
node metastasis and tumor recurrence [124]. Mast cells, along with tumor infiltrating neutrophils,
endothelial cells, and macrophages exhibit heparanase activity [124,125]. However, since mast cells also
secrete large amounts of heparin, they are the cell type that is likely responsible for invasion-associated
heparanase activity in the tumor microenvironment. While the main contribution of mast cells to tumor
progression may be inflammation-mediated recruitment of other cell types into the microenvironment,
their presence also facilitates HNSCC tumor neo-vascularization and dissemination to loco-regional
lymph nodes.
3.2. Neutrophils
Neutrophils are another component of the immune system that contributes to the innate immune
response [126]. Neutrophils are recruited to the tumor microenvironment by pro-inflammatory signals,
including IL-8, transforming growth factor (TGF)-β, IL-4, IL-10, IL-13, GM-CSF, and TNF-α [127,128].
Following recruitment to the tumor microenvironment, neutrophils secrete VEGF-A, stimulating
neovascularization through endothelial cell recruitment and proliferation, which can be abrogated via
anti-VEGF-A antibodies or angiostatin treatment [128–130]. Additionally, neutrophil-derived HGF and
MMP-9 facilitate tumor cell migration and invasion towards the newly formed vascular bed [128]. In
this context, neutrophils bridge the gap between the growing tumor mass and the local vasculature,
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bringing in endothelial cells to an area of growing hypoxia while promoting a chemotactic invasive
phenotype in the tumor cells.
3.3. Macrophages
Macrophages belong to the myeloid lineage of the immune system [131]. Macrophages play a direct
role in immune surveillance through endocytosis of pathogens and cellular debris [131]. Tumor associated
macrophage (TAM) infiltration into the tumor microenvironment correlates with lymph node involvement,
tumor stage, and extracapsular spread [132–134]. Once TAMs arrive in the tumor microenvironment,
TAM secretions set up several paracrine signaling loops that drive tumor cell invasion and metastasis.
In one loop, TAMs secrete EGF stimulating tumor cell growth, migration, and invasion. Correspondingly,
HNSCC cells secrete CSF-1 that drives further TAM proliferation and tumor infiltration [135–137]. In
another loop, TAMs secrete macrophage migration inhibitory factor (MMIF), attracting and activating
neutrophils, which subsequently interact with HNSCC cells as described above [128–130,138]. In
response to HNSCC secreted paracrine factors, TAMs develop podosomes, capable of assisting tumor
cells breach the basement membrane and enter the vascular or lymphatic network [133,139]. Similar to
invadopodia, podosomes are membrane protrusions containing an actin-rich core surrounded by an
integrin ring that mediates interaction with the ECM [140]. Podosomes are formed at the leading edge
of motile cells and contribute to cellular motility, simultaneously allowing cells to adhere to the ECM
and initiating acto-mysoin contractility to pull the cell body forward [139,140]. Podosomes can also
localize MMPs, including MMP-2, MMP-9, and MT1-MMP to proteolytically degrade and rearrange
the ECM [140,141]. TAMs also secrete the chemotactic factor macrophage inflammatory protein (MIP)-3α,
which drives HNSCC cell migration and invasion [142]. Through these signaling pathways, macrophages
are able to promote and maintain the HNSCC invasive phenotype, assist in basement membrane
breakdown and recruitment of other cell types into the tumor microenvironment.
3.4. Endothelial Cells
While endothelial cells play a major role in vascularization of the growing tumor mass, emerging
evidence demonstrates a novel role for endothelial cells in facilitating tumor cell invasion. The chemotactic
factors VEGF, TNF-α, and TGF-β induce podosome formation in endothelial cells along the invasive
tumor front [141,143–146]. This allows endothelial cells to reach hypoxic tumor regions, facilitating
breakdown of basement membrane encapsulating the primary tumor. Once endothelial cells come into
direct contact with tumor cells, endothelial cell Notch activation in response to HNSCC-derived Notch
ligand Jagged1 drives capillary-like sprout formation and neovascularization of the expanding tumor
mass [147]. The combined effort of endothelial cell-mediated rearrangement of the microenvironment
to promote tumor cell access to the vascular network makes endothelial cells important contributors to
HNSCC tumor progression.
3.5. Fibroblasts
The desmoplastic response is a hallmark of cancer progression, where secretion and restructuring of
ECM proteins drives tumor cell proteolytic invasion and production of “tracks” for proteolytic-independent
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invasion modes [148,149]. Fibroblasts are specialized for this task, as they can degrade and rearrange
a variety of ECM proteins including type I and IV collagens, laminin, and fibronectin [145,149,150].
Integrin α6 expression allows such cancer associated fibroblasts (CAFs) to bind the basement membrane
protein laminin, enabling CAF-mediated proteolytic laminin degradation [140,151]. Expression of
integrin α6 in CAFs has been linked to poor prognosis in oral cancer patients [151]. Fibroblast-mediated
proteolytic cleavage of ECM proteins requires direct contact with tumor cells or binding of HNSCC
secreted endothelin-1 (ET-1), leading to localization of a disintegrin and metalloprotease (ADAM)-12
and ADAM-17 at fibroblast podosomes, followed by secretion and activation of MMP-2 and MMP-9
from carcinoma cells and CAFs [34,152–154]. Other studies suggest that chemokine C-X-C motif
receptor type 4 (CXCR4) binding to CAF-secreted chemokine C-X-C motif ligand 12 (CXCL12) initiates
carcinoma derived MMP-9 secretion in the tumor microenvironment [34,155]. Regardless of the source
of MMP secretion, total MMP levels and the ratio of activated MMPs to total MMP concentration
compared with adjacent normal tissue positively correlates with lymph node involvement [155,156]. As
a result, the HNSCC stroma is enriched in infiltrating CAFs, with the highest concentrations
accumulating near the invasive front of the tumor [24,29,157]. Infiltrating CAFs have several
characteristics of myofibroblasts, including enhanced proliferation and motility, expression of cytokeratins,
vimentin, and α-smooth muscle actin (SMA), and secretion of MMP-2 and HGF [122,158,159]. CAF
MMP secretion facilitates ECM degradation and remodeling, whereas HGF enhances HNSCC cell
motility [122,158,159]. In turn, enhanced CAF proliferation and motility allows the CAF population to
expand and spread in accordance with the growing invasive tumor front [122,158,159]. The adaptation
of HNSCC CAFs with myofibroblast characteristics results in extracapsular tumor cell spread, increased
invasion, and lymph node metastasis [160]. Orthotopic floor of mouth co-injection of HNSCC cells with
CAFs or normal fibroblasts in mice indicates that CAFs contribute significantly to lymph node and distal
metastatic disease [161]. The net results of fibroblasts in the tumor microenvironment is rearrangement
of ECM proteins, allowing fibroblasts to lead tumor cells into surrounding tissues or paving pathways
in the stroma for invasive tumor cells to follow. Additionally, TGF-β and miR-210 induced CAF
senescence promotes fibroblast MMP-2 secretion and tumor cell EMT, enhancing in vitro tumor cell
invasion [151,162–164]. Further evidence indicates that coinjection of tumor cells with senescent CAFs
promotes xenograft engraftment and tumor growth [165–167]. These activities ultimately result in
facilitating HNSCC metastatic progression.
4. Anti-Metastatic Therapeutic Approaches
While indolent primary HNSCC tumors are typically treated by surgical resection and/or radiation
therapy, the treatment of invasive and metastatic disease is more complex. The development of
preventative anti-metastatic therapies holds promise to broaden patient treatment options and improve
survival rates. Many recent anti-metastatic treatments have been aimed at Src kinase due to the essential
role Src plays in cancer cell motility and invadopodia formation, as well as the multitude of overexpressed
upstream transmembrane receptors that activate Src in tumors [25–27]. Initial in vitro studies using
saracatinib (AZD0530) resulted in decreased MMP-9 activation and ECM degradation in established
HNSCC cell lines, and also reduced invasion in HNSCC cells lines from primary tumors and matched
lymph node metastases in combination with the phospholipase C inhibitor U73122 [168,169]. Another
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combination study showed that saracatinib with the EGFR small molecule inhibitor gefitinib suppressed
HNSCC cell invasion in vitro to a greater extent than either drug alone [170]. However, a subsequent
Phase II trial of saracatinib resulted in no therapeutic benefit in either recurrent or metastatic HNSCC [171].
Treatment of HNSCC cell lines with the Src/Abl small molecule inhibitor dasatinib (BMS-354825)
decreased migration and invasion while blocking the G1-S transition [172]. A Phase II clinical trial of
dasatinib alone also failed to show clinical benefit to patients with late stage HNSCC [173]. These trial
results clearly demonstrate that targeting Src is insufficient to prevent HNSCC progression, prompting
the need to evaluate additional pro-invasive oncogenic targets. The activity of another oncogenic
tyrosine kinase, Abl, downstream of EGFR and Src kinase facilitates invadopodia formation and
promotes tumor cell invasion and metastasis [30,174–178]. In vitro treatment with the Abl family
inhibitor imatinib mesylate (STI571; Gleevac) resulted in enhanced HNSCC cell invasion, opposite of
what has been observed in invasive breast cancer [179]. Imatinib mesylate stimulates HNSCC shedding
of heparin-binding EGF, which activates EGFR on the HNSCC cell surface, driving invadopodia
formation and ECM degradation [179]. A phase II trial of imatinib mesylate and docetaxel for patients
with metastatic non-small-cell lung carcinoma and HNSCC found no clinical benefit and closed early
due to significant toxicity from this drug regimen [180]. Cetuximab (IMC-C225), an anti-EGFR humanized
monoclonal antibody, shows multifaceted benefit in HNSCC by blocking proliferation, angiogenesis and
metastasis while increasing tumor cell apoptosis [181–183]. Phase II clinical trials for patients with late
stage HNSCC showed partial response to cetuximab alone in a small patient subset, while complete
response was observed in the majority of patients when cetuximab was used in combination with cisplatin,
fluorouracil, and radiotherapy [184,185]. The Erbitux in First-Line Treatment of Recurrent or Metastatic
Head and Neck Cancer (EXTREME) Phase III trial showed significant increases in overall survival,
progression-free survival, and response rate for the combination of cetuximab and platinum/5-fluorouralcil
compared with platinum/5-fluorouracil alone [186–189]. While these trials did not directly investigate an
anti-metastatic role for cetuximab, it is a promising advance in HNSCC treatment. Another study found that
the potassium ionophore antibiotic salinomycin significantly inhibited growth of the cisplatin-resistant
mesenchymal-like HNSCC subpopulation, likely through induction of apoptosis [101,190]. These data
demonstrate a potential mechanism for targeting a drug resistant, highly mobile subpopulation that has
been implicated in metastatic dissemination as well as disease recurrence [100–102]. While these initial
studies have demonstrated some efficacy in patients with advanced disease, direct anti-invasive and antimetastatic therapeutic targeting continues to remain elusive in HNSCC.
5. Conclusions
HNSCC tumors contain a host of aberrant signaling pathways, from cytoskeletal modulation
responsible for driving increased invasion to promoting tumor cell survival in the circulation.
Interactions with the surrounding ECM as well as between individual tumor cells influences the ability
of HNSCC cells to invade into the surrounding tissue and eventually to other parts of the body,
predominantly the cervical lymph nodes. Changes in cell-cell adhesions along with alterations in cellular
morphology allow HNSCC cells to undergo a variety of invasive patterns. Additionally, HNSCC cells
utilize various autocrine and paracrine secreted factors in order to optimize tumor dissemination, whether
through neovascularization by endothelial cells or rearrangement of ECM protein by local fibroblasts.
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The tumor microenvironment, depicted in Figure 1, is therefore a complex, dynamic system, complicating
our understanding of tumor behavior and potential therapeutic interventions.

Figure 1. Diagram of tumor and stromal-based contributions that promote head and neck
squamous cell carcinoma (HNSCC) invasion. Depicted is an invasive HNSCC tumor cell mass
invading into the surrounding stroma and muscle tissue of the oral tongue. Specific cell types
and their respective secreted protein contributions are detailed, demonstrating subsequent
cellular responses and paracrine signaling networks. See text for additional detail.
Use of conventional wet-bench‒based cell and xenograft assays cannot incorporate the breath of
tumor-stromal interactions that occur in patient tumors. The inability of these models to accurately guide
pharmaceutical intervention development, as witnessed by the lack of successful clinical trials to date, is
a testament to the complexity and difficulty of targeting HNSCC invasion and metastasis. This is likely due
to the multitude of pro-invasive signaling networks in HNSCC cells and various tumor-stromal
interactions. Therefore, in order to make meaningful advances in the treatment of HNSCC invasion, new
model systems need to be developed that include, or at least consider, all of the intracellular, cell-cell,
and cell-matrix contributions from carcinoma cells and corresponding tumor-associated stromal cells
found in patient tumors.
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